RESOURCE AND PATIENT MANAGEMENT SYSTEM

IHS Clinical Reporting System

(BGP)

Selected Measures (Local) Report
Performance Measure List and Definitions

Version 18.0 patch 1
April 2018

Office of Information Technology (OIT)
Division of Information Technology
# Table of Contents

## 1.0 CRS Selected Measures (Local) Report ................................................................. 1

1.1 Performance Measures Included in the CRS 2018 National GPRA/GPRAMA Report ................................................................. 1

1.2 CRS Denominator Definitions .................................................................. 6

1.2.1 For All Denominators ........................................................................ 6

1.2.2 Active Clinical Population ..................................................................... 7

1.2.3 User Population ..................................................................................... 7

1.2.4 Active Clinical Plus BH Population ......................................................... 8

## 2.0 Performance Measure Topics and Definitions .................................................. 10

2.1 Diabetes Group ...................................................................................... 10

2.1.1 Diabetes Prevalence ........................................................................... 10

2.1.2 Diabetes: Comprehensive Care .................................................................... 11

2.1.3 Diabetes: Glycemic Control ...................................................................... 18

2.1.4 Diabetes: Blood Pressure Control ........................................................ 20

2.1.5 Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes ........................................................................................................ 22

2.1.6 Diabetes: Nephropathy Assessment ................................................... 33

2.1.7 Diabetic Retinopathy ........................................................................... 35

2.1.8 Diabetic Access to Dental Services ..................................................... 39

2.2 Dental Group ........................................................................................... 40

2.2.1 Access to Dental Services ...................................................................... 40

2.2.2 Dental Sealants ................................................................................... 41

2.2.3 Topical Fluoride ................................................................................ 43

2.3 Immunization Group .............................................................................. 44

2.3.1 Influenza .............................................................................................. 44

2.3.2 Adult Immunizations .......................................................................... 47

2.3.3 Childhood Immunizations ..................................................................... 54

2.3.4 Adolescent Immunizations .................................................................... 68

2.4 Childhood Diseases Group ...................................................................... 71

2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection . 71

2.4.2 Appropriate Testing for Children with Pharyngitis ................................. 73

2.5 Cancer Screen Group ............................................................................ 75

2.5.1 Cancer Screening: Pap Smear Rates ................................................. 75

2.5.2 Cancer Screening: Mammogram Rates ............................................. 78

2.5.3 Colorectal Cancer Screening .............................................................. 81

2.5.4 Tobacco Use and Exposure Assessment .......................................... 84

2.5.5 Tobacco Cessation .............................................................................. 89

2.6 Behavioral Health Group ....................................................................... 94

2.6.1 Alcohol Screening .............................................................................. 94

---

Selected Measures (Local) Report
Performance Measure List and Definitions
April 2018

Table of Contents
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.6.2</td>
<td>Screening, Brief Intervention, and Referral to Treatment (SBIRT)</td>
</tr>
<tr>
<td>2.6.3</td>
<td>Intimate Partner (Domestic) Violence Screening</td>
</tr>
<tr>
<td>2.6.4</td>
<td>Depression Screening</td>
</tr>
<tr>
<td>2.6.5</td>
<td>Antidepressant Medication Management</td>
</tr>
<tr>
<td>2.7</td>
<td>Cardiovascular Disease Related Group</td>
</tr>
<tr>
<td>2.7.1</td>
<td>Obesity Assessment</td>
</tr>
<tr>
<td>2.7.2</td>
<td>Childhood Weight Control</td>
</tr>
<tr>
<td>2.7.3</td>
<td>Weight Assessment and Counseling for Nutrition and Physical Activity</td>
</tr>
<tr>
<td>2.7.4</td>
<td>Nutrition and Exercise Education for At Risk Patients</td>
</tr>
<tr>
<td>2.7.5</td>
<td>Physical Activity Assessment</td>
</tr>
<tr>
<td>2.7.6</td>
<td>Cardiovascular Disease and Blood Pressure Control</td>
</tr>
<tr>
<td>2.7.7</td>
<td>Controlling High Blood Pressure – Million Hearts</td>
</tr>
<tr>
<td>2.7.8</td>
<td>Statin Therapy for the Prevention and Treatment of Cardiovascular Disease</td>
</tr>
<tr>
<td>2.7.9</td>
<td>Appropriate Medication Therapy after a Heart Attack</td>
</tr>
<tr>
<td>2.7.10</td>
<td>Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation</td>
</tr>
<tr>
<td>2.7.11</td>
<td>Heart Failure and Evaluation of LVS Function</td>
</tr>
<tr>
<td>2.8</td>
<td>STD-Related Group</td>
</tr>
<tr>
<td>2.8.1</td>
<td>HIV Screening</td>
</tr>
<tr>
<td>2.8.2</td>
<td>HIV Quality of Care</td>
</tr>
<tr>
<td>2.8.3</td>
<td>Hepatitis C Screening</td>
</tr>
<tr>
<td>2.8.4</td>
<td>Chlamydia Testing</td>
</tr>
<tr>
<td>2.8.5</td>
<td>Sexually Transmitted Infection (STI) Screening</td>
</tr>
<tr>
<td>2.9</td>
<td>Other Clinical Measures Group</td>
</tr>
<tr>
<td>2.9.1</td>
<td>Asthma</td>
</tr>
<tr>
<td>2.9.2</td>
<td>Asthma Assessments</td>
</tr>
<tr>
<td>2.9.3</td>
<td>Medication Therapy for Persons with Asthma</td>
</tr>
<tr>
<td>2.9.4</td>
<td>Proportion of Days Covered by Medication Therapy</td>
</tr>
<tr>
<td>2.9.5</td>
<td>Primary Medication Non-adherence</td>
</tr>
<tr>
<td>2.9.6</td>
<td>Concurrent Use of Opioids and Benzodiazepines</td>
</tr>
<tr>
<td>2.9.7</td>
<td>Medications Education</td>
</tr>
<tr>
<td>2.9.8</td>
<td>Medication Therapy Management Services</td>
</tr>
<tr>
<td>2.9.9</td>
<td>Public Health Nursing</td>
</tr>
<tr>
<td>2.9.10</td>
<td>Breastfeeding Rates</td>
</tr>
<tr>
<td>2.9.11</td>
<td>Use of High Risk Medications in the Elderly</td>
</tr>
<tr>
<td>2.9.12</td>
<td>Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly</td>
</tr>
<tr>
<td>2.9.13</td>
<td>Functional Status in Elders</td>
</tr>
<tr>
<td>2.9.14</td>
<td>Fall Risk Assessment in Elders</td>
</tr>
<tr>
<td>2.9.15</td>
<td>Palliative Care</td>
</tr>
<tr>
<td>2.9.16</td>
<td>Annual Wellness Visit</td>
</tr>
<tr>
<td>2.9.17</td>
<td>Optometry</td>
</tr>
<tr>
<td>2.9.18</td>
<td>Goal Setting</td>
</tr>
</tbody>
</table>
List of Acronyms ....................................................................................................... 201
Contact Information .................................................................................................. 204
1.0 CRS Selected Measures (Local) Report

The performance measure topics and their definitions that are included in the Clinical Reporting System (CRS) 2018 version 18.0 patch 1 Selected Measures (Local) Reports are shown in Section 2.0. Performance measures that are also included in the National Government Performance and Results Act of 1993 (GPRA)/GPRA Modernization Act (GPRAMA) Report are shown in Section 1.1.

Many performance measure topics include both the Active Clinical and User Population denominators. For brevity, the User Population denominator is not listed separately. To see which topics include the User Population denominator, refer to the *CRS Clinical Performance Measure Logic Manual for FY 2018 Clinical Measures*.

1.1 Performance Measures Included in the CRS 2018 National GPRA/GPRAMA Report

The following performance measures are reported in the CRS 2018 National GPRA/GPRAMA Report.

Notations used in this document are described in Table 1-1.

Table 1-1: Document notations

<table>
<thead>
<tr>
<th>Notation</th>
<th>Location</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPRA:</td>
<td>Preceding a measure</td>
<td>An official GPRA measure reported in the National GPRA Report submitted to the Office of Management and Budget (OMB) and Congress in the annual Indian Health Service (IHS) budget process.</td>
</tr>
<tr>
<td>GPRAMA:</td>
<td>Preceding a measure</td>
<td>An official GPRAMA measure reported in the National GPRA Report submitted to the Office of Management and Budget (OMB) and Congress and included in the annual HHS Online Performance Appendix.</td>
</tr>
<tr>
<td>Plus Sign (+)</td>
<td>Preceding a measure</td>
<td>The measure is <em>not</em> an official GPRA measure but <em>is included</em> in the National GPRA Report provided to OMB and Congress to provide context to a GPRA measure.</td>
</tr>
<tr>
<td>Section Symbol ($)</td>
<td>Preceding a measure</td>
<td>The measure is <em>not</em> an official GPRA measure and <em>is not included</em> in the National GPRA Report provided to OMB and Congress. Included in this document to provide context to a GPRA measure.</td>
</tr>
<tr>
<td>Notation</td>
<td>Location</td>
<td>Meaning</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
<td>---------</td>
</tr>
<tr>
<td>Asterisk (*)</td>
<td>Anywhere in a code</td>
<td>A wildcard character indicating that the code given has one or more additional characters at this location.</td>
</tr>
<tr>
<td>Brackets ([])</td>
<td>In logic definitions</td>
<td>Contains the name of the taxonomy where the associated codes reside.</td>
</tr>
</tbody>
</table>

DIABETES GROUP

- DIABETES PREVALENCE
  - +Diabetes Diagnosis Ever
  - §Diabetes Diagnosis during GPRA Year
- GLYCEMIC CONTROL
  - +Documented Alc
  - Poor Glycemic Control
  - §A1c greater than or equal to (>=) 7 and less than (<) 8
  - GPRAMA: Good Glycemic Control
  - A1c less than (<) 7
- BLOOD PRESSURE CONTROL
  - §Blood Pressure (BP) Assessed
  - GPRA: Controlled BP (less than (<) 140/90)
- STATIN THERAPY TO REDUCE CARDIOVASCULAR DISEASE RISK IN PATIENTS WITH DIABETES
  - GPRA: With Statin Therapy
  - §With Denominator Exclusions
- NEPHROPATHY ASSESSMENT
  - GPRA: Estimated Glomerular Filtration Rate (GFR) & Urine Albumin-to-Creatinine Ratio (UACR) or History of End Stage Renal Disease (ESRD)
- RETINOPATHY ASSESSMENT
  - GPRA: Retinopathy Evaluation (No Refusals)

DENTAL GROUP

- ACCESS TO DENTAL
  - GPRA: Annual Dental Visit (No Refusals)
- DENTAL SEALANTS
  - GPRA: Dental Sealants (rate)
- Dental Sealants (No Refusals; count; not rate)

**TOPICAL FLUORIDE**
- GPRA: Topical Fluoride (rate)
- §Topical Fluoride Application (No Refusals; count; not rate)

**IMMUNIZATIONS**

- **INFLUENZA**
  - GPRA: Influenza Immunization 6 months – 17 years
  - GPRA: Influenza Immunization 18 years and older

- **ADULT IMMUNIZATIONS**
  - § Tdap/Td past 10 years
  - § Tdap ever
  - § Influenza
  - § Zoster
  - § PPSV23 or PCV13
  - § PPSV23 after age 65 or in past 5 years or PCV13 in past year
  - § up-to-date PPSV23/PCV13
  - § PCV13 after age 19 or PPSV23 in past year
  - § PPSV23 after age 65 or in past 5 years or PCV13 in past year
  - § PPSV23 and PCV13
  - § PPSV23 after age 65
  - § PCV13 after age 65
  - § 1:1:1 (Tdap/Td, Tdap, Influenza)
  - § 1:1 (Tdap/Td, Tdap)
  - § 1:1:1:1 (Tdap/Td, Tdap, Influenza, Zoster)
  - § 1:1:1 (Tdap/Td, Tdap, Zoster)
  - § 1:1:1:1:1 (Tdap/Td, Tdap, Influenza, Zoster, PPSV23/PCV13)
  - § 1:1:1:1:1* (Tdap/Td, Tdap, Influenza, Zoster, up-to-date PPSV23/PCV13)
  - § 1:1:1:1 (Tdap/Td, Tdap, Zoster, PPSV23/PCV13)
  - § 1:1:1:1* (Tdap/Td, Tdap, Zoster, up-to-date PPSV23/PCV13)
  - § PPSV23/PCV13 ever
  - GPRA: All Age-appropriate Immunizations
• CHILDHOOD IMMUNIZATIONS (19 THROUGH 35 MONTHS)
  − §Active Clinical Patients with 4:3:1:3*:3:1:4 (No Refusals)
  − GPRAMA: Active IMM Patients with 4:3:1:3*:3:1:4 (No Refusals)
  − §4 DTaP
  − §3 Polio
  − §1 MMR (Measles, Mumps, Rubella)
  − §3 or 4 HiB (Hemophilic Influenza Type B)
  − §3 Hepatitis B
  − §1 Varicella
  − §4 Pneumococcal

CANCER SCREENING

• PAP SMEAR RATES
  − GPRA: Pap smear in past 3 years or for age 30+, Pap & HPV in past 5 years (No Refusals)

• MAMMOGRAM RATES
  − GPRA: Mammogram (No Refusals)

• COLORECTAL CANCER SCREENING
  − GPRA: Fecal Occult Blood Test (FOBT) or Fecal Immunochemical Test (FIT) during Report Period, Flexible Sigmoidoscopy in past 5 years, or Colonoscopy in past ten years (No Refusals)
  − §FOBT or FIT

• TOBACCO USE AND EXPOSURE ASSESSMENT
  − §Tobacco Assessment

• §Tobacco Users
  − §Smokers
  − §Smokeless Users
  − §ENDS Users

• §Exposed to Environmental Tobacco Smoke (ETS)

• TOBACCO CESSATION
  − GPRA: Tobacco Cessation Counseling, Smoking Cessation Aid, or Quit Tobacco Use
  − §Tobacco Cessation Counseling or Smoking Cessation Aid (No Refusals)
  − §Quit Tobacco Use
BEHAVIORAL HEALTH

- ALCOHOL SCREENING
  - GPRA: Alcohol Screening 9-75 (No Refusals)
  - §Alcohol-Related Education
  - §Positive Alcohol Screen

- SCREENING, BRIEF INTERVENTION, AND REFERRAL TO TREATMENT
  - §Screening for Alcohol Use
  - §Positive Screen
  - GPRA: Brief Negotiated Interview/Brief Interview (BNI/BI)
  - §Referral to Treatment

- INTIMATE PARTNER VIOLENCE/DOMESTIC VIOLENCE (IPV/DV) SCREENING
  - GPRA: IPV/DV Screening (No Refusals)

- DEPRESSION SCREENING
  - GPRA: Depression Screening or Mood Disorder Diagnosis age 12-17 years (No Refusals)
  - GPRAMA: Depression Screening or Mood Disorder Diagnosis age 18+ years (No Refusals)
  - §Depression Screening
  - §Mood Disorder Diagnosis

CARDIOVASCULAR DISEASE-RELATED

- CHILDHOOD WEIGHT CONTROL
  - GPRA: Body Mass Index (BMI) 95% and Up

- CONTROLLING HIGH BLOOD PRESSURE – MILLION HEARTS
  - GPRA: BP less than (<) 140/90

- STATIN THERAPY FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
  - GPRA: Statin Therapy
  - §With Denominator Exclusions

STD GROUP

- HIV SCREENING
  - §Prenatal HIV Screening (No Refusals)
- GPRA: HIV Screen Ever (No Refusals)

**OTHER CLINICAL**

- **BREASTFEEDING RATES**
  - Patients 30 through 394 days of age screened for infant feeding choice (IFC) at least once
  - Patients 30 through 394 days of age screened for IFC at the age of 2 months
  - Patients 30 through 394 days of age screened for IFC at the age of 6 months
  - Patients 30 through 394 days of age screened for IFC at the age of 9 months
  - Patients 30 through 394 days of age screened for IFC at the age of 1 year
  - GPRA: Patients 30 through 394 days of age who were exclusively or mostly breastfed at 2 months of age
  - Patients 30 through 394 days of age who were exclusively or mostly breastfed at 6 months of age
  - Patients 30 through 394 days of age who were exclusively or mostly breastfed at 9 months of age
  - Patients 30 through 394 days of age who were exclusively or mostly breastfed at the age of 1 year

**Note:** Definitions for all performance measure topics included in CRS begin on Section 2.0. Definitions for numerators and denominators that are preceded by “GPRA” represent measures that are reported to OMB and Congress.

### 1.2 CRS Denominator Definitions

#### 1.2.1 For All Denominators

- All patients with name “DEMO, PATIENT” or who are included in the RPMS Demo/Test Patient Search Template (DPST option located in the Patient Care Component (PCC) Management Reports, Other section), will be excluded automatically for all denominators.
- For all measures except as noted, patient age is calculated as of the beginning of the Report Period.
1.2.2 Active Clinical Population

1.2.2.1 National GPRA/GPRAMA Reporting

- Must have two visits to medical clinics in the past 3 years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2018 Clinical Measures User Manual for a listing of these clinics.

- Must be alive on the last day of the Report Period.

- Must be American Indian/Alaska Native (AI/AN); defined as Beneficiary 01.

- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined Purchased and Referred Care (PRC) catchment area.

1.2.2.2 Local Reports

- Must have two visits to medical clinics in the past 3 years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the CRS for FY2018 Clinical Measures User Manual for a listing of these clinics.

- Must be alive on the last day of the Report Period.

- User defines population type: AI/AN patients only, non-AI/AN, or both.

- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.3 User Population

1.2.3.1 National GPRA/GPRAMA Reporting

- Must have been seen at least once in the 3 years prior to the end of the Report Period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.

- Must be alive on the last day of the Report Period.

- Must be AI/AN; defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined PRC catchment area.

1.2.3.2 Local Reports
- Must have been seen at least once in the 3 years prior to the end of the Report Period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report Period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

1.2.4 Active Clinical Plus BH Population

1.2.4.1 National GPRA/GPRAMA Reporting
- Must have two visits to medical or behavioral health (BH) clinics in the past 3 years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2018 Clinical Measures User Manual for a listing of these clinics.
- Must be alive on the last day of the Report Period.
- Must be AI/AN; defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined PRC catchment area.

1.2.4.2 Local Reports
- Must have two visits to medical or behavioral health clinics in the past 3 years prior to the end of the Report Period. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the Clinical Reporting System (CRS) for FY2018 Clinical Measures User Manual for a listing of these clinics.
- Must be alive on the last day of the Report Period.
- User defines population type: AI/AN patients only, non-AI/AN, or both.
• User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.
2.0 **Performance Measure Topics and Definitions**

The following sections define the performance measure topics and their definitions that are included in the CRS 2018 version 18.0 patch 1 Selected Measures (Local) Report.

2.1 **Diabetes Group**

2.1.1 **Diabetes Prevalence**

2.1.1.1 **Owner and Contact**

Diabetes Program: Dr. Ann Bullock

2.1.1.2 **National Reporting**

NATIONAL (included in National GPRA/GPRAMA Report; not reported to OMB and Congress)

2.1.1.3 **Denominators**

1. User Population patients.

2.1.1.4 **Numerator**

1. Patients diagnosed with diabetes ever.

2. Patients diagnosed with diabetes during the Report Period.

2.1.1.5 **Definitions**

**Diabetes Diagnosis**

Diabetes diagnosis is defined as at least one Purpose of Visit [POV] diagnosis International Classification of Diseases (ICD)-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES].

2.1.1.6 **Patient List**

List of diabetic patients with most recent diagnosis.
2.1.2 Diabetes: Comprehensive Care

2.1.2.1 Owner and Contact

Diabetes Program: Dr. Ann Bullock

2.1.2.2 National Reporting

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.1.2.3 Denominators

1. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits in the past year, and two Diabetes Mellitus (DM)-related visits ever.

2. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, AND at least two visits during the Report Period, AND two DM-related visits ever, without a documented history of bilateral blindness or bilateral eye enucleation.

3. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral foot amputation or two separate unilateral foot amputations.

2.1.2.4 Numerators

1. Patients with A1c and blood pressure assessed and nephropathy assessment and retinal exam and diabetic foot exam.

   Note: This numerator does not include controlled blood pressure, only blood pressure assessment.

2. Patients with hemoglobin A1c documented during the Report Period, regardless of result.

3. Patients with blood pressure documented during the Report Period.

4. Patients with controlled blood pressure during the Report Period, defined as less than 140/90. This measure is not included in the comprehensive measure (Numerator 8).

5. Patients with Low-Density Lipoprotein (LDL) completed during the Report Period, regardless of result.
6. Patients with nephropathy assessment, defined as an estimated Glomerular Filtration Rate (GFR) with result and a Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period or with evidence of diagnosis or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period.

7. Patients receiving a qualified retinal evaluation during the Report Period (with Denominator 2).

**Note:** This numerator does not include refusals.

8. Patients with diabetic foot exam during the Report Period (with Denominator 3).

**Note:** This numerator does not include refusals.

### 2.1.2.5 Definitions

#### Diabetes

First POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

#### A1c

Searches for most recent A1c test with a result during the Report Period. If none found, CRS searches for the most recent A1c test without a result.

A1c defined as:

- Current Procedural Terminology (CPT) 83036, 83037, 3044F through 3046F, 3047F (old code) [BGP HGBA1C CPTS]
- Logical Observations Identifiers, Names, Codes (LOINC) taxonomy
- Site-populated taxonomy DM AUDIT HGB A1C TAX

#### BP Documented

Exclusions: When calculating all Blood Pressure measurements (BPs) (using vital measurements or CPT codes), the following visits will be excluded:

- Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation).
- Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)
CRS uses the mean of the last 3 BPs documented during the Report Period. If 3 BPs are not available, it uses the mean of last 2 BPs, or 1 BP if there is only 1 documented. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) BPs and dividing by 3 (or 2).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 [BGP BP MEASURED CPT, BGP SYSTOLIC BP CPTS, BGP DIASTOLIC BP CPTS] or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS] documented during the Report Period.

**Controlled BP**

CRS uses a mean, as described previously. If the mean systolic and diastolic values do not both meet the criteria for controlled, then the value is considered not controlled.

**BP Documented and Controlled BP**

If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented during the Report Period:

- BP Documented: CPT 0001F, CPT 2000F, G9273, G9274 [BGP BP MEASURED CPT], or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS]; OR
- Systolic: CPT 3074F, 3075F, or 3077F [BGP SYSTOLIC BP CPTS] with Diastolic: CPT 3078F, 3079F, or 3080F [BGP DIASTOLIC BP CPTS]. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.
- The following combinations represent BP less than 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F, OR G9273. All other combinations will not be included in the Controlled BP numerator.

**Nephropathy Assessment**

Defined as any of the following:

- Estimated GFR with result during the Report Period, defined as any of the following:
  - Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX
  - LOINC taxonomy
• Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period, defined as any of the following:
  – CPT 82043 WITH 82570
  – LOINC taxonomy
  – Site-populated taxonomy BGP QUANT UACR TESTS

**Note:** Check with the laboratory supervisor that the names added to the taxonomy reflect quantitative test values.

• End Stage Renal Disease diagnosis or treatment defined as any of the following ever:
  – CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]
  – Diagnosis (POV or Problem List entry where the status is not Deleted):
    SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)
  – International Classification of Diseases (ICD) Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6* [BGP ESRD PROCS]

**Qualified Retinal Evaluation**

Either of the following:

• Diabetic retinal exam
• Other eye exam

The following methods are qualifying for this measure:

• Dilated retinal evaluation by an optometrist or ophthalmologist.
• Seven standard fields stereoscopic photos (Early Treatment Diabetic Retinopathy Study [ETDRS]) evaluated by an optometrist or ophthalmologist.
• Any photographic method formally validated\(^1\) to 7 standard fields (ETDRS).

**Diabetic Retinal Exam**

Any of the following during the Report Period:

• Exam code 03 Diabetic Eye Exam (dilated retinal examination or formally validated\(^2\) ETDRS photographic equivalent).

• CPT 2021F Dilated macular exam, 2022F Dilated retinal eye exam, 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist, 2026F Eye imaging formally validated\(^3\) to match the diagnosis from 7 standard field stereoscopic photos, S0620 Routine ophthalmological examination including refraction; new patient, S0621 Routine ophthalmological examination including refraction; established patient, S3000 Diabetic indicator; retinal eye exam, dilated, bilateral [BGP DM RETINAL EXAM CPTS].

• Procedure ICD-9: 95.02 Comprehensive eye exam, 95.03 Extended ophthalmologic work-up [BGP EYE EXAM PROCS]

**Other Eye Exam**

Any of the following during the Report Period:

• Non-DNKA (did not keep appointment) visits to ophthalmology or optometry clinics with an optometrist or ophthalmologist, or visits to formally validated\(^4\) teleophthalmology retinal evaluation clinics. Searches for the following codes in the following order:
  – CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014 [BGP DM EYE EXAM CPTS]
  – Clinic code A2 (Diabetic Retinopathy)\(^5\)
  – Clinic codes 17\(^6\) or 18\(^7\) with Provider code 08, 24, or 79 where the Service Category is not C (Chart Review) or T (Telecommunications)

---

\(^1\) Validation study properly powered and controlled against the ETDRS gold standard (American Telemedicine Association validation category 3).

\(^2\) Ibid.

\(^3\) Ibid.

\(^4\) Validation study properly powered and controlled against the ETDRS gold standard (American Telemedicine Association validation category 3).

\(^5\) Validated photographic (teleretinal) retinal surveillance (American Telemedicine Association validation category 3).

\(^6\) Ophthalmology or Optometry clinic codes (17, 18) cannot be used for non-qualifying photographic DR examination methods\(^2\) unless a dilated retinal examination by an ophthalmologist or optometrist is also accomplished during the same encounter.

\(^7\) Ibid.
**Bilateral Blindness**

- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0* [BGP BILATERAL BLINDNESS DXS]
  - SNOMED data set PXRM BGP BILAT BLINDNESS (Problem List only)
  - SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral (Problem List only)
  - One code from (SNOMED data set PXRM BGP LEFT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left [Problem List only]) AND one code from (SNOMED data set PXRM BGP RIGHT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right [Problem List only])

**Bilateral Eye Enucleation**

- CPT 65091, 65093, 65101, 65103, 65110, 65112, 65114 with modifier 50 or 09950 (50 and 09950 modifiers indicate bilateral)
- Two separate unilateral eye enucleations with visit dates at least 14 days apart with CPT 65091, 65093, 65101, 65103, 65110, 65112, 65114
- Left eye enucleation: Procedure ICD-10: 08B1*** AND right eye enucleation: Procedure ICD-10: 08B0*** on either the same or different dates of service

**Diabetic Foot Exam**

Any of the following:

- Exam code 28 Diabetic Foot Exam, Complete
- Non-DNKA visit with a podiatrist (Provider codes 33, 84, 25)
- Non-DNKA visit to Podiatry Clinic or Diabetic Foot Clinic (Clinic codes 65 and B7)
- CPT 2028F, G9226 [BGP CPT FOOT EXAM]

**Bilateral Foot Amputation**

- CPT 27290.50 through 27295.50, 27590.50 through 27592.50, 27598.50, 27880.50 through 27882.50 (50 modifier indicates bilateral), G9224 [BGP CPT BILAT FOOT AMP]
- Procedure ICD-10: 0Y640ZZ [BGP BILAT FOOT AMP PROCEDURES]
- Diagnosis (Problem List entry where the status is not Deleted): SNOMED data set PXRM BGP ABSENCE OF FOOT BIL (Problem List only)
Two Separate Foot Amputations
Requires either of the following:
- Must have one code that indicates a right foot amputation and one code that indicates a left foot amputation
- Must have two separate occurrences on two different dates of service for one code that indicates a foot amputation on unknown side and one code that indicates either a right or left foot amputation, or two codes that indicate a foot amputation on unknown side

Right-Foot Amputation
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-10: Z89.511, Z89.611, Z89.431, Z89.441 [BGP RIGHT FOOT AMP DXS]
  - SNOMED data set PXRM BGP ABSENCE OF FOOT RIGHT (Problem List only)
- Procedure ICD-10: 0Y620ZZ, 0Y670ZZ, 0Y6F0ZZ, 0Y6C***, 0Y6H***, 0Y6M0Z0 [BGP RIGHT FOOT AMP PROCS]

Left-Foot Amputation
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-10: Z89.512, Z89.612, Z89.432, Z89.442 [BGP LEFT FOOT AMP DXS]
  - SNOMED data set PXRM BGP ABSENCE OF FOOT LEFT (Problem List only)
- Procedure ICD-10: 0Y630ZZ, 0Y680ZZ, 0Y6G0ZZ, 0Y6D***, 0Y6J***, 0Y6N0Z0 [BGP LEFT FOOT AMP PROCS]

Foot Amputation on Unknown Side
- CPT 27290 through 27295, 27590 through 27598, 27880 through 27889 [BGP FOOT AMP CPTS]
- Procedure ICD-9: 84.10, 84.13 through 84.19 [BGP FOOT AMP PROCEDURES]
  - POV ICD-9: V49.73 through V49.77; ICD-10: Z89.439, Z89.449 [BGP UNILATERAL FOOT AMP DXS]

2.1.2.6 Patient List
Diabetic patients with documented tests, if any.
2.1.3 Diabetes: Glycemic Control

2.1.3.1 Owner and Contact
Diabetes Program: Dr. Ann Bullock

2.1.3.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.1.3.3 Denominators
1. GPRAMA: User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. Key denominator for this and all diabetes-related topics that follow.

2. Active Diabetic patients; defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 and older at the beginning of the Report Period
   - Whose first ever DM diagnosis occurred prior to the Report Period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period
   - Never have had a creatinine value greater than (> 5

2.1.3.4 Numerators
1. Hemoglobin A1c documented during the Report Period, \textit{regardless of result}.

2. Poor control: A1c greater than (> 9. (With Denominator 2)

3. Very poor control: A1c greater than or equal to (>=) 12.

4. Poor control: A1c greater than (> 9 and less than (<) 12.

5. Fair control A1c is greater than or equal to (>=) 8 and less than or equal to (<=) 9.

6. A1c is greater than or equal to (>=) 7 and less than (<) 8
7. GPRAMA: Good control: A1c less than (<) 8.
8. A1c less than (<) 7.
9. Without result. Patients with A1c documented but no value.

### 2.1.3.5 Definitions

#### Diabetes

First Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

#### Serum Creatinine

- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

#### A1c

Searches for most recent A1c test with a result during the Report Period. If more than one A1c test is found on the same day or the same visit and one test has a result and the other does not, the test with the result will be used. If both tests have a result, the last test done on the visit will be used.

If an A1c test with a result is not found, CRS searches for the most recent A1c test without a result.

- A1c defined as any of the following:
  - CPT 83036, 83037, 3044F through 3046F, 3047F (old code) [BGP HGBA1C CPTS]
  - LOINC taxonomy
  - Site-populated taxonomy DM AUDIT HGB A1C TAX
- Without result is defined as A1c documented but with no value.
- CPT 3044F represents A1c less than (<) 7 and will be included in the A1c less than (<) 7 and A1c less than (<) 8 numerators.
- CPT 3046F represents A1c greater than (>) 9 and will be included in the A1c greater than (>) 9 numerator.
2.1.3.6 GPRA 2018 Target

**Good Glycemic Control:** During GPRA Year 2018, achieve the target rate of 36.2% for the proportion of patients with diagnosed diabetes who have good glycemic control (defined as A1c less than (<) 7).

2.1.3.7 Patient List

List of diabetic patients with most recent A1c value, if any.

2.1.4 Diabetes: Blood Pressure Control

2.1.4.1 Owner and Contact

Diabetes Program: Dr. Ann Bullock

2.1.4.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.1.4.3 Denominators

1. GPRA: User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

2. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
   - Who are 19 and older at the beginning of the Report Period
   - Whose first ever DM diagnosis occurred prior to the Report Period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period
   - Never have had a creatinine value greater than (> 5

2.1.4.4 Numerators

1. Patients with blood pressure documented during the Report Period.
2. GPRA: Patients with controlled blood pressure, defined as less than 140/90, i.e., the mean systolic value is less than (<) 140 and the mean diastolic value is less than (<) 90.

3. Patients with blood pressure that is not controlled.

2.1.4.5 Definitions

Diabetes
First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Serum Creatinine
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

Note: CPT codes are not included since they do not store the result, which is used in this topic.

Exclusions
When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded:
- Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation)
- Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)

BP Documented
CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of last 2 BPs, or 1 BP if there is only 1 documented. If a visit contains more than one BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) BPs and dividing by 3 (or 2).

If CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 [BGP BP MEASURED CPT, BGP SYSTOLIC BP CPTS, BGP DIASTOLIC BP CPTS] or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS] documented during the Report Period.
Controlled BP

CRS uses a mean, as described previously where BP is less than (<) 140/90. If both the mean systolic and diastolic values do not meet the criteria for controlled, then the value is considered not controlled.

BP Documented and Controlled BP

If CRS is not able to calculate a mean BP from blood pressure measurements, it will search for the most recent of any of the following codes documented on non-ER visits during the Report Period:


- Systolic: CPT 3074F, 3075F, or 3077F [BGP SYSTOLIC BP CPTS] WITH Diastolic: CPT 3078F, 3079F, or 3080F [BGP DIASTOLIC BP CPTS]. The systolic and diastolic values do not have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.

- The following combinations represent BP less than (<) 140/90 and will be included in the Controlled BP numerator: CPT 3074F or 3075F and 3078F or 3079F, OR G9273. All other combinations will not be included in the Controlled BP numerator.

2.1.4.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 52.3% for the proportion of patients with diagnosed diabetes who have achieved BP control (defined as less than (<) 140/90).

2.1.4.7 Patient List

List of diabetic patients with blood pressure value, if any.

2.1.5 Statin Therapy to Reduce Cardiovascular Disease Risk in Patients with Diabetes

2.1.5.1 Owner and Contact

Diabetes Program: Dr. Ann Bullock

2.1.5.2 National Reporting

NATIONAL (included in IHS Performance Report; reported to OMB and Congress)
2.1.5.3 **Denominators**

1. GPRA: User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, ages 40 through 75; and User Pop Diabetic patients age 21 and older with documented CVD or an LDL greater than or equal to \((\geq)\) 190 or hypercholesterolemia. Broken down by age groups.

2. User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, AND at least 2 visits during the Report Period, AND 2 DM-related visits ever, ages 40 through 75.

3. User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, AND at least 2 visits during the Report Period, AND 2 DM-related visits ever, ages 40 through 75 or age 21 and older with documented CVD or an LDL greater than or equal to \((\geq)\) 190 or hypercholesterolemia, including denominator exclusions.

4. Active Diabetic patients; defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, ages 40 through 75; and Active Diabetic patients age 21 and older with documented CVD or an LDL greater than or equal to \((\geq)\) 190 or hypercholesterolemia. Broken down by age groups.

5. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, AND at least 2 visits during the Report Period, AND 2 DM-related visits ever, ages 40 through 75.

6. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, AND at least 2 visits during the Report Period, AND 2 DM-related visits ever, ages 40 through 75 or age 21 and older with documented CVD or an LDL greater than or equal to \((\geq)\) 190 or hypercholesterolemia, including denominator exclusions.

2.1.5.4 **Numerator**

1. GPRA: Patients who are statin therapy users during the Report Period or who receive an order (prescription) to receive statin therapy at any point during the Report Period.

2. Patients with any of the listed denominator exclusions (with Denominators 3 and 6).

   A. Patients with documented allergy, intolerance, or other adverse effect to statin medication.
2.1.5.5 Definitions

Diabetes
First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Cardiovascular Disease (CVD)
Cardiovascular Disease (CVD) diagnosis defined as any of the following:

- Coronary Heart Disease (CHD) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: 410.0 through 413.*, 414.0 through 414.9, 429.2; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9, Z95.5 [BGP CHD DXS]
    - SNOMED data set PXRM ISCHEMIC HEART DISEASE (Problem List only)

- Acute Myocardial Infarction (AMI) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: 410.0* through 410.9*, 412, 429.79; ICD-10: I21.*, I22.*, I23.*, I25.2 [BGP AMI DXS PAMT]
    - SNOMED data set PXRM BGP AMI (Problem List only)

- Ischemic Vascular Disease (IVD) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - SNOMED data set PXRM BGP IVD (Problem List only)

- Ischemic Stroke or Transient Ischemic Attack (TIA) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 437.1, 438.*, V12.54; ICD-10: G45.0 through G45.2, G45.8, G45.9, G46.0 through G46.8, I63.*, I69.*, Z86.73 [BGP TIA DXS]

SNOMED data set PXRM BGP ISCHEMIC STROKE TIA (Problem List only)

- Atherosclerosis and Peripheral Arterial Disease defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - SNOMED data set PXRM BGP ARTERIAL DISEASE (Problem List only)

- Coronary Artery Bypass Graft (CABG) Procedure defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
    - SNOMED data set PXRM BGP CABG (Problem List only)
    - CPT 33510 through 33514, 33516 through 33519, 33521 through 33523, 33530, 33533 through 33536, 33572, 35600, S2205 through S2209 [BGP CABG CPTS]

- Percutaneous Coronary Interventions (PCI) Procedure defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - POV ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
    - SNOMED data set PXRM BGP PCI (Problem List only)
    - CPT 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
- **Carotid Intervention defined as any of the following:**
  - Procedure ICD-9: 00.61 through 00.65, 38.02, 38.12, 38.22, 38.30 through 38.32, 38.42, 39.22, 39.28, 88.41; ICD-10: 03*H***, 03*J***, 03*K***, 03*L***, 03*M***, 03*N***, 0G*6***, 0G*7***, 0G*8***, B3060ZZ, B3061ZZ, B306YZZ, B3070ZZ, B3071ZZ, B307YZZ, B3080ZZ, B3081ZZ, B308YZZ, B3160ZZ, B3161ZZ, B316YZZ, B3170ZZ, B3171ZZ, B317YZZ, B3180ZZ, B3181ZZ, B318YZZ
  - Diagnosis (Problem List entry where the status is not Inactive or Deleted):
    - SNOMED data set PXRM BGP CAROTID INTERVENTION

- **Coronary Artery Bypass Graft (CABG) Procedure defined as any of the following:**
  - POV ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
  - CPT 33510 through 33514, 33516 through 33519, 33521 through 33523, 33530, 33533 through 33536, 33572, 35600, S2205 through S2209 [BGP CABG CPTS]
  - SNOMED data set PXRM BGP CABG (Problem List only)

- **Percutaneous Coronary Interventions (PCI) Procedure defined as any of the following:**
  - POV ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
  - CPT 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
  - Procedure ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05 (old code), 36.06 through 36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734** [BGP PCI CM PROCS]
  - SNOMED data set PXRM BGP PCI (Problem List only)

- **Carotid Intervention defined as any of the following:**
– Procedure ICD-9: 00.61 through 00.65, 38.02, 38.12, 38.22, 38.30 through 38.32, 38.42, 39.22, 88.41; ICD-10: 03*H***, 03*J***, 03*K***, 03*L***, 03*M***, 03*N***, 0G*6***, 0G*7***, 0G*8***, B3060ZZ, B3061ZZ, B306YZZ, B3070ZZ, B3071ZZ, B307YZZ, B3080ZZ, B3081ZZ, B308YZZ, B3090ZZ, B3091ZZ, B309YZZ, B3100ZZ, B3101ZZ, B310YZZ, B3110ZZ, B3111ZZ, B311YZZ, B3120ZZ, B3121ZZ, B312YZZ
– SNOMED data set PXRM BGP CAROTID INTERVENTION (Problem List only)
  • Other Revascularization:
    – CPT 37220, 37221, 37224-37231 [BGP REVASCULARIZATION CPTS]

**LDL**

For LDL greater than or equal to (>=) 190, CRS will look for any test at any time with result greater than or equal to (>=) 190. LDL defined as any of the following:

- LOINC taxonomy
- Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

**Hypercholesterolemia**

Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):

- POV ICD-9: 272.0; ICD-10: E78.00, E78.01
- SNOMED data set PXRM BGP HYPERCHOLESTEROLEMIA (Problem List only)

**Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

- Patients with documented allergy, intolerance, or other adverse effect to statin medication.
- Patients who have an active diagnosis of pregnancy or who are breastfeeding.
- Patients with a diagnosis of cirrhosis of the liver or liver disease during the Report Period or the year prior to the Report Period.
- Patients who are receiving palliative care during the Report Period.
- Patients with end-stage renal disease (ESRD).
- Patients with diabetes whose most recent LDL result is less than (<) 70 and who have never had an LDL result greater than or equal to (>=) 190 and who are not taking statin therapy.
- Patients with Hepatitis A or Hepatitis B.

**Contraindications to Statins**
Contraindications to Statins defined as any of the following:

- Pregnancy: See the definition that follows
- Breastfeeding: See the definition that follows
- Acute Alcoholic Hepatitis: Defined as POV or Problem List entry where the status is not Inactive or Deleted during the Report Period:
  - ICD-9: 571.1; ICD-10: K70.10, K70.11 [BGP ALCOHOL HEPATITIS DXS]
  - SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
- NMI refusal for any statin at least once during the Report Period.

**Adverse Drug Reaction or Documented Statin Allergy**
Defined as any of the following:

- ALT or AST greater than 3 times the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period
- Creatine Kinase (CK) levels greater than 10 times ULN or CK greater than 10,000 IU/L during the Report Period
- Myopathy or Myalgia, defined as any of the following during the Report Period:
  - POV or Problem List entry where the status is not Inactive or Deleted
  ICD-9: 359.0 through 359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80 through M60.9, M79.1 [BGP MYOPATHY/MYALGIA]; SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)
- Rhabdomyolysis, defined as any of the following during the Report Period:
  Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  - ICD-10: M62.82, T79.6XX*
  - SNOMED data set PXRM BGP Rhabdomyolysis (Problem List only)
- Any of the following occurring ever:
  - POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.9 [BGP ADV EFF CARDIOVASC NEC]
- “Statin” or “Statins” entry (except "Nystatin") in ART (Patient Allergies File)
- “Statin” or “Statins” (except "Nystatin") contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR STATIN

**Pregnancy Definition**

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period
- At least one visit during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following:

– Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

– CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

– Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

• Miscarriage definition:
- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion definition:**
- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Breastfeeding Definition**
Any of the following documented during the Report Period:
- POV ICD-9: V24.1; ICD-10: O91.03, O91.13, O91.23, O92.03, O92.13, O92.5, O92.70, O92.79, Z39.1 [BGP BREASTFEEDING DXS]

**Cirrhosis of the Liver**
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 571.2, 571.5, 571.6; ICD-10: K70.30, K70.31, K71.7, K74.3 through K74.5, K74.60, K74.69, P78.81 [BGP CIRRHOSIS OF LIVER DXS]
  - SNOMED data set PXRM BGP CIRRHOSIS (Problem List only)

**Liver Disease Definition**
Diagnosis (POV or Problem List entry where the status is not Deleted):
- ICD-9: ICD-9: 070.41 through 070.71, 570, 571.0, 571.2 through 571.9, 572.4, 572.8; ICD-10: B17.*, B18.2 through B19.0, B19.20, B19.21, B19.9, K70.0 through K74.69, K75.4, O98.41* [BGP LIVER DISEASE DXS]
- SNOMED data set PXRM BGP LIVER DISEASE (Problem List only)

**Palliative Care**
- POV ICD-9: V66.7; ICD-10: Z51.5 [BGP PALLIATIVE CARE DXS]
ESRD

End Stage Renal Disease diagnosis or treatment defined as any of the following ever:

- CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  - SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)

- Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6* [BGP ESRD PROCS]

Hepatitis A Definition

Diagnosis (POV or Problem List entry where the status is not Deleted):

- ICD-9: 070.0, 070.1; ICD-10: B15.* [BGP HEPATITIS A EVIDENCE]

- SNOMED data set PXRM BGP HEPATITIS A (Problem List only)

Hepatitis B Definition

Diagnosis (POV or Problem List entry where the status is not Deleted):

- ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B18.0, B18.1, B19.1*, Z22.51 [BGP HEPATITIS B EVIDENCE]

- SNOMED data set PXRM BGP HEPATITIS B (Problem List only)

Statins Numerator Logic

- Statin Therapy Users
  - CPT 4013F

- Statin Medication Codes
  - Defined with medication taxonomy BGP PQA STATIN MEDS.
  - Statin medications are: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

- Statin Combination Products

Patients must have an active prescription for statin therapy during the Report Period. This includes patients who receive an order during the Report Period, or prior to the Report Period with enough days’ supply to take them into the Report Period.

Rx Days’ Supply greater than or equal to (>=) (Report Period Begin Date - Prescription Date)

Active prescriptions include active outside medications, defined as V Med entry at any time with EHR OUTSIDE MED field not blank and DATE DISCONTINUED field blank.

2.1.5.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 37.5% for the proportion of patients with diagnosed diabetes and cardiovascular disease who are on statin therapy.

2.1.5.7 Patient List

List of diabetic patients with statin therapy or exclusion, if any.

2.1.6 Diabetes: Nephropathy Assessment

2.1.6.1 Owner and Contact

Diabetes Program: Dr. Ann Bullock

2.1.6.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.1.6.3 Denominators

1. GPRA: User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

2. Active Diabetic patients; defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits in the past year, and two DM-related visits ever.

3. Active Adult Diabetic patients, defined by meeting the following criteria:
• Who are 19 and older at the beginning of the Report Period
• Whose first ever DM diagnosis occurred prior to the Report Period
• Who had at least two DM related visits ever
• With at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period
• Never have had a creatinine value greater than (> ) 5

2.1.6.4 Numerators
1. GPRA: Patients with nephropathy assessment, defined as an estimated Glomerular Filtration Rate (GFR) with result and a Urine Albumin-to-Creatinine Ratio (UACR) during the Report Period or with evidence of diagnosis or treatment of end-stage renal disease (ESRD) at any time before the end of the Report Period.

2.1.6.5 Definitions
Diabetes
First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Serum Creatinine
• Site-populated taxonomy DM AUDIT CREATININE TAX, or
• LOINC taxonomy

Note: CPT codes are not included since they do not store the result, which is used in this topic.

Estimated GFR
• Site-populated taxonomy BGP GPRA ESTIMATED GFR TAX or
• LOINC taxonomy

Urine Albumin-to-Creatinine Ratio
• CPT 82043 WITH 82570
• LOINC taxonomy, or
• Site-populated taxonomy BGP QUANT UACR TESTS
Note: Check with your laboratory supervisor to confirm that the names you add to your taxonomy reflect quantitative test values.

**ESRD**
- End Stage Renal Disease diagnosis or treatment defined as any of the following ever:
  - CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]
  - Diagnosis (POV or Problem List entry where the status is not Deleted):
    SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)
  - Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6.* [BGP ESRD PROCS]

**2.1.6.6 GPRA 2018 Target**
During GPRA Year 2018, achieve the target rate of 34.0% for the proportion of patients with diagnosed diabetes who are assessed for nephropathy.

**2.1.6.7 Patient List**
List of diabetic patients with nephropathy assessment, if any.

**2.1.7 Diabetic Retinopathy**

**2.1.7.1 Owner and Contact**
Diabetes Program: Dr. Mark Horton

**2.1.7.2 National Reporting**
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)
2.1.7.3 Denominators

1. GPRA: User Pop Diabetic patients, defined as User Population patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever, without a documented history of bilateral blindness or bilateral eye enucleation.

2. Active Diabetic patients; defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits in the past year, and two DM-related visits ever, without a documented history of bilateral blindness or bilateral eye enucleation.

3. Active Adult Diabetic patients, without a documented history of bilateral blindness or bilateral eye enucleation, defined by meeting the following criteria:
   - Who are 19 and older at the beginning of the Report Period
   - Whose first ever DM diagnosis occurred prior to the Report Period
   - Who had at least two DM related visits ever
   - With at least one encounter with DM POV in a primary clinic with a primary provider during the Report Period
   - Never have had a creatinine value greater than (> 5

2.1.7.4 Numerators

1. GPRA: Patients receiving a qualified retinal evaluation during the Report Period.

   **Note:** This numerator does *not* include refusals.

   A. Patients receiving diabetic retinal exam during the Report Period.
   B. Patients receiving other eye exams during the Report Period.
   C. Patients with a validated teleretinal\(^8\) visit during the Report Period.
   D. Patients with an Ophthalmology visit during the Report Period.
   E. Patients with an Optometry visit during the Report Period.

---

\(^8\) Validation study properly powered and controlled against the ETDRS gold standard (American Telemedicine Association validation category 3).
2.1.7.5 Definitions

Diabetes
First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Serum Creatinine
Either of the following:
- Site-populated taxonomy DM AUDIT CREATININE TAX
- LOINC taxonomy

**Note:** CPT codes are not included since they do not store the result, which is used in this topic.

Qualified Retinal Evaluation
- Diabetic retinal exam
- Other eye exam.

The following methods are qualifying for this measure:
- Dilated retinal evaluation by an optometrist or ophthalmologist.
- Seven standard fields stereoscopic photos (ETDRS) evaluated by an optometrist or ophthalmologist.
- Any photographic method formally validated\(^9\) to seven standard fields (ETDRS).

Diabetic Retinal Exam
Any of the following during the Report Period:
- Exam code 03 Diabetic Eye Exam (dilated retinal examination or formally validated\(^10\) ETDRS photographic equivalent)

---

\(^9\) Ibid.

\(^10\) Validation study properly powered and controlled against the ETDRS gold standard (American Telemedicine Association validation category 3).
• CPT 2021F Dilated macular exam, 2022F Dilated retinal eye exam, 2024F Seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist, 2026F Eye imaging formally validated\textsuperscript{11} to match the diagnosis from 7 standard field stereoscopic photos, S0620 Routine ophthalmological examination including refraction; new patient, S0621 Routine ophthalmological examination including refraction; established patient, or S3000 Diabetic indicator; retinal eye exam, dilated, bilateral [BGP DM RETINAL EXAM CPTS].

• Procedure ICD-9: 95.02 Comprehensive eye exam, 95.03 Extended ophthalmologic work-up [BGP EYE EXAM PROCS]

Other Eye Exam

• Non-DNKA (did not keep appointment) visits to ophthalmology or optometry clinics with an optometrist or ophthalmologist, or visits to formally validated\textsuperscript{12} teleophthalmology retinal evaluation clinics. Searches for the following codes in the following order:
  – CPT 67028, 67038 (old code), 67039, 67040, 92002, 92004, 92012, 92014 [BGP DM EYE EXAM CPTS]
  – Clinic code A2 (Diabetic Retinopathy)\textsuperscript{13}
  – Clinic codes 17\textsuperscript{14} or 18\textsuperscript{15} with Provider code 08, 24, or 79 where the Service Category is not C (Chart Review) or T (Telecommunications).

JVN Visit

• Clinic code A2

Ophthalmology Visit

• Clinic code 17 with Provider code 79 where the Service Category is not C (Chart Review) or T (Telecommunications)

Optometry Visit

• Clinic code 18 with Provider codes 08 or 24 where the Service Category is not C (Chart Review) or T (Telecommunications)

Bilateral Blindness

• Diagnosis (POV or Problem List entry where the status is not Deleted):

\textsuperscript{11} Ibid.

\textsuperscript{12} Ibid.

\textsuperscript{13} Validated photographic (teleretinal) retinal surveillance (American Telemedicine Association validation category 3).

\textsuperscript{14} Ophthalmology or Optometry clinic codes (17, 18) cannot be used for non-qualifying photographic DR examination methods\textsuperscript{9} unless a dilated retinal examination by an ophthalmologist or optometrist is also accomplished during the same encounter.

\textsuperscript{15} Ibid.
ICD-9: 369.01, 369.03, 369.04; ICD-10: H54.0* [BGP BILATERAL BLINDNESS DXS]

SNOMED data set PXRM BGP BILAT BLINDNESS (Problem List only)

SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Bilateral (Problem List only)

One code from (SNOMED data set PXRM BGP LEFT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Left [Problem List only]) AND one code from (SNOMED data set PXRM BGP RIGHT EYE BLIND (Problem List only) OR SNOMED data set PXRM BGP BLINDNESS UNSPECIFIED with Laterality equal to Right [Problem List only])

**Bilateral Eye Enucleation**

- CPT 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114 with modifier 50 or 09950 (50 and 09950 modifiers indicate bilateral)
- Two separate unilateral eye enucleations with visit dates at least 14 days apart with CPT 65091, 65093, 65101, 65103, 65105, 65110, 65112, 65114
- Left eye enucleation: Procedure ICD-10: 08B1*** AND right eye enucleation: Procedure ICD-10: 08B0*** on either the same or different dates of service

**2.1.7.6 GPRA 2018 Target:**

During GPRA Year 2018, achieve the target rate of 49.7% for the proportion of patients with diagnosed diabetes who receive an annual retinal examination.

**2.1.7.7 Patient List**

List of diabetic patients with qualified retinal evaluation, if any.

**2.1.8 Diabetic Access to Dental Services**

**2.1.8.1 Owner and Contact**

Dental Program: Timothy L. Lozon, D.D.S., Chris Halliday, DDS, MPH

**2.1.8.2 National Reporting**

Not reported nationally
2.1.8.3 Denominators

1. Active Diabetic patients; defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

2.1.8.4 Numerators

1. Patients with a documented dental visit during the Report Period.

Note: This numerator does not include refusals.

2.1.8.5 Definitions

Diabetes

First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Documented Dental Visit

For non-PRC visits, searches for any of the following:

- RPMS Dental code 0000, 0190, 0191
- ADA CDT code D0190, D0191
- Exam code 30
- POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21 [BGP DENTAL EXAM DXS]

For PRC dental visits, searches for any visit with an American Dental Association (ADA) code. PRC visit defined as Type code of C in Visit file.

2.1.8.6 Patient List

List of diabetic patients and documented dental visit, if any.

2.2 Dental Group

2.2.1 Access to Dental Services

2.2.1.1 Owner and Contact

Dental Program: Timothy L. Lozon, D.D.S., Chris Halliday, DDS, MPH
2.2.1.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.2.1.3 Denominators

1. GPRA: User Population patients. Broken down by age groups: 0 through 2, 3 through 5, 0 through 5, 6 through 9, 10 through 12, 13 through 15, 16 through 21, 22 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older.

2.2.1.4 Numerators

1. GPRA: Patients with documented dental visit during the Report Period.

   Note: This numerator does not include refusals.

2.2.1.5 Definitions

Documented Dental Visit

For non-PRC dental visits, searches for any of the following:

- RPMS Dental codes 0000, 0190, 0191
- ADA CDT code D0190, D0191
- Exam 30
- POV ICD-9: V72.2; ICD-10: Z01.20, Z01.21 [BGP DENTAL EXAM DXS]

For PRC dental visits, searches for any visit with an ADA code. PRC visit defined as Type code of C in Visit file.

2.2.1.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 27.2% for the proportion of patients who receive dental services.

2.2.1.7 Patient List

List of patients with documented dental visit and date.

2.2.2 Dental Sealants

2.2.2.1 Owner and Contact

Dental Program: Timothy L. Lozon, D.D.S., Chris Halliday, DDS, MPH
2.2.2.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.2.2.3 Denominators

1. GPRA: User Population patients ages 2 through 15. Broken down by age groups: 2, 3 through 5, 6 through 9, 10 through 12, and 13 through 15.

2.2.2.4 Numerators

1. GPRA: Patients with at least one or more intact dental sealants.

2. Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of dental sealants during the Report Period. Broken down by age group 2 through 15.

   **Note:** This numerator does *not* include refusals.

2.2.2.5 Definitions

Intact Dental Sealant

- Any of the following documented during the Report Period:
  - RPMS Dental codes 1351, 1352, 1353
  - ADA CDT codes D1351, D1352, D1353
- OR any of the following documented during the past 3 years from the end of the Report Period:
  - IHS Dental Tracking code 0007

If both RPMS Dental and ADA CDT codes are found on the same visit, only the RPMS Dental code will be counted. IHS Dental Tracking code 0007 will be counted regardless of whether another sealant code is submitted on the same visit or date of service.

For the count measure, only two sealants per tooth and only one repair (RPMS Dental code 1353 or ADA CDT D1353) per tooth will be counted during the Report Period. Each tooth is identified by the data element Operative Site in RPMS.

2.2.2.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 16.0% for the proportion of patients with at least one or more intact dental sealants.
2.2.2.7 Patient List
List of patients with intact dental sealants.

2.2.3 Topical Fluoride

2.2.3.1 Owner and Contact
Dental Program: Timothy L. Lozon, D.D.S., Chris Halliday, DDS, MPH

2.2.3.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.2.3.3 Denominators
1. GPRA: User Population patients ages 1 through 15. Broken down by age groups: 1 through 2, 3 through 5, 1 through 5, 6 through 9, 10 through 12, and 13 through 15.

2.2.3.4 Numerators
1. GPRA: Patients who received one or more topical fluoride applications during the Report Period.
2. Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of patients with at least one topical fluoride treatment during the Report Period. Broken down by age group 1 through 15.

**Note:** This numerator does not include refusals.
3. Count only (no percentage comparison to denominator). For patients meeting the User Population definition, the total number of appropriate topical fluoride applications based on a maximum of four per patient per year.

2.2.3.5 Definitions

**Topical Fluoride Application**
Defined as any of the following:
- RPMS Dental codes 1201 (old code), 1203 (old code), 1204 (old code), 1205 (old code), 1206, 1208, 5986
• ADA CDT codes D1201 (old code), D1203 (old code), D1204 (old code), D1205 (old code), D1206, D1208, D5986, 99188 [BGP CPT TOPICAL FLUORIDE]

• POV ICD-9: V07.31; ICD-10: Z29.3 [BGP TOPICAL FLUORIDE DXS]

For the count measure, a maximum of one application per patient per visit is allowed. A maximum of four topical fluoride applications are allowed per patient per year for the applications measure.

2.2.3.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 30.0% for the proportion of patients who received one or more topical fluoride applications.

2.2.3.7 Patient List

List of patients who received at least one topical fluoride application during Report Period.

2.3 Immunization Group

2.3.1 Influenza

2.3.1.1 Owner and Contact

Epidemiology Program: Amy Groom, MPH

2.3.1.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.3.1.3 Denominators

1. Active Clinical patients broken down by age groups: 6 months through 17 years, 18 years and older, 18 through 49 years, 50 through 64 years, 65 years and older.

2. Active Clinical patients ages 18 through 49 years and considered high risk for influenza.

3. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and at least two DM-related visits ever.
4. User Population patients broken down by age groups: 6 months through 17 years, 18 years and older, 18 through 49 years, 50 through 64 years, 65 years and older.

   A. GPRA: Active Clinical patients ages 6 months to 17 years.
   B. GPRA: Active Clinical patients ages 18 years and older.

5. User Population patients ages 18 through 49 years and considered high risk for influenza

2.3.1.4 Numerators

1. GPRA: Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.

   Note: The only refusals included in this numerator are not medically indicated (NMI) refusals.

   A. Patients with a contraindication or a documented NMI refusal.

2.3.1.5 Definitions

Diabetes

First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Influenza Vaccine

Any of the following during the Report Period:

- Immunization (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186
- POV ICD-9: V04.8 (old code), V04.81 not documented with 90663, 90664, 90666 through 90668, 90470, G9141 or G9142, or V06.6 not documented with 90663, 90664, 90666 through 90668, 90470, G9141 or G9142 [BGP FLU IZ DX V04.8]
- CPT 90630, 90653 through 90662, 90672 through 90674, 90682, 90685 through 90688, 90724 (old code), 90756, G0008, G8108 (old code) [BGP CPT FLU]

Contraindication to Influenza Vaccine

Any of the following documented at any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Anaphylaxis”
- PCC NMI Refusal

**Persons Considered High Risk for Influenza**

Those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following [BGP HIGH RISK FLU DXS]:

- HIV Infection: ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08; ICD-10: B20, B52.0, B97.35, Z21
- Diabetes: ICD-9: 250.00 through 250.93; ICD-10: E08.2*, E09.2*, E10.* through E13.*
- Rheumatic Heart Disease: ICD-9: 393. through 398.99; ICD-10: I05.* through I09.*
- Hypertensive Heart Disease: ICD-9: 402.00 through 402.91; ICD-10: I11.*
- Hypertensive Heart or Renal Disease: ICD-9: 404.00 through 404.93; ICD-10: I13.*
- Ischemic Heart Disease: ICD-9: 410.00 through 414.9; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9
- Pulmonary Heart Disease: ICD-9: 415.0 through 416.9; ICD-10: I26.* through I27.*
- Other Endocardial Heart Disease: ICD-9: 424.0 through 424.9; ICD-10: I34.* through I39
- Cardiomyopathy: ICD-9: 425.0 through 425.9; ICD-10: I42.*, I43
- Congestive Heart Failure: ICD-9: 428.0 through 428.9, 429.2; ICD-10: I50.1, I50.20, I50.22 through I50.32 through I50.42 through I50.9
- Chronic Bronchitis: ICD-9: 491.0 through 491.9; ICD-10: J41.*, J42
- Emphysema: ICD-9: 492.0 through 492.8; ICD-10: J43.*
- Asthma: ICD-9: 493.00 through 493.91; ICD-10: J45.21 through J45.902
- Bronchiectasis, CLD, COPD: ICD-9: 494.0 through 496.; ICD-10: J44.*, J47.*
- Pneumoconioses: ICD-9: 500 through 505; ICD-10: J60 through J64, J66.8 through J67.6, J67.8 through J67.9
- Chronic Liver Disease: ICD-9: 571.0 through 571.9; ICD-10: K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
- Nephrotic Syndrome: ICD-9: 581.0 through 581.9; ICD-10: N02.*, N04.*, N08
- Renal Failure: ICD-9: 585.6, 585.9; ICD-10: N18.6 through N19
• Transplant: ICD-9: 996.80 through 996.89; ICD-10: T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
• Kidney Transplant: ICD-9: V42.0 through V42.89
• Chemotherapy: ICD-9: V58.1; ICD-10: Z51.11, Z51.12
• Chemotherapy follow-up: ICD-9: V67.2; ICD-10: Z08

2.3.1.6 GPRA 2018 Target

Children: During GPRA Year 2018, achieve the target rate of 20.6% for the proportion of patients age 6 months through 17 years who receive an influenza immunization.

Adults: During GPRA Year 2018, achieve the target rate of 18.8% for the proportion of patients age 18 years and older who receive an influenza immunization.

2.3.1.7 Patient List

List of patients with Influenza code, if any.

2.3.2 Adult Immunizations

2.3.2.1 Owner and Contact

Epidemiology Program: Amy Groom, MPH

2.3.2.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.3.2.3 Denominators

1. Active Clinical patients ages 19 through 59.
2. Active Clinical patients ages 60 through 64.
3. Active Clinical patients ages 65 and older.
4. Active Clinical patients ages 19 and older.
5. Active Clinical patients ages 18 through 64 years and considered high risk for pneumococcal.
6. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at two visits during the Report Period, and two DM-related visits ever.

7. User Population patients ages 19 through 59 years.

8. User Population patients ages 60 through 64 years.

9. User Population patients ages 65 years and older.

10. GPRA: User Population patients ages 19 and older.

11. User Population patients ages 18 through 64 years and considered high risk for pneumococcal.

12. Active Clinical patients ages 18 years and older. Broken down by age groups: 18 through 64.

13. User Population patients ages 18 years and older. Broken down by age groups: 18 through 64.

2.3.2.4 Numerators

Note: The only refusals included in all numerators are documented NMI refusals.

1. Patients who have received 1 dose of Tdap or Td in the past 10 years, including contraindications (with Denominators 1 through 3, 7 through 9, 12 and 13).

2. Patients who have received 1 dose of Tdap ever, including contraindications (with Denominators 1 through 3, 7 through 9, 12 and 13).

3. Patients with influenza vaccine documented during the Report Period or with a contraindication documented at any time before the end of the Report Period (with Denominators 1 through 3 and 7 through 9).

4. Patients who have received 1 dose of Zoster ever, including contraindications (with Denominators 2, 3, 8, and 9).

5. Patients with Pneumococcal Polysaccharide (PPSV23) or Pneumococcal Conjugate (PCV13) vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of PPSV23/PCV13 vaccine after the age of 65 or a dose of PPSV23/PCV13 vaccine in the past 5 years (with Denominators 3 and 9).
6. Patients who received A) a dose of PCV13 on or after age 19 years or a contraindication to PCV13 OR who received a dose of PPSV23 in the past year AND B) a dose of PPSV23 on or after age 65 years or a dose of PPSV23 in the past 5 years or a contraindication to PPSV23 OR who received a dose of PCV13 in the past year (with Denominator 3 and 9).

7. Patients who received a dose of PCV13 on or after age 19 years or a contraindication to PCV13 OR who received a dose of PPSV23 in the past year (with Denominator 3 and 9).

8. Patients who received a dose of PPSV23 on or after age 65 years or a dose of PPSV23 in the past 5 years or a contraindication to PPSV23 OR who received a dose of PCV13 in the past year (with Denominator 3 and 9).

9. Patients who received a dose of PPSV23 AND a dose of PCV13 on or after age 65 years (with Denominator 3 and 9).

10. Patients who have received a dose of PPSV23 on or after age 65 years (with Denominator 3 and 9).

11. Patients who have received a dose of PCV13 on or after age 65 years (with Denominator 3 and 9).

12. Patients with Pneumococcal Polysaccharide (PPSV23) or Pneumococcal Conjugate (PCV13) vaccine or contraindication documented at any time before the end of the Report Period (with Denominator 3).

13. Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period), including contraindications (with Denominators 1 and 7).

14. Patients who have received the 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever), including contraindications (with Denominators 1 and 7).

15. Patients who have received the 1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever), including contraindications (with Denominators 2 and 8).

16. Patients who have received the 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever), including contraindications (with Denominators 2 and 8).

17. Patients who have received the 1:1:1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever, 1 Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate [PCV13]), including contraindications (with Denominator 3 and 9)
18. Patients who have received the 1:1:1:1:1* combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 influenza during the Report Period, 1 Zoster ever, 1 up-to-date Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate [PCV13]), including contraindications (with Denominators 3 and 9).

19. Patients who have received the 1:1:1:1 combination (i.e. 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever, 1 Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate), including contraindications (with Denominator 3 and 9).

20. Patients who have received the 1:1:1:1* combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever, 1 up-to-date Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate [PCV13]), including contraindications (with Denominators 3 and 9).

21. GPRA: Patients who have received all age-appropriate immunization combinations (with Denominators 4 and 10).

22. Patients with Pneumococcal Polysaccharide vaccine (PPSV23) vaccine or contraindication documented ever and, if patient is older than 65 years, either a dose of PPSV23 after the age of 65 or a dose of PPSV23 in the past 5 years (with Denominators 5, 6 and 11).

2.3.2.5 Definitions

Diabetes
First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Age-appropriate Immunization Combinations
• Ages 19-59: 1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever)
• Ages 60-64: 1:1:1 combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever)
• Ages 65+: 1:1:1:1* combination (i.e., 1 Tdap/Td in the past 10 years, 1 Tdap ever, 1 Zoster ever, 1 up-to-date Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate [PCV13])

Up-to-date Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate (PCV13) is defined as: Patients who received A) a dose of PCV13 on or after age 19 years OR who received a dose of PPSV23 in the past year AND B) a dose of PPSV23 on or after age 65 years OR a dose of PPSV23 in the past 5 years OR who received a dose of PCV13 in the past year.
In select combination measures, 1 Pneumococcal Polysaccharide vaccine (PPSV23)/Pneumo conjugate (PCV13) is defined as: Patients with Pneumococcal Polysaccharide vaccine (PPSV23) or contraindication documented ever and, if patient is older than 65 years, either a dose of PPSV23 after the age of 65 or a dose of PPSV23 in the past 5 years or a dose of pneumococcal conjugate vaccine in the last year.

**Pneumococcal Polysaccharide (PPSV23) Vaccine**

Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 33, 109
- POV ICD-9: V03.82 [BGP PNEUMO IZ DXS]
- CPT 90732, G0009, G8115 (old code), G9279 [BGP PNEUMO IZ CPT DEV]

**Pneumococcal Conjugate (PCV13)**

Any of the following documented any time before the end of the Report Period:

- Immunization (CVX) codes 100, 133, 152
- CPT 90669, 90670 [BGP PNEUMO CONJUGATE CPTS]

**Pneumococcal Contraindication**

Any of the following documented any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Anaphylaxis”
- PCC NMI Refusal

**Persons Considered High Risk for Pneumococcal**

Those who have two or more visits in the past 3 years with a POV or Problem diagnosis of any of the following [BGP HIGH RISK PNEUMO DXS]:

- HIV Infection: ICD-9: 042, 042.0 through 043.9 (old codes), 044.9 (old code), 079.53, V08; ICD-10: B20, B52, B97.35, Z21
- Diabetes: ICD-9: 250.00 through 250.93; ICD-10: E08.2*, E09.2*, E10.* through E13.*
- Chronic alcoholism: ICD-9: 303.90, 303.91; ICD-10: F10.20, F10.220 through F10.29
- Congestive Heart Failure: ICD-9: 428.0 through 428.9, 429.2; ICD-10: I50.1, I50.20, I50.22 through I50.30, I50.32 through I50.40, I50.42 through I50.9
- Emphysema: ICD-9: 492.0 through 492.8; ICD-10: J43.*
- Asthma: ICD-9: 493.00 through 493.91; ICD-10: J45.21 through J45.902
• Pneumoconioses: ICD-9: 501. through 505.; ICD-10: J60 through J64, J66.8 through J67.6, J67.8 through J67.9
• Chronic Liver Disease: ICD-9: 571.0 through 571.9; ICD-10: K70.11 through K70.41, K73.0 through K74.5, K74.69, K75.81
• Nephrotic Syndrome: ICD-9: 581.0 through 581.9; ICD-10: N02.*, N04.*, N08
• Renal Failure: ICD-9: 585.6, 585.9; ICD-10: N18.6 through N19
• Injury to spleen: ICD-9: 865.00 through 865.19
• Transplant: ICD-9: 996.80 through 996.89; ICD-10: T86.00 through T86.819, T86.83*, T86.850 through T86.899, Z48.21 through Z48.280, Z48.290, Z94.0 through Z94.4, Z94.6, Z94.81 through Z94.84, Z95.3, Z95.4
• Kidney Transplant: ICD-9: V42.0 through V42.89
• Chemotherapy: ICD-9: V58.1; ICD-10: Z51.11, Z51.12
• Chemotherapy follow-up: ICD-9: V67.2; ICD-10: Z08

**Tdap Immunization:**
Any of the following documented during the applicable time frame:
- Immunization (CVX) code: 115
- CPT 90715 [BGP CPT TDAP/TD]

**Tdap Contraindication**
Any of the following documented any time before the end of the Report Period:
- Immunization Package contraindication of "Anaphylaxis"
- PCC NMI Refusal

**Td Immunization**
Any of the following documented in the past 10 years:
- Immunization (CVX) code 9, 113, 138, 139
- POV ICD-9: V06.5 [BGP TD IZ DXS]
- CPT 90714, 90718 [BGP CPT TDAP/TD]

**Td Contraindication**
Any of the following documented any time before the end of the Report Period:
- Immunization Package contraindication of "Anaphylaxis"
- PCC NMI Refusal
**Influenza Vaccine**

Any of the following during the Report Period:

- Immunization (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186
- POV ICD-9: V04.8 (old code), V04.81 not documented with 90663, 90664, 90666 through 90668, 90470, G9141 or G9142, or V06.6 not documented with 90663, 90664, 90666 through 90668, 90470, G9141 or G9142 [BGP FLU IZ DX V04.8]
- CPT 90630, 90653 through 90662, 90672 through 90674, 90682, 90685 through 90688, 90724 (old code), 90756, G0008, G8108 (old code) [BGP CPT FLU]

**Contraindication to Influenza Vaccine**

Any of the following documented at any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Anaphylaxis”
- PCC NMI Refusal

**Zoster Vaccine**

Either one dose of Zostavax or two doses of Shingrix documented ever:

- Zostavax:
  - Immunization (CVX) codes 121, 188CPT 90736 [BGP ZOSTER IZ CPTS]
- Shingrix:
  - Immunization (CVX) codes 187
  - CPT 90750 [BGP ZOSTER SHINGRIX CPTS]

**Contraindication to Zoster Vaccine**

Any of the following documented at any time before the end of the Report Period:

- Contraindication in the Immunization Package of “Immune Deficiency” or “Anaphylaxis”
- PCC NMI Refusal

**2.3.2.6 GPRA 2018 Target**

During GPRA Year 2018, establish a baseline for the proportion of adult patients 19 years and older who receive their age-appropriate immunizations.
2.3.2.7 Patient List
List of patients 18 years and older or DM diagnosis with IZ or contraindication, if any.

2.3.3 Childhood Immunizations

2.3.3.1 Owner and Contact
Epidemiology Program: Amy Groom, MPH

2.3.3.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.3.3.3 Denominators
1. Active Clinical patients ages 19 through 35 months at end of Report Period.
2. GPRAMA: User Population patients ages 19 through 35 months at end of Report Period.
3. User Population patients active in the Immunization Package who are 19 through 35 months of age at end of Report Period.

Note: Sites must be running the RPMS Immunization package for this denominator. Sites not running the package will have a value of zero for this denominator.

2.3.3.4 Numerators

Note: The only refusals included in all numerators are documented NMI refusals.

1. GPRAMA: Patients who have received the 4:3:1:3*:3:1:4 combination (i.e., 4 DTaP, 3 Polio, 1 MMR, 3 or 4 HiB, 3 Hepatitis B, 1 Varicella, and 4 Pneumococcal), including contraindications, and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
2. Patients who have received 4 doses of DTaP ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
3. Patients who have received 3 doses of Polio ever, including contraindications, and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
4. Patients who have received 1 dose of MMR ever, including contraindications, and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
5. Patients who have received 3 or 4 doses of HiB ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
6. Patients who have received 3 doses of Hepatitis B vaccine ever, including contraindications, and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
7. Patients who have received 1 dose of Varicella ever, including contraindications, and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
8. Patients who have received 4 doses of Pneumococcal conjugate vaccine ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
9. Patients who have received 1 dose of Hepatitis A vaccine ever, including contraindications and evidence of disease.
   A. Patients with (1) evidence of the disease, (2) a contraindication, or (3) a documented NMI refusal.
10. Patients who have received 2 or 3 doses of Rotavirus vaccine ever, including contraindications.
    A. Patients with (1) a contraindication or (2) a documented NMI refusal.
11. Patients who have received 2 doses of Influenza ever, including contraindications.
    A. Patients with (1) a contraindication or (2) a documented NMI refusal.
2.3.3.5 Definitions

Patient Age
Since the age of the patient is calculated at the beginning of the Report Period, the age range will be adjusted to 7 through 23 months at the beginning of the Report Period, which makes the patient between the ages of 19 through 35 months at the end of the Report Period.

Timing of Doses
Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

Active Immunization Package Patients Denominator
Same as User Population definition except includes only patients flagged as active in the Immunization Package.

Note: Only values for the Report Period will be reported for this denominator since currently there is not a way to determine if a patient was active in the Immunization Package during the previous year or baseline periods.

Dosage and Types of Immunizations

- 4 Doses of DTaP
  - 4 DTaP or DTP or Tdap
  - 1 DTaP or DTP or Tdap and 3 DT or Td
  - 1 DTaP or DTP or Tdap and 3 each of Diphtheria and Tetanus
  - 4 DT and 4 Acellular Pertussis
  - 4 Td and 4 Acellular Pertussis
  - 4 each of Diphtheria, Tetanus, and Acellular Pertussis

- 3 Doses of Polio
  - 3 OPV
  - 3 IPV
  - Combination of OPV and IPV totaling 3 doses

- 1 Dose of MMR
  - MMR
  - 1 M/R and one Mumps
  - 1 R/M and one Measles
  - 1 each of Measles, Mumps, and Rubella

- 3 or 4 doses of HIB, depending on the vaccine administered
- 3 doses of Hepatitis B
- 1 dose of Varicella
- 4 doses of Pneumococcal
- 1 dose of Hepatitis A
- 2 or 3 doses of Rotavirus, depending on the vaccine administered
- 2 doses of Influenza

**Not Medically Indicated (NMI) Refusal, Contraindication, and Evidence of Disease Information**

Except for the Immunization Program Numerators, the following will also count toward meeting the definition, as defined in the following subsections:

- NMI refusals
- Evidence of disease
- Contraindications for individual immunizations

**Note:** NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations that allow a different number of doses (e.g., 2 or 3 Rotavirus): To count toward the numerator with the smaller number of doses, all of the patient's vaccinations must be part of the smaller dose series. For example, for a patient to count toward the Rotavirus numerator with only 2 doses, all 2 doses must be included in the 2-dose series codes listed in the Rotavirus definition. A patient with a mix of 2-dose and 3-dose series codes will need 3 doses to count toward the numerator. An exception to this is for the HIB vaccine: if the first 2 doses are part of the 3-dose series, then the patient only needs 3 doses (even if the third dose is included in the 4-dose series).

- Each immunization must be refused and documented separately. For example, if a patient has an NMI refusal for Rubella only, then there must be an immunization, contraindication, or separate NMI refusal for the Measles and Mumps immunizations.

- For immunizations where required number of doses is greater than one, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
• For immunizations where required number of doses is greater than one, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

• Evidence of disease will be checked for at any time in the child's life (prior to the end of the Report Period).

• To be counted in Subnumerator A, a patient must meet the numerator definition AND have evidence of disease, a contraindication, or an NMI refusal for any of the immunizations in the numerator. For example, if a patient was Rubella immune but had a Measles and Mumps immunization, the patient would be included in Subnumerator A.

• For the separate numerator for REF refusal (Patient Refusal for Service) in PCC or a Parent or Patient refusal in the IZ program, the conditions must be met:
  – Each immunization must be refused and documented separately. For example, if a patient has a REF refusal for Rubella, then there also must be an immunization, contraindication, or separate REF refusal for Measles and Mumps.
  – Where the required number of doses is greater than one, only one REF refusal in PCC or one Parent or Patient refusal in the IZ program is necessary to be counted in the numerator. For example, for the 4 DTaP numerators, only one refusal is necessary to be counted in the refusal numerator.

NMI Refusal Definitions
PCC Refusal type NMI for any of the following codes:

• DTaP
  – Immunization (CVX) codes 20, 50, 102, 106, 107, 110, 120, 130, 132, 146
  – CPT 90696 through 90698, 90700, 90721, 90723 [BGP CPT DTAP/DTP/TDAP]

• DTP
  – Immunization (CVX) codes 1, 22, 102
  – CPT 90701, 90711 (old code), 90720 [BGP CPT DTAP/DTP/TDAP]

• Tdap
  – Immunization (CVX) code 115
  – CPT 90715 [BGP CPT DTAP/DTP/TDAP]

• DT
- Immunization (CVX) code 28
- CPT 90702

- **Td**
  - Immunization (CVX) codes 9, 113, 138, 139
  - CPT 90714, 90718 [BGP CPT TDAP/TD]

- **Diphtheria**
  - CPT 90719

- **Tetanus**
  - Immunization (CVX) codes 35, 112
  - CPT 90703

- **Acellular Pertussis**
  - Immunization (CVX) code 11

- **OPV**
  - Immunization (CVX) codes 2, 89
  - CPT 90712

- **IPV**
  - Immunization (CVX) codes 10, 89, 110, 120, 130, 132, 146
  - CPT 90696 through 90698, 90711 (old code), 90713, 90723

- **MMR**
  - Immunization (CVX) codes 3, 94
  - CPT 90707, 90710

- **M/R**
  - Immunization (CVX) code 4
  - CPT 90708

- **R/M**
  - Immunization (CVX) code 38
  - CPT 90709 (old code)

- **Measles**
  - Immunization (CVX) code 5
  - CPT 90705

- **Mumps**
  - Immunization (CVX) code 7
  - CPT 90704
- Rubella
  - Immunization (CVX) code 6
  - CPT 90706

- HiB
  - Immunization (CVX) codes 17, 22, 46 through 49, 50, 51, 102, 120, 132, 146, 148
  - CPT 90644 through 90648, 90697, 90698, 90720 through 90721, 90737 (old code), 90748 [BGP HIB CPT]

- Hepatitis B
  - Immunization (CVX) codes 8, 42 through 45, 51, 102, 104, 110, 132, 146, 189
  - CPT 90636, 90697, 90723, 90731 (old code), 90739, 90740, 90743 through 90748, G0010, Q3021 (old code), Q3023 (old code) [BGP HEPATITIS CPTS]

- Varicella
  - Immunization (CVX) codes 21, 94
  - CPT 90710, 90716

- Pneumococcal
  - Immunization (CVX) codes 33, 100, 109, 133, 152
  - CPT 90669, 90670, 90732, G0009, G8115 (old code), G9279 [BGP PNEUMO IZ CPTS]

- Hepatitis A
  - Immunization (CVX) codes 31, 52, 83, 84, 85, 104
  - CPT 90632 through 90634, 90636, 90730 (old code) [BGP HEPATITIS A CPTS]

- Rotavirus
  - Immunization (CVX) codes 74, 116, 119, 122
  - CPT 90680

- Influenza
  - Immunization (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186
  - CPT 90630, 90653 through 90658, 90659 (old code), 90660 through 90662, 90672 through 90674, 90682, 90685 through 90688, 90724 (old code), 90756, G0008, G8108 (old code) [BGP CPT FLU]

**Contraindication Definitions**

- Encephalopathy due to vaccination
- POV or Problem List entry where the status is not Deleted: ICD-9: 323.51; ICD-10: G04.32 [BGP ENCEPHALOPATHY DXS]

- **Vaccine adverse-effect**
  - POV or Problem List entry where the status is not Deleted: ICD-9: E948.4 through E948.6; ICD-10: T50.A15* [BGP VACCINE ADVERSE EFFECT]

- **Immunodeficiency**
  - POV or Problem List entry where the status is not Deleted: ICD-9: 279.*; ICD-10: D80.*, D81.0 through D81.7, D81.89, D81.9, D82.* through D84.*, D89.3, D89.8*, D89.9 [BGP IMMUNODEFICIENCY DXS]

- **HIV**
  - POV or Problem List entry where the status is not Deleted: ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]; SNOMED data set PXRM HIV (Problem List only)

- **Lymphoreticular cancer, multiple myeloma or leukemia**
  - POV or Problem List entry where the status is not Deleted: ICD-9: 200.00 through 208.92; ICD-10: C81.00 through C86.6, C88.2 through C88.9, C90.00 through C93.*, C94.00 through C94.32, C94.80, C95.*, C96.0 through C96.4, C96.9, C96.A, C96.Z [BGP LYMPHO CANCER DXS]

- **Severe combined immunodeficiency**
  - POV or Problem List entry where the status is not Deleted: ICD-9: 279.2; ICD-10: D81.0 through D81.2, D81.9 [BGP SCID DXS]

- **History of intussusception**
  - POV or Problem List entry where the status is not Deleted: ICD-9: 560.0; ICD-10: K56.1 [BGP INTUSSUSCEPTION DXS]

### Immunization Definitions

- **DTaP IZ Definitions**
  - Immunization (CVX) codes 20, 50, 102, 106, 107, 110, 120, 130, 132, 146
  - POV ICD-9: V06.1
  - CPT 90696 through 90698, 90700, 90721, 90723 [BGP CPT DTAP/DTP/Tdap]

- **DTaP Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
  - Encephalopathy due to vaccination with a vaccine adverse-effect

- **DTP IZ Definitions**
- Immunization (CVX) codes 1, 22, 102
- POV ICD-9: V06.1, V06.2, V06.3 [BGP DTP IZ DXS]
- CPT 90701, 90711 (old code), 90720 [BGP CPT DTAP/DTP/TDAP]
- **DTP Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **Tdap IZ Definitions**
  - Immunization (CVX) code 115
  - CPT 90715 [BGP CPT DTAP/DTP/TDAP]
- **Tdap contraindication definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **DT IZ Definitions**
  - Immunization (CVX) code 28
  - POV ICD-9: V06.5 [BGP TD IZ DXS]
  - CPT 90702
- **DT Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **Td IZ Definitions**
  - Immunization (CVX) codes 9, 113, 138, 139
  - POV ICD-9: V06.5 [BGP TD IZ DXS]
  - CPT 90714, 90718 [BGP CPT TDAP/TD]
- **Td Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **Diphtheria IZ Definitions**
  - POV ICD-9: V03.5 [BGP DIPHTHERIA IZ DXS]
  - CPT 90719
- **Diphtheria Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **Tetanus Definitions**
  - Immunization (CVX) codes 35, 112
  - POV ICD-9: V03.7 [BGP TETANUS TOXOID IZ DXS]
  - CPT 90703
- **Tetanus Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **Acellular Pertussis Definitions**
  - Immunization (CVX) code 11
  - POV ICD-9: V03.6 [BGP PERTUSSIS IZ DXS]
- **Acellular Pertussis Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
- **OPV Definitions**
  - Immunization (CVX) codes 2, 89
  - CPT 90712
- **OPV Contraindication Definition**
  - Immunization Package contraindication of “Immune Deficiency”
- **IPV Definitions**
  - Immunization (CVX) codes 10, 89, 110, 120, 130, 132, 146
  - POV ICD-9: V04.0, V06.3 [BGP IPV IZ DXS]
  - CPT 90696 through 90698, 90711 (old code), 90713, 90723
- **IPV Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) ICD-9: 730.70 through 730.79; ICD-10: M89.6* [BGP OPV EVID DISEASE]
  - SNOMED data set PXRM BGP POLIO (Problem List only)
- **IPV contraindication definition:**
  - Immunization Package contraindication of “Anaphylaxis” or “Neomycin Allergy”
- **MMR Definitions**
  - Immunization (CVX) codes 3, 94
  - POV ICD-9: V06.4 [BGP MMR IZ DXS]
  - CPT 90707, 90710
- **MMR Contraindication Definitions**
  - Immunization Package contraindication of “Anaphylaxis”, “Immune Deficiency”, or “Neomycin Allergy”
  - Immunodeficiency
  - HIV
  - Lymphoreticular cancer, multiple myeloma or leukemia
- **M/R Definitions**
  - Immunization (CVX) code 4
  - CPT 90708
- **M/R Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **R/M Definitions**
  - Immunization (CVX) code 38
  - CPT 90709 (old code)

- **R/M Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Measles Definitions**
  - Immunization (CVX) code 5
  - POV ICD-9: V04.2 [BGP MEASLES IZ DXS]
  - CPT 90705

- **Measles Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) ICD-9: 055*; ICD-10: B05.* [BGP MEASLES EVIDENCE]
  - SNOMED data set PXRM BGP MEASLES (Problem List only)

- **Measles Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Mumps Definitions**
  - Immunization (CVX) code 7
  - POV ICD-9: V04.6 [BGP MUMPS IZ DXS]
  - CPT 90704

- **Mumps Evidence of Disease Definition**
  - POV or PCC Problem List (active or inactive) ICD-9: 072*; ICD-10: B26.* [BGP MUMPS EVIDENCE]

- **Mumps Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Rubella Definitions**
  - Immunization (CVX) code 6
  - POV ICD-9: V04.3 [BGP RUBELLA IZ DXS]
  - CPT 90706

- **Rubella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) ICD-9: 056*, 771.0; ICD-10: B06.* [BGP RUBELLA EVIDENCE]
  - SNOMED data set PXRM BGP RUBELLA (Problem List only)
- **Rubella Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **HiB Definitions**
  - 3-dose series:
    - Immunization (CVX) codes 49, 51
    - CPT 90647, 90748
  - 4-dose series:
    - Immunization (CVX) codes 17, 22, 46 through 48, 50, 102, 120, 132, 146, 148
    - POV ICD-9: V03.81 [BGP HIB IZ DXS]
    - CPT 90644 through 90646, 90648, 90697, 90698, 90720, 90721, 90737 (old code)

- **HiB Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Hepatitis B Definitions**
  - Immunization (CVX) codes 8, 42 through 45, 51, 102, 104, 110, 132, 146, 189
  - CPT 90636, 90697, 90723, 90731 (old code), 90739, 90740, 90743 through 90748, G0010, Q3021 (old code), Q3023 (old code) [BGP HEPATITIS CPTS]
  - POV or PCC Problem List (active or inactive) ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B18.0, B18.1, B19.1*, Z22.51 [BGP HEP EVIDENCE]
  - SNOMED data set PXRM BGP HEPATITIS B (Problem List only)

- **Hepatitis B Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B18.0, B18.1, B19.1*, Z22.51 [BGP HEP EVIDENCE]
  - SNOMED data set PXRM BGP HEPATITIS B (Problem List only)

- **Hepatitis B contraindication definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Varicella Definitions**
  - Immunization (CVX) codes 21, 94
  - POV ICD-9: V05.4 [BGP VARICELLA IZ DXS]
  - CPT 90710, 90716

- **Varicella Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) ICD-9: 052*, 053*; ICD-10: B01.* through B02.* [BGP VARICELLA EVIDENCE]
  - SNOMED data set PXRM BGP VARICELLA (Problem List only)
- Immunization Package contraindication of “Hx of Chicken Pox” or “Immune”

- **Varicella Contraindication Definitions**
  - Immunization Package contraindication of “Anaphylaxis”, “Immune Deficiency”, or “Neomycin Allergy”
  - Immunodeficiency
  - HIV
  - Lymphoreticular cancer, multiple myeloma or leukemia

- **Pneumococcal Definitions**
  - Immunization (CVX) codes 33, 100, 109, 133, 152
  - POV ICD-9: V06.6, V03.82 [BGP PNEUMO IZ DXS]
  - CPT 90669, 90670, 90732, G0009, G8115 (old code), G9279 [BGP PNEUMO IZ CPTS]

- **Pneumococcal Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Hepatitis A Definitions**
  - Immunization (CVX) codes 31, 52, 83, 84, 85, 104
  - CPT 90632 through 90634, 90636, 90730 (old code) [BGP HEPATITIS A CPTS]

- **Hepatitis A Evidence of Disease Definitions**
  - POV or PCC Problem List (active or inactive) ICD-9: 070.0, 070.1; ICD-10: B15.* [BGP HEPATITIS A EVIDENCE]
  - SNOMED data set PXRM BGP HEPATITIS A (Problem List only)

- **Hepatitis A Contraindication Definition**
  - Immunization Package contraindication of "Anaphylaxis"

- **Rotavirus Definitions**
  - 2-dose series
    Immunization (CVX) codes 119
    CPT 90681
  - 3-dose series
    Immunization (CVX) codes 74, 116, 122
    POV ICD-9: V05.8
    CPT 90680

- **Rotavirus Contraindication Definition**
IHS Clinical Reporting System (BGP) Version 18.0 patch 1

Selected Measures (Local) Report
Performance Measure List and Definitions
Performance Measure Topics and Definitions
April 2018

67

- Immunization Package contraindication of "Anaphylaxis" or "Immune Deficiency"
- Severe combined immunodeficiency
- History of intussusception

• **Influenza Definitions**
  - Immunizations (CVX) codes 15, 16, 88, 111, 135, 140, 141, 144, 149, 150, 151, 153, 155, 158, 161, 166, 168, 171, 185, 186
  - POV ICD-9: V04.8 (old code), V04.81, V06.6 [BGP FLU IZ DXS]
  - CPT 90630, 90653 through 90658, 90659 (old code), 90660 through 90662, 90672 through 90674, 90682, 90685 through 90688, 90724 (old code), 90756, G0008, G8108 (old code) [BGP CPT FLU]

• **Influenza Contraindication Definition**
  - Immunization Package contraindication of "Anaphylaxis"
  - Immunodeficiency
  - HIV
  - Lymphoreticular cancer, multiple myeloma or leukemia

2.3.3.6 **GPRA 2018 Target**
During GPRA Year 2018, achieve the target rate of 45.6% for the proportion of AI/AN children ages 19 through 35 months who have received the recommended immunizations.

**Notes:** In FY 2013, the GPRA measure changed to the 4:3:1:3*:3:1:4 combination, which includes 3 or 4 HiB.

In FY 2011, the GPRA measure changed to the 4:3:1:3:3:1:4 combination, which includes pneumococcal.

2.3.3.7 **Patient List**
List of patients 19 through 35 months of age with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 2 DTaP, no IZ will be listed for DTaP.

**Note:** Because age is calculated at the beginning of the Report Period, the patient's age on the list will be between 7 and 23 months.
2.3.4 Adolescent Immunizations

2.3.4.1 Owner and Contact
Epidemiology Program: Dr. Scott Hamstra, Amy Groom, MPH

2.3.4.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.3.4.3 Denominators
1. Active Clinical patients age 13 years.
2. Male Active Clinical patients age 13 years.
3. Female Active Clinical patients age 13 years.
4. Active Clinical patients ages 13 through 17 years.
5. Male Active Clinical patients ages 13 through 17 years.
6. Female Active Clinical patients ages 13 through 17 years.

2.3.4.4 Numerators

Note: The only refusals included in all numerators are documented NMI refusals.

1. Patients who have received the 1:1:2* combination (i.e., 1 Tdap or Td, 1 Meningococcal, 2 or 3 HPV), including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
2. Patients who have received the 1:1 combination (i.e., 1 Tdap or Td, 1 Meningococcal), including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
3. Patients who have received 1 dose of Tdap or Td ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.
   B. Patients who have received 1 dose of Tdap ever, including contraindications.
4. Patients who have received 1 dose of meningococcal ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.

5. Patients who have received 2 or 3 doses of HPV ever, including contraindications.
   A. Patients with (1) a contraindication or (2) a documented NMI refusal.

2.3.4.5 Definitions

Timing of Doses
Because IZ data comes from multiple sources, any IZ codes documented on dates within 10 days of each other will be considered as the same immunization.

Dosage and Types of Immunizations
- 1 dose of Td or Tdap
- 1 dose of Meningococcal
- 2 or 3 doses of HPV—in order to qualify for 2 doses, the patient must have the first dose prior to their 15th birthday and the 2 doses must be separated by a minimum of 5 months

Not Medically Indicated (NMI) Refusal and Contraindication Information
Not Medically Indicated refusals and contraindications for individual immunizations will also count toward meeting the definition, as defined in the following subsections.

Note: NMI refusals are not counted as refusals; rather, they are counted as contraindications.

- For immunizations where required number of doses is greater than one, only one NMI refusal is necessary to be counted in the numerator. For example, if there is a single NMI refusal for Hepatitis B, the patient will be included in the numerator.
- For immunizations where required number of doses is greater than one, only one contraindication is necessary to be counted in the numerator. For example, if there is a single contraindication for HiB, the patient will be included in the numerator.

NMI Refusal Definitions
PCC Refusal type NMI for any of the following codes:

- Tdap
- Immunization (CVX) codes 115
- CPT 90715

- **Td**
  - Immunization (CVX) codes 9, 113
  - CPT 90714, 90718

- **Meningococcal**
  - CPT 90644, 90733, 90734

- **HPV**
  - Immunization (CVX) codes 62, 118, 137, 165
  - CPT 90649, 90650, 90651

**Immunization Definitions**

- **Tdap**
  - Immunization (CVX) code 115

- **CPT 90715 Tdap Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Td**
  - Immunization (CVX) code 9, 113, 138, 139
  - POV ICD-9: V06.5 [BGP TD IZ DXS]
  - CPT 90714, 90718

- **Td Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **Meningococcal**
  - CPT 90644, 90733, 90734

- **Meningococcal Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”

- **HPV**
  - Immunization (CVX) codes: 62, 118, 137, 165
  - CPT 90649, 90650, 90651

- **HPV Contraindication Definition**
  - Immunization Package contraindication of “Anaphylaxis”
2.3.4.6 Patient List

List of patients 13 through 17 years of age with IZ, if any. If a patient did not have all doses in a multiple dose vaccine, the IZ will not be listed. For example, if a patient only had 1 HPV, no IZ will be listed for HPV.

2.4 Childhood Diseases Group

2.4.1 Appropriate Treatment for Children with Upper Respiratory Infection

2.4.1.1 Owner and Contact
Dr. Scott Hamstra

2.4.1.2 National Reporting
Not reported nationally

2.4.1.3 Denominators

1. Active Clinical patients who were ages 3 months through 18 years who were diagnosed with an upper respiratory infection during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

2.4.1.4 Numerators

1. Patients who were not prescribed an antibiotic on or within 3 days after diagnosis. In this measure, appropriate treatment is not to receive an antibiotic.

2.4.1.5 Definitions

Age

Age is calculated as follows: Children 3 months as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

Upper Respiratory Infection

- POV ICD-9: 460, 465.*; ICD-10: J00, J04.*, J05.0, J06.* [BGP URI DXS]

Outpatient Visit

- Service Category A, S, O

Antibiotic Medications:
• Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS.
  – Medications are: Amoxicillin, Amoxicillin and Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefditoren, Cefixime, Cefpodoxime, Cefprozil, Ceftibuten, Ceftriaxone, Cefuroxime, Cephalexin, Ciprofloxacin, Clarithromycin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate, Erythromycin-sulfisoxazole, Levofloxacin, Minocycline, Moxifloxacin, Ofloxacin, Penicillin VK, Penicillin G, Sulfisoxazole, Tetracycline, Trimethoprim. Medications must not have a comment of RETURNED TO STOCK.
  – Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04029, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0K829, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U29, 3E0V329, 3E0W329, 3E0Y329 [BGP INJECTION ANTIBIOTIC PROCS]

• To be included in the denominator all of the following conditions must be met:
  – Patient’s diagnosis of an upper respiratory infection (URI) must have occurred at an outpatient visit.
  – If outpatient visit was to Clinic code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as Service Category H, either on the same day or the next day with URI diagnosis.
  – Patient’s visit must only have a diagnosis of URI (multiple URI diagnoses are allowed). If any diagnosis other than URI exists, the visit will be excluded.
  – The patient did not have a new or refill prescription (Rx) for antibiotics within 30 days prior to the URI visit date.
  – The patient did not have an active prescription for antibiotics as of the URI visit date. “Active” prescription defined as:
    – Rx Days’ Supply must be greater than or equal to the URI Visit Date minus the Rx Date

If there are multiple visits that meet the criteria, the first visit will be used.

2.4.1.6 Patient List

List of patients 3 months to 18 years with upper respiratory infection, with antibiotic prescription, if any.
2.4.2 Appropriate Testing for Children with Pharyngitis

2.4.2.1 Owner and Contact
Dr. Scott Hamstra

2.4.2.2 National Reporting
Not reported nationally

2.4.2.3 Denominators
1. Active Clinical patients who were ages 3 through 18 years who were diagnosed with pharyngitis and prescribed an antibiotic during the period 6 months (182 days) prior to the Report Period through the first 6 months of the Report Period.

2.4.2.4 Numerators
1. Patients who received a Group A strep test.

2.4.2.5 Definitions
Age
Age is calculated as follows: Children 3 years as of 6 months (182 days) of the year prior to the Report Period to 18 years as of the first 6 months of the Report Period.

Pharyngitis
• POV ICD-9: 462, 463, 034.0; ICD-10: J02.0, J03.* [BGP PHARYNGITIS DXS]

Outpatient Visit
• Service Category A, S, O

Antibiotic Medications
• Medication taxonomy BGP HEDIS ANTIBIOTIC MEDS
Medications are: Amoxicillin, Amoxicillin and Clavulanate, Ampicillin, Azithromycin, Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefixime, Cefditoren, Cefotibuten, Cefpodoxime, Cefprozil, Ceftriaxone, Cefuroxime, Cephalexin, Ciprofloxacin, Clarithromycin, Clindamycin, Dicloxacillin, Doxycycline, Erythromycin, Erythromycin ethylsuccinate, Erythromycin lactobionate, Erythromycin stearate, Erythromycin-sulfisoxazole, Levofoxacin, Minocycline, Moxifloxacin, Ofloxacin, Penicillin VK, Penicillin G, Sulfisoxazole, Tetracycline, Trimethoprim. Medications must not have a comment of RETURNED TO STOCK.

- Procedure ICD-9: 99.21; ICD-10: 3E00X29, 3E01329, 3E02329, 3E03029, 3E03329, 3E04329, 3E05029, 3E05329, 3E06029, 3E06329, 3E0E329, 3E0E729, 3E0E829, 3E0F329, 3E0F729, 3E0F829, 3E0G329, 3E0G729, 3E0G829, 3E0H329, 3E0H729, 3E0H829, 3E0J329, 3E0J729, 3E0J829, 3E0K329, 3E0K729, 3E0L329, 3E0M329, 3E0N329, 3E0N729, 3E0N829, 3E0P329, 3E0P729, 3E0P829, 3E0Q329, 3E0R329, 3E0S329, 3E0U029, 3E0U329, 3E0V329, 3E0W329, 3E0Y329 [BGP INJECTION ANTIBIOTIC PROCs]

**Group A Streptococcus Test**

- CPT 87430 (by enzyme immunoassay), 87650 through 87652 (by nucleic acid), 87880 (by direct optical observation), 87081 (by throat culture), 3210F (Group A Strep Test) [BGP GROUP A STREP CPT]
- Site-populated taxonomy BGP GROUP A STREP
- LOINC taxonomy

To be included in the denominator all of the following conditions must be met:

- Patient's diagnosis of pharyngitis must have occurred at an outpatient visit.
- If outpatient visit was to Clinic code 30 (Emergency Medicine), it must not have resulted in a hospitalization, defined as service category H, either on the same day or the next day with pharyngitis diagnosis.
- Patient's visit must only have a diagnosis of pharyngitis (multiple pharyngitis diagnoses are allowed). If any diagnosis other than pharyngitis exists, the visit will be excluded.
- The patient did not have a new or refill prescription for antibiotics within 30 days prior to the pharyngitis visit date.
- The patient did not have an active prescription for antibiotics as of the pharyngitis visit date. “Active” prescription defined as:
- Rx Days’ Supply must be greater than or equal to the URI Visit Date minus the Rx Date
- The patient filled a prescription for antibiotics on or within 3 days after the pharyngitis visit.

**If there are multiple visits that meet the criteria, the first visit will be used.**

- **To be included in the numerator**
  - A patient must have received a Group A Streptococcus test within the 7-day period beginning 3 days prior through 3 days after the Pharyngitis visit date.

### 2.4.2.6 Patient List

List of patients 3 through 18 years of age with pharyngitis and a Group A Strep test, if any.

### 2.5 Cancer Screen Group

#### 2.5.1 Cancer Screening: Pap Smear Rates

##### 2.5.1.1 Owner and Contact

CAPT Suzanne England, DNP, APRN

##### 2.5.1.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

##### 2.5.1.3 Denominators

1. Female Active Clinical patients ages 24 through 64 years without a documented history of hysterectomy. Patients must be at least 24 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period.

2. Female Active Clinical patients ages 24 through 29 without documented history of hysterectomy.

3. Female Active Clinical patients ages 30 through 64 without documented history of hysterectomy.

4. GPRA: Female User Population patients ages 24 through 64 years without a documented history of hysterectomy.
5. Female User Population patients ages 24 through 29 without documented history of hysterectomy.

6. Female User Population patients ages 30 through 64 without documented history of hysterectomy.

2.5.1.4 Numerators

1. GPRA: Patients with documented Pap smear in past 3 years, or if patient is 30 to 64 years of age, either a Pap Smear documented in the past 3 years or a Pap Smear and an HPV DNA documented in the past 5 years. (With Denominators 1 and 4)

   **Note:** This numerator does not include refusals.

2. Patients with a Pap Smear documented in the past 3 years. (With Denominators 2 and 5)

   **Note:** This numerator does not include refusals.

3. Patients with a Pap Smear documented 3 to 5 years ago, and an HPV DNA documented in the past 5 years. (With Denominators 3 and 6)

   **Note:** This numerator does not include refusals.

2.5.1.5 Definitions

**Age**

Age of the patient is calculated at the beginning of the Report Period. Patients must be at least 24 years of age at the beginning of the Report Period and less than 65 years of age as of the end of the Report Period.

**Hysterectomy**

Defined as any of the following ever:

- Procedure ICD-9: 68.4 through 68.9; ICD-10: 0UTC*ZZ [BGP HYSTERECTOMY PROCEDURES]
- CPT 51925, 56308 (old code), 58150, 57540, 57545, 57550, 57555, 57556, 58152, 58200 through 58294, 58548, 58550 through 58554, 58570 through 58573, 58951, 58953 through 58954, 58956, 59135 [BGP HYSTERECTOMY CPTS]
- Diagnosis (POV or Problem List entry where the status is not Deleted):
– ICD-9: 618.5, 752.43, V88.01, V88.03; ICD-10: N99.3, Z12.72, Z90.710, Z90.712, Q51.5 [BGP HYSTERECTOMY DXS]
– SNOMED data set PXRM BGP HYSTERECTOMY DX (Problem List only)

• Women’s Health procedure called Hysterectomy

**Pap Smear**

• Lab Pap Smear

• POV ICD-9: V76.2 Screen Mal Neop-Cervix, V72.32 Encounter for Pap Cervical Smear to Confirm Findings of Recent Normal Smear Following Initial Abnormal Smear, 795.0*; ICD-10: R87.61*, R87.810, R87.820, Z01.42, Z12.4 [BGP PAP SMEAR DXS]

• CPT 88141 through 88154, 88160 through 88167, 88174 through 88175, G0123, G0124, G0141, G0143 through G0145, G0147, G0148, P3000, P3001, Q0091 [BGP CPT PAP]

• Women’s Health procedure called Pap Smear and where the result does NOT have “ERROR/DISREGARD”

• LOINC taxonomy

• Site-populated taxonomy BGP PAP SMEAR TAX

**HPV DNA**

**Note:** CRS will only search for a documented HPV DNA if the patient had a Pap Smear 3 to 5 years ago.

• Lab HPV

• POV ICD-9: V73.81, 079.4, 795.05, 795.09, 795.15, 795.19, 796.75, 796.79; ICD-10: B97.7, R85.618, R85.81, R85.82, R87.628, R87.810, R87.811, R87.820, R87.821, Z11.51 [BGP HPV DXS]

• CPT 87620 through 87622 (old codes), 87623 through 87625, G0476 [BGP HPV CPTS]

• Women’s Health procedure called HPV Screen and where the result does NOT have “ERROR/DISREGARD”

• Women’s Health procedure called Pap Smear and where the HPV field equals Yes

• LOINC taxonomy

• Site-populated taxonomy BGP HPV TAX
2.5.1.6 **GPRA 2018 Target**

During GPRA Year 2018, achieve the target rate of 35.9% for the proportion of female patients ages 24 through 64 years without a documented history of hysterectomy who have had a Pap screen within the previous 3 years, or if the patient is over 30, had a Pap screen in the past 3 years or a Pap screen and HPV DNA within the previous 5 years.

2.5.1.7 **Patient List**

List of women 24 through 64 years of age with documented Pap smear, if any.

2.5.2 **Cancer Screening: Mammogram Rates**

2.5.2.1 **Owner and Contact**

CAPT Suzanne England, DNP, APRN

2.5.2.2 **National Reporting**

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.5.2.3 **Denominators**

1. Female Active Clinical patients ages 52 through 64 years, without a documented bilateral mastectomy or two separate unilateral mastectomies.

2. GPRA: Female User Population patients ages 52 through 64 years, without a documented bilateral mastectomy or two separate unilateral mastectomies.

2.5.2.4 **Numerators**

1. GPRA: Patients with documented mammogram in past 2 years.

   **Note:** This numerator does *not* include refusals.

2. Patients with documented mammogram refusal in past year.
2.5.2.5 Definitions

Age
Age of the patient is calculated at the beginning of the Report Period. For all denominators, patients must be at least the minimum age as of the beginning of the Report Period. For the 52 through 64 years of age denominator, the patients must be less than 65 years of age as of the end of the Report Period.

Bilateral Mastectomy
- CPT 19300.50 through 19307.50 or 19300 through 19307 with modifier 09950 (50 and 09950 modifiers indicate bilateral), or old codes 19180, 19200, 19220, or 19240, with modifier of 50 or 09950 [BGP MASTECTOMY CPTS]
- Procedure ICD-9: 85.42, 85.44, 85.46, 85.48; ICD-10: 0HBV0ZZ, 0HCV0ZZ, 0HTV0ZZ [BGP MASTECTOMY PROCEDURES]
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-10: Z90.13 [BGP MASTECTOMY DXS]
  - SNOMED data set PXRM BGP BILAT MASTECTOMY (Problem List only)

Two Separate Unilateral Mastectomies
Requires either of the following:
- Must have one code that indicates a right mastectomy and one code that indicates a left mastectomy
- Must have two separate occurrences on two different dates of service for one code that indicates a mastectomy on unknown side and one code that indicates either a right or left mastectomy, or two codes that indicate a mastectomy on unknown side

Right Mastectomy
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-10: Z90.11 [BGP RIGHT MASTECTOMY DXS]
  - SNOMED data set PXRM BGP RIGHT MASTECTOMY (Problem List only)
- Procedure ICD-10: 07T50ZZ, 07T80ZZ, 0HBT0ZZ, 0HCT0ZZ, 0HTT0ZZ [BGP UNI RIGHT MASTECTOMY PROCS]

Left Mastectomy
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-10: Z90.12 [BGP LEFT MASTECTOMY DXS]
- SNOMED data set PXRM BGP LEFT MASTECTOMY (Problem List only)
  - Procedure ICD-10: 07T60ZZ, 07T90ZZ, 0HBU0ZZ, 0HCU0ZZ, 0HTU0ZZ [BGP UNI LEFT MASTECTOMY PROCS]

**Mastectomy on Unknown Side**
- CPT 19300 through 19307, or old codes 19180, 19200, 19220, 19240 [BGP UNI MASTECTOMY CPTS]
- Procedure ICD-9: 85.41, 85.43, 85.45, 85.47 [BGP UNI MASTECTOMY PROCEDURES]

**Mammogram**
- Radiology or CPT 77052 through 77059, 77065 through 77067, 76090 (old code), 76092 (old code), G0206, G0204, G0202 [BGP CPT MAMMOGRAM]
- POV ICD-9: V76.11 screening mammogram for high risk patient, V76.12 other screening mammogram, 793.80 Abnormal mammogram, unspecified, 793.81 Mammographic microcalcification, 793.89 Other abnormal findings on radiological exam of breast; ICD-10: R92.0, R92.1, R92.8, Z12.31 [BGP MAMMOGRAM DXS]
- Procedure ICD-9: 87.36 Xerography of breast, 87.37 Other Mammography; ICD-10: BH00ZZZ, BH01ZZZ, BH02ZZZ [BGP MAMMOGRAM PROCEDURES]
- Women’s Health procedure called Mammogram Screening, Mammogram Diagnosis Bilateral, Mammogram Diagnosis Unilateral, and where the mammogram result does not have "ERROR/DISREGARD"

**Refusal Mammogram**
Any of the following in the past year:
- Radiology MAMMOGRAM for CPT 77052 through 77059, 77065 through 77067, 76090 (old code), 76091 (old code), 76092 (old code), G0206, G0204, G0202 [BGP CPT MAMMOGRAM]

### 2.5.2.6 GPRA 2018 Target
During GPRA Year 2018, achieve the target rate of 42.0% for the proportion of female patients ages 52 through 64 years who have had mammography screening within the last 2 years.

### 2.5.2.7 Patient List
List of women 52 through 74 with mammogram or refusal, if any.
2.5.3 Colorectal Cancer Screening

Notes: Based on the HEDIS definition which has lowered the upper age from 80 to 75 years.
Numerator does not include Double Contrast Barium Enema (DCBE).

2.5.3.1 Owner: Contact
Epidemiology Program: Don Haverkamp

2.5.3.2 National Reporting
NATIONAL (included in IHS Performance Report; reported to OMB and Congress)

2.5.3.3 Denominators
1. Active Clinical patients ages 50 through 75 years without a documented history of colorectal cancer or total colectomy. Broken down by gender.

Note: Since HEDIS calculates age at the end of the Report Period, the patients at the beginning of the Report Period must be at least 50 years of age and 51 years of age at the end of the Report Period.

2. GPRA: User Population patients ages 50 through 75 years without a documented history of colorectal cancer or total colectomy. Broken down by gender.

2.5.3.4 Numerators
1. GPRA: Patients who have had any Colorectal Cancer (CRC) screening, defined as any of the following:
   A. Fecal Occult Blood Test (FOBT) or FIT during the Report Period
   B. Flexible sigmoidoscopy in the past 5 years
   C. Colonoscopy in the past 10 years
2. Patients with documented CRC screening refusal in the past year.
3. Patients with Fecal Occult Blood test (FOBT) or Fecal Immunochemical Test (FIT) during the Report Period.
4. Patients with a flexible sigmoidoscopy in the past 5 years or a colonoscopy in the past 10 years.
2.5.3.5 Definitions

Denominator Exclusions

Any diagnosis ever of one of the following:

- Colorectal Cancer
  - Diagnosis (POV or Problem List entry where the status is not Deleted):
    ICD-9: 153.*, 154.0, 154.1, 197.5, V10.05, V10.06; ICD-10: C18.*, C19, C20, C21.2, C21.8, C78.5, Z85.030, Z85.038, Z85.048 [BGP COLORECTAL CANCER DXS]
    SNOMED data set PXRM COLORECTAL CANCER (Problem List only)
    CPT G0213 through G0215 (old codes), G0231 (old code) [BGP COLORECTAL CANCER CPTS]
  - Total Colectomy
    CPT 44150 through 44151, 44152 (old code), 44153 (old code), 44155 through 44158, 44210 through 44212 [BGP TOTAL COLECTOMY CPTS]
    Procedure ICD-9: 45.8*; ICD-10: 0DTE*ZZ [BGP TOTAL COLECTOMY PROCS]

Colorectal Cancer Screening

The most recent of any of the following during applicable timeframes:

- FOBT or FIT
  CPT 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code) [BGP FOBT CPTS]
  LOINC taxonomy
  Site-populated taxonomy BGP GPRA FOB TESTS
- Flexible Sigmoidoscopy
  Procedure ICD-9: 45.24; ICD-10: 0DJD8ZZ [BGP SIG PROCS]
  CPT 45330 through 45347, 45349, 45350, G0104 [BGP SIG CPTS]
- Colonoscopy
– Procedure ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; ICD-10: 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5N8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E8ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F8ZX, 0D9G3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K8ZX, 0D9L3ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9N4ZX, 0D9N7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBE7ZX, 0DBE8ZX, 0DBE8ZZ, 0DBF3ZX, 0DBF4ZX, 0DBF7ZX, 0DBF8ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBG7ZX, 0DBG8ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBH8ZX, 0DBH8ZZ, 0DBK3ZX, 0DBK4ZX, 0DBK7ZX, 0DBK8ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBL7ZX, 0DBL8ZX, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBN3ZX, 0DBN4ZX, 0DBN7ZX, 0DBN8ZX, 0DBN8ZZ, 0DJD8ZZ [BGP COLO PROCS]
– CPT 44388 through 44394, 44397, 44401 through 44408, 45355, 45378 through 45393, 45398, G0105, G0121, G9252, G9253 [BGP COLO CPTS]

Screening Refusals in Past Year

• FOBT or FIT
  Refusal of any of the following:
  – Lab Fecal Occult Blood test
  – CPT code 82270, 82274, 89205 (old code), G0107 (old code), G0328, G0394 (old code) [BGP FOBT CPTS]

• Flexible Sigmoidoscopy
  Refusal of any of the following:
  – Procedure ICD-9: 45.24; ICD-10: 0DJD8ZZ [BGP SIG PROCS]
  – CPT 45330 through 45347, 45349, 45350, G0104 [BGP SIG CPTS]

• Colonoscopy
Refusal of any of the following:

- Procedure ICD-9: 45.22, 45.23, 45.25, 45.42, 45.43; 0D5E4ZZ, 0D5E8ZZ, 0D5F4ZZ, 0D5F8ZZ, 0D5G4ZZ, 0D5G8ZZ, 0D5H4ZZ, 0D5H8ZZ, 0D5K4ZZ, 0D5K8ZZ, 0D5L4ZZ, 0D5L8ZZ, 0D5M4ZZ, 0D5M8ZZ, 0D5N4ZZ, 0D5N8ZZ, 0D9E3ZX, 0D9E4ZX, 0D9E7ZX, 0D9E8ZX, 0D9F3ZX, 0D9F4ZX, 0D9F7ZX, 0D9F8ZX, 0D9G3ZX, 0D9G4ZX, 0D9G7ZX, 0D9G8ZX, 0D9H3ZX, 0D9H4ZX, 0D9H7ZX, 0D9H8ZX, 0D9K3ZX, 0D9K4ZX, 0D9K7ZX, 0D9K8ZX, 0D9L3ZX, 0D9L4ZX, 0D9L7ZX, 0D9L8ZX, 0D9M3ZX, 0D9M4ZX, 0D9M7ZX, 0D9M8ZX, 0D9N3ZX, 0D9N4ZX, 0D9N7ZX, 0D9N8ZX, 0DBE3ZX, 0DBE4ZX, 0DBE7ZX, 0DBE8ZX, 0DBE8ZZ, 0DBF3ZX, 0DBF4ZX, 0DBF7ZX, 0DBF8ZX, 0DBF8ZZ, 0DBG3ZX, 0DBG4ZX, 0DBG7ZX, 0DBG8ZX, 0DBG8ZZ, 0DBH3ZX, 0DBH4ZX, 0DBH7ZX, 0DBH8ZX, 0DBH8ZZ, 0DBK3ZX, 0DBK4ZX, 0DBK7ZX, 0DBK8ZX, 0DBK8ZZ, 0DBL3ZX, 0DBL4ZX, 0DBL7ZX, 0DBL8ZX, 0DBL8ZZ, 0DBM3ZX, 0DBM4ZX, 0DBM7ZX, 0DBM8ZX, 0DBM8ZZ, 0DBN3ZX, 0DBN4ZX, 0DBN7ZX, 0DBN8ZX, 0DBN8ZZ, 0JDJ8ZZ [BGP COLO PROCS]
- CPT 44388 through 44394, 44397, 44401 through 44408, 45355, 45378 through 45393, 45398, G0105, G0121, G9252, G9253 [BGP COLO CPTS]

2.5.3.6 **GPRA 2018 Target**

During GPRA Year 2018, achieve the target rate of 32.6% for the proportion of clinically appropriate patients ages 50 through 75 who have received colorectal screening.

2.5.3.7 **Patient List**

List of patients 50 through 75 with CRC screening or refusal, if any.

2.5.4 **Tobacco Use and Exposure Assessment**

2.5.4.1 **Owner and Contact**

Chris Lamer, PharmD, Epidemiology Program: Dayle Knutson

2.5.4.2 **National Reporting**

NATIONAL (included in National GPRA/GPRAMA Report; *not* reported to OMB and Congress)
2.5.4.3 Denominators

1. Active Clinical patients ages 5 and older. Broken down by gender and age groups: 5 through 13 years, 14 through 17 years, 18 through 24 years, 25 through 44 years, 45 through 64 years, 65 years and older (HP 2020).

2. Pregnant female User Population patients with no documented miscarriage or abortion.

2.5.4.4 Numerators

1. Patients screened for tobacco use during the Report Period (during the past 20 months for pregnant female patients denominator).

2. Patients identified during the Report Period (during the past 20 months for pregnant female patients denominator) as current tobacco users.
   A. Current smokers
   B. Current smokeless tobacco users
   C. Current ENDS user

3. Patients exposed to ETS during the Report Period (during the past 20 months for pregnant female patients denominator).

2.5.4.5 Definitions

Pregnancy

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.
- At least two visits during the past 20 months, where the primary provider is not a CHR (Provider code 53) with any of the following:

Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.
The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes". The time period is extended to include patients who were pregnant during the Report Period but who had their tobacco assessment prior to that.

**Miscarriage**
- Occurring after the second pregnancy POV and during the past 20 months
  - POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion**
- Occurring after the second pregnancy POV and during the past 20 months
  - POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Tobacco Screening**
Time frame for pregnant female patients is the past 20 months
- Any Health Factor for category Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS-CHEWING/DIP), TOBACCO (ELECTRONIC NICOTINE DELIVERY SYSTEMS [ENDS]), TOBACCO (EXPOSURE)
- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted):
  - ICD-9: 305.1, 305.1* (old codes), 649.00 through 649.04, V15.82 (tobacco-related diagnosis); ICD-10: F17.2*, O99.33*, Z72.0, Z87.891 [BGP TOBACCO DXS]
  - SNOMED data set PXRM BGP TOBACCO SCREENED (Problem List only)
- Dental code 1320
• Patient Education codes containing “TO-”, “-TO”, “-SHS”, 305.1, 305.1* (old codes), 649.00 through 649.04, V15.82, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F, 1000F, G8455 through G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, or SNOMED codes 160603005, 160604004, 160605003, 160606002, 160619003, 191887008, 191888003, 191889006, 228494002, 228504007, 228514003, 228515002, 228516001, 228517005, 228518000, 230059006, 230060001, 230062009, 230063004, 230064005, 230065006, 266920004, 428041000124106, 428061000124105, 428071000124103, 449868002, 59978006, 65568007, 77176002, 81703003, 82302008, 89765005.

• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), G8455 through G8457 (old codes), G8402 (old code), G8453 (old code), G9275, G9276, 1034F (Current Tobacco Smoker), 1035F (Current Smokeless Tobacco User), 1036F (Current Tobacco Non-User), 1000F (Tobacco Use Assessed) [BGP TOBACCO SCREEN CPTS]

Tobacco Users
Time frame for pregnant female patients is the past 20 months

• Health Factors: Current Smoker, Current Smokeless, Current Smoker and Smokeless, Current ENDS user, Cessation-Smoker, Cessation-Smokeless, Cessation ENDS user, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day, Heavy Tobacco Smoker, Light Tobacco Smoker

• Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  – ICD-9: 305.1, 305.10 through 305.12 (old codes), 649.00 through 649.04; ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*, Z72.0 [BGP TOBACCO USER DXS]
  – SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only)

• CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, 1036F (Current Tobacco Non-User), G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276 [BGP TOBACCO USER CPTS]

Current Smokers
Time frame for pregnant female patients is the past 20 months

• Health Factors: Current Smoker, Current Smoker and Smokeless, Cessation-Smoker, Current Smoker, status unknown, Current smoker, every day, Current smoker, some day, Heavy Tobacco Smoker, Light Tobacco Smoker

• Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
– ICD-9: 305.1, 305.10 through 305.12 (old codes), 649.00 through 649.04; ICD-10: F17.200, F17.203 through F17.210, F17.213 through F17.219, F17.290, F17.293 through F17.299, O99.33* [BGP GPRA SMOKING DXS]
– SNOMED data set PXRM BGP TOBACCO SMOKER (Problem List only)
  • CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, G8455 (old code), G8402 (old code), G8453 (old code) [BGP SMOKER CPTS]

Current Smokeless
Time frame for pregnant female patients is the past 20 months
• Health Factors: Current Smokeless, Current Smoker and Smokeless, or Cessation-Smokeless
• Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  – ICD-10: F17.220, F17.223 through F17.229 [BGP GPRA SMOKELESS DXS]
  – SNOMED data set PXRM BGP TOBACCO SMOKELESS (Problem List only)
  • CPT 1035F, G8456 (old code) [BGP SMOKELESS TOBACCO CPTS]

ENDS
• Health Factors: Current ENDS user or Cessation ENDS user

ETS
Time frame for pregnant female patients is the past 20 months
• Health Factors: Smoker in Home, Exposure to ETS

2.5.4.6 Patient List
List of patients 5 and older with documented tobacco screening, if any.

2.5.5 Tobacco Cessation

2.5.5.1 Owner: Contact
Chris Lamer, PharmD, Epidemiology Program: Dayle Knutson

2.5.5.2 National Reporting
NATIONAL (included in IHS Performance Report; reported to OMB and Congress)
2.5.5.3 Denominators

1. Active clinical patients identified as current tobacco users or tobacco users in cessation. Broken down by gender and age groups: younger than 12 years, 12 through 17 years, 18 years and older.

2. GPRA: User Population patients identified as current tobacco users or tobacco users in cessation. Broken down by gender and age groups: younger than 12 years, 12 through 17 years, 18 years and older.

2.5.5.4 Numerators

1. Patients who have received tobacco cessation counseling or received a prescription for a smoking cessation aid anytime during the Report Period.

2. Patients identified as having quit their tobacco use anytime during the Report Period.

3. GPRA: Patients who received tobacco cessation counseling, received a prescription for a tobacco cessation aid, or quit their tobacco use anytime during the Report Period.

2.5.5.5 Definitions

Denominator

Current Tobacco Users or Tobacco Users in Cessation:

CRS will search first for all health factors documented in the Tobacco, TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP) and TOBACCO (ELECTRONIC NICOTINE DELIVERY SYSTEMS [ENDS]) categories during the Report Period.

If health factor(s) are found and at least one of them is one of the health factors listed below, the patient is counted as a current tobacco user or tobacco user in cessation. The patient is not counted as receiving cessation counseling.

Tobacco User Health Factors (TUHFs):

- Cessation-Smoker
- Cessation-Smokeless
- Cessation ENDS user
- Current Smoker
- Current Smokeless
- Current Smoker and Smokeless
- Current ENDS user
- Current Smoker, status unknown
- Current Smoker, every day
- Current Smoker, some day
- Heavy Tobacco Smoker
- Light Tobacco Smoker

If a health factor is found and it is not a TUHF, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a tobacco user.

If no health factor was found, CRS will then search for any of the following codes documented during the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted):
  - ICD-9: 305.1, 305.10 through 305.12 (old codes), 649.00 through 649.04;
    ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*, Z72.0 [BGP TOBACCO USER DXS]
  - SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only)
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276 [BGP TOBACCO USER CPTS]

If any of these codes are found, the patient will be considered a tobacco user.

If no health factor or other tobacco user-defining code listed above was found during the specified timeframe, CRS will then search for the most recent health factor in the TOBACCO (SMOKING), TOBACCO (SMOKELESS – CHEWING/DIP) and TOBACCO (ELECTRONIC NICOTINE DELIVERY SYSTEMS [ENDS]) categories documented during an expanded timeframe of any time prior to the Report Period. For example, a patient with the most recent health factor being documented 5 years prior to the Report Period.

**Note:** If multiple health factors were documented on the same date and if any of them are TUHF(s), all of the health factors will be considered as TUHF(s).

If a health factor is found during the expanded timeframe, and is a TUHF, the patient will be considered a potential tobacco user.
If a health factor is found during the expanded timeframe and it is not one of the TUHFs, CRS will then search for CPT 1034F or 1035F documented after the health factor. If one of these codes is found, the patient will be considered a potential tobacco user.

If no health factor was found, CRS will then search for any of the following codes documented through the beginning of the Report Period:

- Tobacco-related diagnoses (POV or Problem List entry where the status is not Inactive or Deleted):
  - ICD-9: 305.1, 305.10 through 305.12 (old codes), 649.00 through 649.04; ICD-10: F17.2*0, F17.2*3, F17.2*8, F17.2*9, O99.33*, Z72.0 [BGP TOBACCO USER DXS]
  - SNOMED data set PXRM BGP CURRENT TOBACCO (Problem List only)
- CPT 99406, 99407, G0375 (old code), G0376 (old code), 1034F, 1035F, G8455 (old code), G8456 (old code), G8402 (old code), G8453 (old code), G9276 [BGP TOBACCO USER CPTS]

If any of these codes are found, the patient will be considered a potential tobacco user. If one of these codes is not found, the patient is considered a non-tobacco user and will not be included in the denominator.

If the patient is considered a potential tobacco user, CRS will then search for diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2*1, Z87.891 [BGP TOBACCO PAST USE DXS]; SNOMED data set PXRM BGP QUIT TOBACCO (Problem List only) with a date occurring after the health factor date and through the beginning of the Report Period. If one of these diagnoses is found, the patient will be considered as having quit their tobacco use and will not be included in the denominator. If a diagnosis is not found, the patient is included as a current tobacco user and will be included in the denominator.

**Tobacco Cessation Counseling**

Any of the following documented anytime during the Report Period:

- Patient education codes containing "TO-", "-TO", "-SHS", 305.1, 305.1* (old codes), 649.00 through 649.04, D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402, G8453, or SNOMED data set PXRM BGP TOBACCO TOPICS.
- Clinic code 94 (tobacco cessation clinic)
- Dental code 1320
• CPT D1320, 99406, 99407, G0375 (old code), G0376 (old code), 4000F, G8402, G8453

**Prescription for Tobacco Cessation Aid**

Any of the following documented anytime during the Report Period:

- Prescription for medication in the site-populated BGP CMS SMOKING CESSATION MEDS taxonomy that does not have a comment of RETURNED TO STOCK

- Prescription for any medication with name containing “NICOTINE PATCH”, “NICOTINE POLACRILEX”, “NICOTINE INHALER”, “NICOTINE NASAL SPRAY” that does not have a comment of RETURNED TO STOCK

- CPT 4001F

**Quit Tobacco Use**

Any of the following documented anytime during the Report Period and after the date of the code found indicating the patient was a current tobacco user:

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  - ICD-9: 305.13 Tobacco use in remission (old code), V15.82; ICD-10: F17.2*1, Z87.891 [BGP TOBACCO PAST USE DXS]
  - SNOMED data set PXRM BGP QUIT TOBACCO (Problem List only)

- Health Factor (looks at the last documented health factor): Previous Smoker, Previous Smokeless, Previous (former) smoker, Previous (former) smokeless, Previous (former) ENDS user.

### 2.5.5.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 27.5% for the proportion of tobacco-using patients who receive tobacco cessation intervention or quit tobacco use.

### 2.5.5.7 Patient List

List of tobacco users with tobacco cessation intervention, if any, or who have quit tobacco use.
2.6 Behavioral Health Group

2.6.1 Alcohol Screening

2.6.1.1 Owner and Contact
Marcy Ronyak, Ph.D., LCSW, CDP, IHS Division of Behavioral Health (DBH)

2.6.1.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.6.1.3 Denominators
1. Active Clinical Plus BH patients ages 9 through 75. Broken down by age groups: 9-11, 12-19, 20-24, 25-34, 35-44, 45-54, and 55-75.

2. Active Clinical Plus BH patients ages 9 through 75 screened for alcohol use during the Report Period, not including refusals or patient education. Broken down by age groups: 12-19, 20-24, 25-34, 35-44, 45-54, and 55-75.

   Note: This denominator does NOT include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.

3. Active Clinical Plus BH patients ages 9 through 75.

4. Female Active Clinical patients ages 14 through 46 (child-bearing age).

5. Female Active Clinical patients ages 14 through 46 screened for alcohol use during the Report Period, not including refusals.

   Note: This denominator does NOT include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.

6. GPRA: User Population patients ages 9 through 75.

7. User Population patients ages 9 through 75 screened for alcohol use during the Report Period, not including refusals or patient education.

   Note: This denominator does NOT include patients with a screening refusal or an alcohol-related diagnosis, procedure, or patient education.
2.6.1.4 Numerators

1. GPRA: Patients screened for alcohol use or had an alcohol-related diagnosis or procedure during the Report Period. (With Denominators 1, 3, 6, and 7)

   Note: This numerator does not include refusals or alcohol-related patient education.

2. Patients with alcohol-related patient education during the Report Period. (With Denominator 1)

3. Patients who were screened positive for alcohol use. (With Denominators 2 and 5)

4. Patients screened for alcohol use, had an alcohol-related diagnosis or procedure, received alcohol-related patient education, during the Report Period. (With Denominator 4)

   Note: This numerator does not include refusals.

   A. Patients with alcohol screening during the Report Period.
   B. Patients with alcohol-related diagnosis or procedure during the Report Period.
   C. Patients with alcohol-related patient education during the Report Period.

2.6.1.5 Definitions

Alcohol Screening

Any of the following during the Report Period:

- Exam code 35
- Any CAGE Alcohol Health Factor
- POV ICD-9: V11.3, V79.1 [BGP ALCOHOL SCREEN DXS], or Behavioral Health System (BHS) Problem code 29.1
- CPT 99408, 99409, G0396, G0397, H0049, H0050, 3016F [BGP ALCOHOL SCREENING CPTS]
- Measurement in PCC or Behavioral Health (BH) of AUDT, AUDC, or CRFT

Alcohol-Related Diagnosis or Procedure

Any of the following during the Report Period:

- Alcohol-related Diagnosis
- SNOMED data set PXRM BGP ETOH RELATED DX (Problem List only)
- BHS POV or Problem Codes 10, 12.1, 14.2, 17.1, 18.1, 20.1, 22.1, 27, 29
  - Alcohol-related Procedure
    - Procedure ICD-9: 94.46, 94.53, 94.61 through 94.63, 94.67 through 94.69 [BGP ALCOHOL PROCEDURES]

### Alcohol-Related Patient Education

Any of the following during the Report Period:

- All Patient Education codes containing “AOD-” or “-AOD”, “CD-” or “-CD” (old codes), or V11.3, V79.1, 303.*, 305.0*, 291.*, 357.5* [BGP ALCOHOL EDUC DXS], 99408, 99409, G0396, G0397, H0049, H0050, 3016F [BGP ALCOHOL SCREENING CPTS], or SNOMED codes 15167005, 18653004, 191471000, 191475009, 191476005, 191477001, 191478006, 191480000, 191802004, 191804003, 191805002, 191811004, 191812006, 191813001, 19303008, 281004, 284591009, 2882810001, 119100, 29212009, 30491001, 34938008, 41083005, 42344001, 53936005, 61144001, 66590003, 7052005, 7200002, 73097000, 78524005, 79578000, 8635005.

### Positive Screen for Alcohol Use

Any of the following for patients with alcohol screening:

- Exam code 35 Alcohol Screening result of “Positive”
- Health factor of CAGE result of 1/4, 2/4, 3/4 or 4/4
- CPT G0396, G0397, 99408, 99409 [BGP ALCOHOL POSITIVE SCRN CPTS]
- AUDT result of greater than or equal (>=) to 8, AUDC result of greater than or equal to (>=) 4 for men and greater than or equal to (>=) 3 for women, CRFT result of 2 to 6

#### 2.6.1.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 37.0% for the proportion of patients ages 9 through 75 years who receive screening for alcohol use.

#### 2.6.1.7 Patient List

List of patients with documented alcohol screening and result if any.
2.6.2 Screening, Brief Intervention, and Referral to Treatment (SBIRT)

2.6.2.1 Owner: Contact
Marcy Ronyak, Ph.D., LCSW, CDP, IHS Division of Behavioral Health (DBH)

2.6.2.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.6.2.3 Denominators
1. Active Clinical Plus BH patients age 9 through 75 years. Broken down by gender and age groups: 9 through 12, 13 through 18, 19 through 24, 25 through 34, 45 through 54, 65 through 75.

2. Active Clinical Plus BH patients age 9 through 75 years screened positive for risky or harmful alcohol use during the Report Period. Broken down by gender and age groups: 9 through 12, 13 through 18, 19 through 24, 25 through 34, 45 through 54, 65 through 75.

3. User Population patients age 9 through 75 years.

4. GPRA: User Population patients age 9 through 75 years who screened positive for risky or harmful alcohol use during the Report Period.

2.6.2.4 Numerators
1. Patients screened in Ambulatory Care for risky or harmful alcohol use (with Denominator 1).
   A. Patients screened positive for risky or harmful alcohol use.
   B. Patients provided a brief negotiated interview (BNI) or Brief Intervention (BI) in Ambulatory care within 7 days of screen.

2. GPRA: Patients provided a brief negotiated interview (BNI) or Brief Intervention (BI) in Ambulatory Care within 7 days of screen (with Denominators 2 and 3).
   A. Patients who received a BNI/BI on same day as screen.
   B. Patients who received a BNI/BI 1-3 days after screen.
   C. Patients who received a BNI/BI 4-7 days after screen.
   D. Patients who were referred treatment within 7 days of screen.
2.6.2.5 Definitions

Ambulatory Care

- Service Category A (Ambulatory)

Screening for Risky or Harmful Alcohol Use

Any of the following:

- Exam code 35
- Any Alcohol Health Factor (i.e., CAGE)
- POV ICD-9: V79.1 Screening for Alcoholism [BGP SCREEN FOR ALCOHOLISM DX]
- CPT G0396, G0397, H0049, H0050, 99408, 99409, 3016F [BGP ALCOHOL SCREENING CPTS]
- Measurement in PCC of AUDT, AUDC, CRFT

Positive Screen for Risky or Harmful Alcohol Use

Any of the following for the screening performed:

- Exam code 35 Alcohol Screening result of Positive
- Health factor of CAGE result of 1/4, 2/4, 3/4 or 4/4
- Any of the following:
  - AUDT result ≥ 8
  - AUDC result ≥ 4 (men)
  - AUDC result ≥ 3 (women)
  - CRFT result ≥ 2 and CRFT result ≤ 6

BNI/BI

Any of the following documented at the Ambulatory Care visit or within seven days of the Ambulatory Care visit at a face-to-face visit, which excludes chart reviews and telecommunication visits:

- CPT G0396, G0397, H0050, 99408, 99409, 96150 through 96155 [BGP BNI CPTS]
- Patient education code containing AOD-BNI, G0396, G0397, H0050, 99408, 99409, 96150 through 96155

Referral to Treatment

- Patient education code AOD-TX
2.6.2.6 **GPRA 2018 Target**

During GPRA Year 2018, achieve the target rate of 8.9% for the proportion of patients ages 9 through 75 who screened positive for risky or harmful alcohol use and who received a Brief Negotiated Interview (BNI) or Brief Intervention (BI) within 7 days of screen.

2.6.2.7 **Patient List**

- List of patients with screening for risky or harmful alcohol use, results of screen, BNI/BI, and referral, if any.

2.6.3 **Intimate Partner (Domestic) Violence Screening**

2.6.3.1 **Owner and Contact**

Terry Friend, IHS Division of Behavioral Health (DBH)

2.6.3.2 **National Reporting**

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.6.3.3 **Denominators**

1. Female Active Clinical patients ages 14 through 46 years.
2. GPRA: Female User Population patients ages 14 through 46 years.

2.6.3.4 **Numerators**

1. GPRA: Patients screened for or diagnosed with IPV/DV during the Report Period.

   **Note:** This numerator does not include refusals.

   A. Patients with documented IPV/DV exam.
   B. Patients with IPV/DV related diagnosis.
   C. Patients provided with IPV/DV patient education or counseling.

2.6.3.5 **Definitions**

**IPV/DV Screening**

Defined as at least one of the following:

- IPV/DV Screening
- Exam code 34
- BHS IPV/DV exam

**IPV/DV Related Diagnosis**
- POV, Current PCC or BHS Problem List ICD-9: 995.80 through 83, 995.85, V15.41, V15.42, V15.49; ICD-10: T74.11XA, T74.21XA, T74.31XA, T74.91XA, T76.11XA, T76.21XA, T76.31XA, T76.91XA, Z91.410 [BGP DV DXS]
- SNOMED data set PXRM BGP IPV DV DX (Problem List only)
- BHS POV 43.*, 44.*

**IPV/DV Patient Education**
- Patient Education codes containing “DV-” or “-DV”, 995.80 through 995.83, V15.41, V15.42, V15.49 [BGP IPV/DV EDUC DXS], or SNOMED 3027571011, 3027627017, 371772001, 406138006, 412732008, 429746005, 431027007, 432527004

**IPV/DV Counseling**
- POV ICD-9: V61.11; ICD-10: Z69.11 [BGP IPV/DV COUNSELING ICDS]

### 2.6.3.6 GPRA 2018 Target
During GPRA Year 2018, achieve the target rate of 41.6% for the proportion of female patients ages 14 through 46 years who receive screening for domestic violence.

### 2.6.3.7 Patient List
List of female patients 14-46 with documented IPV/DV screening, if any.

### 2.6.4 Depression Screening

#### 2.6.4.1 Owner and Contact
Miranda Carman, IHS Division of Behavioral Health (DBH)

#### 2.6.4.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

#### 2.6.4.3 Denominators
1. Active Clinical patients ages 12 through 17. Broken down by gender.
2. Active Clinical patients ages 18 and older. Broken down by gender.
   
   A. Active Clinical patients ages 65 and older. Broken down by gender

3. Active Diabetes patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever. Broken down by gender.

4. Active coronary heart disease (CHD) patients, defined as Active Clinical patients diagnosed with CHD prior to the Report Period, and at least two visits during the Report Period, and either two CHD-related visits ever or CHD entry on the Problem List. Broken down by gender.


2.6.4.4 Numerators

1. GPRAMA: Patients screened for depression or diagnosed with mood disorder at any time during the Report Period.
   
   **Note:** This numerator does not include refusals.

   A. Patients screened for depression during the Report Period.
   
   B. Patients with a diagnosis of a mood disorder during the Report Period.
   
   C. Patients who were screened in a Behavioral Health clinic.

2. Patients with depression-related education in past year.

   **Note:** Depression-related patient education does not count toward the GPRAMA numerator and is included as a separate numerator only.

2.6.4.5 Definitions

**Diabetes**

First DM Purpose of Visit ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.
CHD

For Problem List entries, must have Date of Onset or Date Entered prior to the Report Period:

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 410.0 through 413.*, 414.0 through 414.9, 429.2; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9, Z95.5 [BGP CHD DXS]

- One or more Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Interventions (PCI) procedures, defined as any of the following:
  - CABG Procedure:
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
      - SNOMED data set PXRM BGP CABG (Problem List only)
    - CPT 33510 through 33514, 33516 through 33519, 33521 through 33523, 33530, 33533 through 33536, 33572, 35600, S2205 through S2209 [BGP CABG CPTS]
  - PCI Procedure
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
      - SNOMED data set PXRM BGP PCI (Problem List only)
    - CPT 92920, 92924, 92928, 92932, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
    - Procedure ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06 through 36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02732**, 0274**, 02733**, 02734** [BGP PCI CM PROCS]

Depression Screening

Any of the following:

- Exam code 36
- POV ICD-9: V79.0 [BGP DEPRESSION SCRN DXS]
- CPT 1220F, 3725F, G0444 [BGP DEPRESSION SCREEN CPTS]
- BHS Problem code 14.1 (screening for depression)
- Measurement in PCC or BH of PHQ2, PHQ9 or PHQT

### Mood Disorders

At least two visits in PCC or BHS during the Report Period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. These POV codes are:

- BHS POV 14, 15

### Depression-Related Patient Education

Any of the following during the Report Period:

- Patient education codes containing “DEP-” (depression), 296.2* or 296.3*, “BH-” (behavioral and social health), 290 through 319, 995.5*, or 995.80 through 995.85, “SB-” (suicidal behavior) or 300.9, or “PDEP-” (postpartum depression) or 648.44, or SNOMED codes 14183003, 15193003, 15639000, 18818009, 191610000, 191611001, 191613003, 191616006, 191659001, 192080009, 19527009, 19694002, 20250007, 231504006, 231542000, 2506003, 25922000, 2618002, 268621008, 28475009, 3109008, 319768000, 320751009, 33078009, 35489007, 36170009, 36474008, 36923009, 370143000, 38451003, 38694004, 39809009, 40379007, 40568001, 42925002, 430852001, 440257004, 48589009, 63778009, 66344007, 67711008, 69392006, 71336009, 73867007, 75084000, 75837004, 76441001, 77486005, 77911002, 78667006, 79298009, 81319007, 83176005, 832007, 84760002, 85080004, 87512008

### Behavioral Health Clinic

Clinic codes C4, C9, 14, 43, 48
2.6.4.6  GPRA 2018 Target
Age 12-17: During GPRA Year 2018, achieve the target rate of 27.6% for the proportion of patients ages 12 through 17 who receive annual screening for depression.

Age 18 and older: During GPRA Year 2018, achieve the target rate of 42.2% for the proportion of adults ages 18 and older who receive annual screening for depression.

2.6.4.7  Patient List
List of patients with documented depression screening or diagnosed with mood disorder, if any.

2.6.5  Antidepressant Medication Management

2.6.5.1  Owner and Contact
Kevin Brooks, RPh MHA, IHS Division of Behavioral Health (DBH)

2.6.5.2  National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.6.5.3  Denominators
1. As of the 120th day of the Report Period, Active Clinical Plus BH patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

2. As of the 120th day of the Report Period, User Population patients 18 years and older who were diagnosed with a new episode of depression and treated with antidepressant medication in the past year.

2.6.5.4  Numerators
1. Effective Acute Phase Treatment: Patients who filled a sufficient number of separate prescriptions or refills of antidepressant medication for continuous treatment of at least 84 days (12 weeks).

2. Effective Continuation Phase Treatment: Patients who filled a sufficient number of separate prescriptions or refills of antidepressant medication treatment to provide continuous treatment for at least 180 days (6 months).
2.6.5.5 Definitions

Major Depression
POV ICD-9: 296.20 through 296.25, 296.30 through 296.35, 298.0, 311; ICD-10: F32.0 through F32.4, F32.8 through F33.3, F33.41, F33.9 [BGP MAJOR DEPRESSION (ADM)]

Index Prescription (Rx) Start Date
The date of the earliest prescription for antidepressant medication filled during the denominator inclusion period. Note: Outside medications and e-prescribed medications (prescription number begins with "X" or days' supply is zero) will not be included in these measures.

Antidepressant Medications
Medication taxonomy BGP HEDIS ANTIDEPRESSANT MEDS.

- Medications are: Tricyclic antidepressants (TCA) and other cyclic antidepressants, Selective serotonin reuptake inhibitors (SSRI), Monoamine oxidase inhibitors (MAOI), Serotonin-norepinephrine reuptake inhibitors (SNRI), and other antidepressants. Medications must not have a comment of RETURNED TO STOCK.

Denominator Inclusions
To be included in the denominator, patient must meet the following condition:

- Filled a prescription for an antidepressant medication (see the list of medications above) within the 121st day of the year prior to the Report Period to the 120th day of the Report Period. For example, if Report Period is July 1, 2017 through June 30, 2018, patient must have filled a prescription during November 01, 2016 through October 29, 2017. In V Medication, Date Discontinued must not be equal to the prescription, (i.e., visit date).

Denominator Exclusions
Patients with any of the following will be excluded from the denominator:

- Patients who did not have a diagnosis of major depression in an inpatient, outpatient, ED, intensive outpatient or partial hospitalization setting (defined as Service Categories A and H) during the 60 days prior to the IPSD (inclusive) through 60 days after the IPSD (inclusive).
- Patients who had a new or refill prescription for antidepressant medication (see the list of medications that follows) within 105 days prior to the Index Rx Start Date are excluded as they do not represent new treatment episodes.
Effective Acute Phase Treatment Numerator

For all antidepressant medication prescriptions filled (see the list of medications that follows) within 114 days of the Index Rx Date, from V Medication CRS counts the days prescribed (i.e., treatment days) from the Index Rx Date until a total of 84 treatment days has been established. If the patient had a total gap exceeding 31 days or if the patient does not have 84 treatment days within the 114 day timeframe, the patient is not included in the numerator.

Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed: \( November 19, 2018 - November 15, 2018 = 4 \)

Example of Patient Included in Numerator:

- First prescription:
  - Index Rx Date: November 1, 2017
  - Number of Days Prescribed: 30
  \( November 1, 2017 + 30 \text{ days} = December 1, 2017 \)
  Prescription covers the patient through December 1, 2017

- Second prescription:
  - Rx Date: December 15, 2017
  - Number of Days Prescribed: 30:
    - Gap #1 equals 14 days:
      \( December 15, 2017 - December 1, 2017 = 14 \text{ days} \)

- Third prescription:
  - Rx Date: January 10, 2018
  - Number of Days Prescribed: 30
  - No gap days
  \( November 1, 2017 + 114 \text{ days} = February 23, 2018 \)
  Prescription covers the patient through February 13, 2018.
• Patient’s 84th treatment day occurs on February 7, 2018:

\[ February 7, 2018 \leq February 23, 2018 \]

Number of gap days = 14, which is < 31

Patient is included in the Numerator.

Example of Patient Not Included in Numerator:

• First prescription:
  – Index Rx Date: November 1, 2017
  – Number of Days Prescribed: 30
  \[ November 1, 2017 + 30 \text{ days} = December 1, 2017 \]

Prescription covers the patient through December 1, 2017.

• Second prescription:
  – Rx Date: December 15, 2017
  – Number of Days Prescribed: 30:
  – Gap #1 equals 14 days:
  \[ December 15, 2017 - December 1, 2017 = 14 \text{ days} \]


• Third prescription:
  – Rx Date: February 1, 2018
  – Number of Days Prescribed: 30
  – Gap #2 equals 18 days:
  \[ February 1, 2018 - January 14, 2018 = 18 \]

  – Total number of gap days = 32:
  \[ 14 + 18 = 32 \]

Patient is not included in the numerator.
Effective Continuation Phase Treatment Numerator

For all antidepressant medication prescriptions (see the previous list of medications) filled within 231 days of the Index Rx Date, CRS counts the days prescribed (i.e., treatment days) (from V Medication) from the Index Rx Date until a total of 180 treatment days has been established. If the patient had a total gap exceeding 51 days or if the patient does not have 180 treatment days within the 231-day timeframe, the patient is not included in the numerator.

Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed: November 19, 2018 – November 15, 2018 = 4

2.6.5.6 GPRA 2018 Target

Acute Treatment: During GPRA Year 2018, achieve the target rate of 41.9% for the proportion of patients ages 18 and older with acute treatment for depression.

Continuous Treatment: During GPRA Year 2018, achieve the target rate of 21.9% for the proportion of patients ages 18 and older with continuous treatment for depression.

2.6.5.7 Patient List

List of patients with new depression diagnosis and acute phase treatment (APT) and continuation phase treatment (CONPT), if any.

2.7 Cardiovascular Disease Related Group

2.7.1 Obesity Assessment

2.7.1.1 Owner and Contact

Nutrition Program, Kelli Begay
2.7.1.2 Denominators

1. Active Clinical patients ages 2 through 74 years. Broken down by gender and age groups: 2 through 5 years, 6 through 11 years, 12 through 19 years, 20 through 24 years, 25 through 34 years, 35 through 44 years, 45 through 54 years, 55 through 74 years.

2. User Population patients ages 2 through 74 years. Broken down by gender and age groups: 2 through 5 years, 6 through 11 years, 12 through 19 years, 20 through 24 years, 25 through 34 years, 35 through 44 years, 45 through 54 years, 55 through 74 years.

2.7.1.3 Numerators

1. Patients for whom BMI can be calculated.

   Note: This numerator does not include refusals.

   A. For those with a BMI calculated, patients considered overweight but not obese using BMI and standard tables.

   B. For those with a BMI calculated, patients considered obese using BMI and standard tables.

   C. Total of overweight and obese.

2. Patients with documented refusal in past year.

2.7.1.4 Definitions

BMI

CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the Report Period. For ages 19 through 50 years, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50 years of age, height and weight within last 2 years, not required to be recorded on same day. Overweight but not obese is defined as BMI of 25 through 29 for adults ages 19 years and older. Obese is defined as BMI of 30 or more for adults 19 years of age and older. For ages 2 through 18 years, definitions are based on standard tables.

Patients whose BMI either is greater or less than the Data Check Limit range shown in the BMI Standard Reference Data Table in PCC will not be included in the report counts for Overweight or Obese.
Refusals

Include REF (refused), NMI, and UAS (unable to screen) and must be documented during the past year. For ages 18 years and under, both the height and weight must be refused on the same visit at any time during the past year. For ages 19 years and older, the height and weight must be refused during the past year and are not required to be on the same visit.

2.7.1.5 Patient List

List of patients with current BMI, if any.

2.7.2 Childhood Weight Control

2.7.2.1 Owner and Contact

Dr. Ann Bullock

2.7.2.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.7.2.3 Denominators

1. Active Clinical Patients 2 to 5 years for whom a BMI could be calculated. Broken down by gender and age groups: 2, 3, 4, 5.

2. GPRA: User Population Patients 2 to 5 years for whom a BMI could be calculated.

2.7.2.4 Numerators

1. Patients with BMI in the 85th to 94th percentile

2. GPRA: Patients with a BMI at or above the 95th percentile.

3. Patients with a BMI at or above the 85th percentile.
2.7.2.5 Definitions

Age

All patients for whom a BMI could be calculated and who are between the ages of 2 and 5 at the beginning of the Report Period and who do not turn age 6 during the Report Period are included in this measure. Age in the age groups is calculated based on the date of the most current BMI found. For example, a patient may be 2 at the beginning of the time period but is 3 at the time of the most current BMI found. That patient will fall into the Age 3 group.

BMI

CRS looks for the most recent BMI in the Report Period. CRS calculates BMI at the time the report is run, using NHANES II. A height and weight must be taken on the same day any time during the Report Period. The BMI values for this measure reported differently than in Obesity Assessment since this age group is children ages 2 to 5, whose BMI values are age-dependent. The BMI values are categorized as Overweight for patients with a BMI in the 85th to 94th percentile and Obese for patients with a BMI at or above the 95th percentile.

A patient whose BMI either is greater or less than the Data Check Limit range shown in Table 2-2 will not be included in the report counts for Overweight or Obese.

Table 2-1: Data Check Limit

<table>
<thead>
<tr>
<th>Low-High Ages</th>
<th>Sex</th>
<th>BMI (Overweight)</th>
<th>BMI (Obese)</th>
<th>Data Check Limits BMI &gt;</th>
<th>Data Check Limits BMI &lt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-2</td>
<td>Male</td>
<td>17.7</td>
<td>18.7</td>
<td>36.8</td>
<td>7.2</td>
</tr>
<tr>
<td>2-2</td>
<td>Female</td>
<td>17.5</td>
<td>18.6</td>
<td>37.0</td>
<td>7.1</td>
</tr>
<tr>
<td>3-3</td>
<td>Male</td>
<td>17.1</td>
<td>18.0</td>
<td>35.6</td>
<td>7.1</td>
</tr>
<tr>
<td>3-3</td>
<td>Female</td>
<td>17.0</td>
<td>18.1</td>
<td>35.4</td>
<td>6.8</td>
</tr>
<tr>
<td>4-4</td>
<td>Male</td>
<td>16.8</td>
<td>17.8</td>
<td>36.2</td>
<td>7.0</td>
</tr>
<tr>
<td>4-4</td>
<td>Female</td>
<td>16.7</td>
<td>18.1</td>
<td>36.0</td>
<td>6.9</td>
</tr>
<tr>
<td>5-5</td>
<td>Male</td>
<td>16.9</td>
<td>18.1</td>
<td>36.0</td>
<td>6.9</td>
</tr>
<tr>
<td>5-5</td>
<td>Female</td>
<td>16.9</td>
<td>18.5</td>
<td>39.2</td>
<td>6.8</td>
</tr>
</tbody>
</table>

2.7.2.6 GPRA 2018 Target

During GPRA Year 2018, achieve the long-term target rate of 22.6% for the proportion of children with a BMI of 95% or higher.
2.7.2.7 Patient List
List of patients ages 2 through 5 years, with current BMI.

2.7.3 Weight Assessment and Counseling for Nutrition and Physical Activity

2.7.3.1 Owner and Contact
Nutrition Program, Kelli Begay

2.7.3.2 Denominators
1. Active Clinical patients ages 3 and older with no current diagnosis of pregnancy. Broken down by gender and age groups: 3 through 11, 12 through 17, 18 and older.

2.7.3.3 Numerators
1. Patients with comprehensive assessment, defined as having BMI documented, counseling for nutrition, and counseling for physical activity during the Report Period.
2. Patients with BMI documented during the Report Period.
3. Patients with counseling for nutrition during the Report Period.
4. Patients with counseling for physical activity during the Report Period.

2.7.3.4 Definitions
Age
Age is calculated at the end of the Report Period.

Pregnancy Definition
Any of the following:
- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.
- At least one visit during the Report Period, where the primary provider is not a Community Health Representative (CHR) (Provider code 53) with any of the following:

Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

**Miscarriage definition:**
- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion definition:**
- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**BMI**

Any of the following during the Report Period:
- CRS calculates BMI at the time the report is run, using NHANES II. For 18 and under, a height and weight must be taken on the same day any time during the Report Period. For ages 19 through 50 years, height and weight must be recorded within last 5 years, not required to be on the same day. For over 50 years of age, height and weight within last 2 years, not required to be recorded on same day.
- POV ICD-9: V85*; ICD-10: Z68.20 through Z68.54 [BGP BMI DXS]

**Counseling for Nutrition**
- CPT 97802 through 97804, G0270, G0271, G0447, S9449, S9452, S9470 [BGP CPT NUTRITION COUNSELING]
- POV ICD-9: V65.3; ICD-10: Z71.3 [BGP DIETARY SURVEILLANCE DXS]
- Patient Education codes ending “-N” or "-MNT" (or old code “-DT” [Diet]) or containing V65.3, Z71.3, 97802 through 97804, G0270, G0271, G0447, S9449, S9452, S9470

**Counseling for Physical Activity**
- CPT G0447, S9451 [BGP CPT PHYSICAL ACTIVITY]
- POV ICD-9: V65.41; ICD-10 Z71.82 [BGP EXERCISE COUNSELING DXS]
- Patient education codes ending “-EX” (Exercise) or containing V65.41, Z71.82, G0447, or S9451
2.7.3.5 Patient List
List of patients ages 3 and older with assessments, if any.

2.7.4 Nutrition and Exercise Education for At Risk Patients

2.7.4.1 Owner and Contact
Patient Education Program: Chris Lamer, PharmD
Nutrition Program: Kelli Begay

2.7.4.2 National Reporting
Not reported nationally

2.7.4.3 Denominators
1. Active Clinical patients ages 6 and older considered overweight (including obese). Broken down by gender.
   A. Active Clinical patients ages 6 and older considered obese. Broken down by age and gender and age groups.
2. Active Diabetic patients, defined as Active Clinical patients diagnosed with diabetes prior to the Report Period, and at least two visits during the Report Period, and two DM-related visits ever.

2.7.4.4 Numerators
1. Patients provided with medical nutrition therapy during the Report Period.
2. Patients provided with nutrition education during the Report Period.
3. Patients provided with exercise education during the Report Period.
4. Patients provided with other related exercise and nutrition (lifestyle) education.

2.7.4.5 Definitions
Diabetes
First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Overweight Categories
Defined as including both obese and overweight categories calculated by BMI.
• **Overweight**
  - Ages 19 years and older, BMI greater than or equal to 25.

• **Obese**
  - Ages 19 years and older, BMI greater than or equal to 30.

• For ages 18 years and under, definition based on standard tables. CRS calculates BMI at the time the report is run, using NHANES II. For ages 18 years and under, a height and weight must be taken on the same day any time during the Report Period. For ages 19 through 50 years, height and weight must be recorded within last 5 years, not required to be on the same day. For over ages 50 years, height and weight within last 2 years, not required to be recorded on same day.

**Medical Nutrition Therapy**

• CPT 97802 through 97804, G0270, G0271 [BGP CPT NUTRITION COUNSELING]

• Primary or secondary provider codes 07, 29

• Clinic codes 67, 36

**Nutrition Education**

• Patient Education codes ending “-N” or ”-MNT” (or old code “-DT” [Diet]) or containing V65.3, Z71.3, 97802 through 97804, G0270, G0271

• POV ICD-9: V65.3; ICD-10: Z71.3 [BGP DIETARY SURVEILLANCE DXS]

**Exercise Education**

POV ICD-9: V65.41 exercise counseling; ICD-10 Z71.82 [BGP EXERCISE COUNSELING DXS] or patient education codes ending ”-EX” (Exercise) or containing V65.41 or Z71.82.

**Related Exercise and Nutrition Education**

• Patient education codes ending "-LA" (lifestyle adaptation) or containing "OBS-" (obesity) or 278.00, 278.01, S9449, S9451, S9452, S9470, or SNOMED codes 111036000, 162863004, 162863004, 162864005, 162864005, 170798000, 190965006, 190966007, 238131007, 238132000, 238133005, 238134004, 238136002, 248311001, 248312008, 270486005, 275947003, 276792008, 290439001, 292464007, 293481008, 294493008, 295509007, 296526005, 297500005, 298464002, 360566006, 363247006, 408512008, 413487000, 414438005, 414916001, 414917005, 414918000, 414919008, 414920002, 415530009, 444862003, 444862003, 44772007, 450451007, 48499001, 5036006, 53146006, 62999006, 703316004, 705131003, 80660001, 82793005
2.7.4.6 Patient List
List of at risk patients, with education if any.

2.7.5 Physical Activity Assessment

2.7.5.1 Owner and Contact
Patient Education Program: Chris Lamer, PharmD
Nutrition Program: Alberta Becenti

2.7.5.2 Denominators
1. Active Clinical patients ages 5 and older. Broken down by gender and age groups:
   5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older.

2. Numerator 1 (Active Clinical Patients assessed for physical activity during the Report Period). Broken down by gender and age groups: 5 through 11, 12 through 19, 20 through 24, 25 through 34, 35 through 44, 45 through 54, 55 through 74, 75 and older.


2.7.5.3 Numerators
1. Patients assessed for physical activity during the Report Period. (With Denominators 1 and 3)
   A. Patients from Numerator 1 who have received exercise education following their physical activity assessment (with Denominators 2 and 4).
   B. Patients from Numerator 1 who have set at least one exercise goal following their physical activity assessment (with Denominators 2 and 4).

2.7.5.4 Definitions

Physical Activity Assessment
Any health factor for category Activity Level documented during the Report Period.
Exercise Education
- POV ICD-9: V65.41 exercise counseling; ICD-10 Z71.82 [BGP EXERCISE COUNSELING DXS]
- Patient education codes ending “-EX” (Exercise) or containing V65.41 or Z71.82

Exercise Goal
- Patient Goal with Goal Type of "Physical Activity" and Goal Status of "Goal Set".

2.7.5.5 Patient List
List of patients with physical activity assessment and any exercise education or goals.

2.7.6 Cardiovascular Disease and Blood Pressure Control

2.7.6.1 Owner and Contact
Dr. Dena Wilson, Chris Lamer, PharmD, and Mark Veazie

2.7.6.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.6.3 Denominators
1. Active Clinical patients ages 18 and older. Broken down by gender.
2. Active CHD patients, defined as Active Clinical patients diagnosed with CHD prior to the Report Period, and at least two visits during the Report Period, and either two CHD-related visits ever or CHD entry on the Problem List. Broken down by gender.

2.7.6.4 Numerators
1. Patients with BP value documented during the Report Period.
2.7.6.5 Definitions

CHD

For Problem List entries, must have Date of Onset or Date Entered prior to the Report Period:

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted) ICD-9: 410.0 through 413.*, 414.0 through 414.9, 429.2; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9, Z95.5 [BGP CHD DXS]

- One or more Coronary Artery Bypass Graft (CABG) or Percutaneous Coronary Interventions (PCI) procedures, defined as any of the following:
  - CABG Procedure
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
      - SNOMED data set PXRM BGP CABG (Problem List only)
    - CPT 33510 through 33514, 33516 through 33519, 33521 through 33523, 33530, 33533 through 33536, 33572, 35600, S2205 through S2209 [BGP CABG CPTS]
  - PCI Procedure
    - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
      - ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
      - SNOMED data set PXRM BGP PCI (Problem List only)
    - CPT 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
    - Procedure ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06 through 36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734** [BGP PCI CM PROCS]
BP Values (all numerators)

Exclusions: When calculating all BPs (using vital measurements or CPT codes), the following visits will be excluded:

- Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation)
- Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)

CRS uses mean of last 3 BPs documented during the Report Period. If 3 BPs are not available, uses mean of the last 2 BPs, or 1 BP if there is only 1 documented. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not both meet the current category, then the value that is least controlled determines the category.

For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 0001F, 2000F, 3074F through 3080F, G9273, G9274 [BGP BP MEASURED CPT, BGP SYSTOLIC BP CPTS, BGP DIASTOLIC BP CPTS] or POV ICD-9: V81.1 [BGP HYPERTENSION SCREEN DXS] documented the Report Period.

2.7.6.6 Patient List

List of Patients 18 years of age and older, or who have CHD with BP value, if any.

2.7.7 Controlling High Blood Pressure – Million Hearts

2.7.7.1 Owner and Contact

Dr. Dena Wilson, Chris Lamer, PharmD, and Mark Veazie

2.7.7.2 National Reporting

NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.7.7.3 Denominators

1. GPRA: Million Hearts (NQF 0018): User Population patients ages 18 through 85 years diagnosed with hypertension and no documented history of ESRD or current diagnosis of pregnancy. Broken down by age groups 18 through 59 and 60 through 85.
2.7.7.4 Numerators

1. GPRA: Million Hearts (NQF 0018): Patients with blood pressure less than (<) 140/90, i.e., the systolic value is less than (<) 140 AND the diastolic value is less than (<) 90.

2. Patients with blood pressure less than (<) 150/90 (i.e., the mean systolic value is less than 150 AND the mean diastolic value is less than 90).

2.7.7.5 Definitions

Age

Age of the patient is calculated at end of the Report Period.

Hypertension

Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):

- ICD-9: 401.*; ICD-10: I10 [BGP HYPERTENSION DXS] ever through the first 6 months of the Report Period, and at least one hypertension POV during the Report Period.
- SNOMED data set PXRM ESSENTIAL HYPERTENSION (Problem List only)

ESRD

Any of the following ever:

- CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90918 through 90925 (old codes), 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90951 through 90970, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]
- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)
- Procedure ICD-9: 39.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6* [BGP ESRD PROCS]
Pregnancy Definition

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.

- At least one visit during the Report Period where the primary provider is not a CHR (Provider code 53) with any of the following:
  

  - Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

  - CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
– Miscarriage or abortion (see definitions below)
Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

• Miscarriage definition:
  – POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
  – CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

• Abortion definition:
  – POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  – CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  – Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**BP Values**
Exclusions: When calculating all BPs, the following visits will be excluded:

• Service Category H (Hospitalization), I (In Hospital), S (Day Surgery), or O (Observation)

• Clinic code 23 (Surgical), 30 (ER), 44 (Day Surgery), 79 (Triage), C1 (Neurosurgery), or D4 (Anesthesiology)

CRS uses the last blood pressure documented during the Report Period. If a patient has more than 1 blood pressure documented on the same day, CRS will first look for a blood pressure less than (<) 140/90 on that day, and if not found, will look for a blood pressure less than (<) 150/90.

**2.7.7.6 GPRA 2018 Target**
During GPRA Year 2018, achieve the target rate of 42.3% for the proportion of patients with blood pressure less than (<) 140/90.

**2.7.7.7 Patient List**
List of patients with hypertension and BP value, if any.
2.7.8 Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

2.7.8.1 Owner: Contact
Dr. Dena Wilson, Chris Lamer, PharmD

2.7.8.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.7.8.3 Denominators
1. GPRAMA: User Population patients ages 40 through 75 with diabetes or age 21 and older with documented CVD or an LDL greater than or equal to (>=) 190 or hypercholesterolemia.

2. User Population patients ages 21 through 39 with documented CVD or an LDL greater than or equal to (>=) 190 or hypercholesterolemia.

3. User Population patients ages 40 through 75 with documented CVD or an LDL greater than or equal to (>=) 190 or hypercholesterolemia.

4. User Population patients age 76 and older with documented CVD or an LDL greater than or equal to (>=) 190 or hypercholesterolemia.

5. User Population patients ages 40 through 75 with diabetes.

6. User Population patients ages 40 through 75 with diabetes or age 21 and older with documented CVD or an LDL >=190 or hypercholesterolemia, including denominator exclusions.

2.7.8.4 Numerators
1. GPRAMA: Patients who are statin therapy users during the Report Period or who receive an order (prescription) to receive statin therapy at any point during the Report Period.

2. Patients with any of the listed denominator exclusions. (With Denominator 6).
   A. Patients with documented allergy, intolerance, or other adverse effect to statin medication.
2.7.8.5 Definitions

Diabetes
First DM POV ICD-9: 250.00 through 250.93 or ICD-10: E10.* through E13.* [SURVEILLANCE DIABETES] recorded in the V POV file prior to the Report Period.

Cardiovascular Disease (CVD)
Cardiovascular Disease (CVD) diagnosis defined as any of the following:

- Coronary Heart Disease (CHD) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: 410.0 through 413.*, 414.0 through 414.9, 429.2; ICD-10: I20.0 through I22.8, I24.0 through I25.83, I25.89, I25.9, Z95.5 [BGP CHD DXS]
    - SNOMED data set PXRM ISCHEMIC HEART DISEASE (Problem List only)
- Acute Myocardial Infarction (AMI) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: 410.0* through 410.9*, 412, 429.79; ICD-10: I21.*, I22.*, I23.*, I25.2 [BGP AMI DXS PAMT]
    - SNOMED data set PXRM BGP AMI (Problem List only)
- Ischemic Vascular Disease (IVD) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - SNOMED data set PXRM BGP IVD (Problem List only)
- Ischemic Stroke or Transient Ischemic Attack (TIA) defined as any of the following:
  - Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    - ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 437.1, 438.*, V12.54; ICD-10: G45.0 through G45.2, G45.8, G45.9, G46.0 through G46.8, I63.*, I69.*, Z86.73 [BGP TIA DXS]
• SNOMED data set PXRM BGP ISCHEMIC STROKE TIA (Problem List only)

• Atherosclerosis and Peripheral Arterial Disease defined as any of the following:
  – Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):

SNOMED data set PXRM BGP ARTERIAL DISEASE (Problem List only)

• Coronary Artery Bypass Graft (CABG) Procedure defined as any of the following:
  – Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    • ICD-9: V45.81; ICD-10: Z95.1 [BGP CABG DXS]
    • SNOMED data set PXRM BGP CABG (Problem List only)
      – CPT 33510 through 33514, 33516 through 33519, 33521 through 33523, 33530, 33533 through 33536, 33572, 33500, 35600, S2205 through S2209 [BGP CABG CPTS]

• Percutaneous Coronary Interventions (PCI) Procedure defined as any of the following:
  – Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
    • POV ICD-9: V45.82; ICD-10: Z95.5, Z98.61 [BGP PCI DXS]
    • SNOMED data set PXRM BGP PCI (Problem List only)
      – CPT 92920, 92924, 92928, 92933, 92937, 92941, 92943, 92980 (old code), 92982 (old code), 92995 (old code), G0290, C9600, C9602, C9604, C9606, C9607 [BGP PCI CPTS]
      – Procedure ICD-9: 00.66, 36.01 (old code), 36.02 (old code), 36.05 (old code), 36.06 through 36.07; ICD-10: 02703**, 02704**, 02713**, 02714**, 02723**, 02724**, 02733**, 02734** [BGP PCI CM PROCS]

• Carotid Intervention defined as any of the following:
– Procedure ICD-9: 00.61 through 00.65, 38.02, 38.12, 38.22, 38.30 through 38.32, 38.42, 39.22, 39.28, 88.41; ICD-10: 03*H***, 03*J***, 03*K***, 03*L***, 03*M***, 03*N***, 0G*6***, 0G*7***, 0G*8***, B3060ZZ, B3061ZZ, B306YZZ, B3070ZZ, B3071ZZ, B307YZZ, B3080ZZ, B3081ZZ, B308YZZ, B3160ZZ, B3161ZZ, B316YZZ, B3170ZZ, B3171ZZ, B317YZZ, B3180ZZ, B3181ZZ, B318YZZ

– Diagnosis (Problem List entry where the status is not Inactive or Deleted):
  • SNOMED data set PXRM BGP CAROTID INTERVENTION
  • Other Revascularization:
    – CPT 37220, 37221, 37224 through 37231 [BGP REVASCULARIZATION CPTS]

**LDL**

For LDL greater than or equal to (>=) 190, CRS will look for any test at any time with result greater than or equal to (>=) 190. LDL defined as any of the following:

• LOINC taxonomy
• Site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX

**Hypercholesterolemia**

Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):

• POV ICD-9: 272.0; ICD-10: E78.00, E78.01
• SNOMED data set PXRM BGP HYPERCHOLESTEROLEMIA (Problem List only)

**Denominator Exclusions**

Patients meeting any of the following conditions will be excluded from the denominator.

• Patients with documented allergy, intolerance, or other adverse effect to statin medication.
• Patients who have an active diagnosis of pregnancy or who are breastfeeding.
• Patients with a diagnosis of cirrhosis of the liver or liver disease during the Report Period or the year prior to the Report Period.
• Patients who are receiving palliative care during the Report Period.
• Patients with end-stage renal disease (ESRD).
• Patients with diabetes whose most recent LDL result is less than (<) 70 and who have never had an LDL result greater than or equal to (>=) 190 and who are not taking statin therapy.
• Patients with Hepatitis A or Hepatitis B.

**Contraindications to Statins**
Contraindications to statins defined as any of the following:
• Pregnancy: See the definition that follows.
• Breastfeeding: See the definition that follows.
• Acute Alcoholic Hepatitis: defined as POV or Problem List entry where the status is not Inactive or Deleted during the Report Period:
  – ICD-9: 571.1; ICD-10: K70.10, K70.11 [BGP ALCOHOL HEPATITIS DXS]
  – SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
• NMI refusal for any statin at least once during the Report Period.

**Adverse drug reaction or documented statin allergy**
Defined as any of the following:
• ALT or AST greater than three times the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period.
• Creatine Kinase (CK) levels greater than 10 times ULN or CK greater than 10,000 IU/L during the Report Period.
• Myopathy or Myalgia, defined as any of the following during the Report Period:
  – POV or Problem List entry where the status is not Inactive or Deleted
    ICD-9: 359.0 through 359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80 through M60.9, M79.1 [BGP MYOPATHY/MYALGIA]; SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)
• Rhabdomyolysis, defined as any of the following during the Report Period:
  Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  – ICD-10: M62.82, T79.6XX*
  – SNOMED data set PXRM BGP Rhabdomyolysis (Problem List only)
• Any of the following occurring ever:
– POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.9 [BGP ADV EFF CARDIOVASC NEC]
– “Statin” or “Statins” entry (except "Nystatin") in ART (Patient Allergies File)
– “Statin” or “Statins” (except "Nystatin") contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
– Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR STATIN

Pregnancy Definition

Any of the following:

• The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.

• At least one visit during the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following:
- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
- CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]
- Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

- **Miscarriage definition:**

...
- POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

**Abortion definition:**
- POV ICD-9: 635*, 636* 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**Breastfeeding Definition**

Any of the following documented during the Report Period:
- POV ICD-9: V24.1; ICD-10: O91.03, O91.13, O92.03, O92.13, O92.5, O92.70, O92.79, Z39.1 [BGP BREASTFEEDING DXS]

**Cirrhosis of the Liver**

- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 571.2, 571.5, 571.6; ICD-10: K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81 [BGP CIRRHOSIS OF LIVER DXS]
  - SNOMED data set PXRM BGP CIRRHOSIS (Problem List only)

**Liver Disease Definition**

Diagnosis (POV or Problem List entry where the status is not Deleted):
- ICD-9: 070.41 through 070.71, 570, 571.0, 571.2 through 571.9, 572.4, 572.8; ICD-10: B17.*, B18.2 through B19.0, B19.20, B19.21, B19.9, K70.0 through K74.69, K75.4, O98.41* [BGP LIVER DISEASE DXS]
- SNOMED data set PXRM BGP LIVER DISEASE (Problem List only)

**Palliative Care**

- POV ICD-9: V66.7; ICD-10: Z51.5 [BGP PALLIATIVE CARE DXS]
ESRD

End Stage Renal Disease diagnosis or treatment defined as any of the following ever:

- CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, 90951 through 90970 or old codes 90918 through 90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, 3066F, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]

- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
  - SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)

- Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6* [BGP ESRD PROCS]

Hepatitis A Definition

Diagnosis (POV or Problem List entry where the status is not Deleted):

- ICD-9: 070.0, 070.1; ICD-10: B15.* [BGP HEPATITIS A EVIDENCE]
- SNOMED data set PXRM BGP HEPATITIS A (Problem List only)

Hepatitis B Definition

Diagnosis (POV or Problem List entry where the status is not Deleted):

- ICD-9: V02.61, 070.2*, 070.3*; ICD-10: B16.*, B18.0, B18.1, B19.1*, Z22.51 [BGP HEPATITIS B EVIDENCE]
- SNOMED data set PXRM BGP HEPATITIS B (Problem List only)

Statins Numerator Logic

- Statin Therapy Users
  - CPT 4013F

- Statin Medication Codes
  - Defined with medication taxonomy BGP PQA STATIN MEDS.
  - Statin medications are: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

- Statin Combination Products

Patients must have an active prescription for statin therapy during the Report Period. This includes patients who receive an order during the Report Period, or prior to the Report Period with enough days’ supply to take them into the Report Period.

\[ \text{Rx Days’ Supply } \geq (\text{Report Period Begin Date} - \text{Prescription Date}) \]

Active prescriptions include active outside medications, defined as V Med entry at any time with EHR OUTSIDE MED field not blank and DATE DISCONTINUED field blank.

2.7.8.6 GPRA 2018 Target
During GPRA Year 2018, achieve the target rate of 26.6% for the proportion of at-risk patients who receive statin therapy.

2.7.8.7 Patient List
List of patients 40-75 with diabetes or 21+ with CVD or LDL \( \geq 190 \) or hypercholesterolemia with statin therapy or exclusion, if any.

2.7.9 Appropriate Medication Therapy after a Heart Attack

2.7.9.1 Owner and Contact
Dr. Dena Wilson, Chris Lamer, PharmD, and Mark Veazie

2.7.9.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.9.3 Denominators
1. Active Clinical patients 35 and older discharged for an Acute Myocardial Infarction (AMI) during the first 51 weeks of the Report Period and were not readmitted for any diagnosis within 7 days of discharge. Broken down by gender.

2.7.9.4 Numerators
1. Patients with active prescription for or who have a contraindication or previous adverse reaction to beta-blockers.
Note: This numerator does not include refusals.

A. Patients with active prescription for beta-blockers.
B. Patients with contraindication or previous adverse reaction to beta-blocker therapy.

2. Patients with active prescription for or who have a contraindication or previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

Note: This numerator does not include refusals.

A. Patients with active prescription for ASA (aspirin) or other anti-platelet agent.
B. Patients with contraindication or previous adverse reaction to ASA (aspirin) or other anti-platelet agent.

3. Patients with active prescription for or who have a contraindication or previous adverse reaction to Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptor Blocker (ACEIs/ARBs.)

Note: This numerator does not include refusals.

A. Patients with active prescription for ACEIs/ARBs
B. Patients with contraindication or previous adverse reaction to ACEIs/ARBs

4. Patients with active prescription for or who have a contraindication or previous adverse reaction to statins.

Note: This numerator does not include refusals.

A. Patients with active prescription for statins
B. Patients with contraindication or previous adverse reaction to statins

5. Patients with active prescriptions for all post-AMI medications (i.e., beta-blocker, ASA or anti-platelet, ACEI/ARB, and statin) or who have a contraindication or previous adverse reaction.

Note: This numerator does not include refusals.
2.7.9.5 Definitions

AMI
POV ICD-9: 410.0*-410.9*, 412, 429.79; ICD-10: I21.*, I22.*, I23.*, I25.2 [BGP AMI DXS PAMT] with Service Category H. If patient has more than one episode of AMI during the first 51 weeks of the Report Period, CRS will include only the first discharge.

Denominator Exclusions
Patients meeting any of the following conditions will be excluded from the denominator.

- Patients with Discharge Type of Irregular (Against Medical Advice [AMA]), Transferred, or contains “Death.”
- Patients readmitted for any diagnosis within 7 days of discharge.
- Patients with a Diagnosis Modifier of C (Consider), D (Doubtful), M (Maybe, Possible, Perhaps), O (Rule Out), P (Probable), R (Resolved), S (Suspect, Suspicious), or T (Status Post).

To Be Included in the Numerators,
A patient must meet one of the following two conditions:

- An active prescription (not discontinued as of (discharge date plus 7 days) and does not have a comment of RETURNED TO STOCK) that was prescribed prior to admission, during the inpatient stay, or within 7 days after discharge. "Active" prescription defined as:
  \[
  \text{Days Prescribed} > (\text{Discharge Date} + 7 \text{ days} – \text{Order Date})
  \]
- Have a contraindication or previous adverse reaction to the indicated medication.

Contraindication or previous ADR or allergies are only counted if a patient did not have a prescription for the indicated medication. Patients without a prescription who have a contraindication, ADR, or allergy will be counted in sub-numerator B.
Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed: November 19, 2018 – November 15, 2018 = 4

Numerator Logic
In the logic that follows, “ever” is defined as anytime through the end of the Report Period.

Beta-Blocker Numerator Logic

- **Beta-blocker medication codes**
  Defined with medication taxonomy BGP PQA BETA BLOCKER MEDS:
  - Noncardioselective Beta Blockers: Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol
  - Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol

- **Contraindications to beta-blockers**
  Defined as any of the following occurring ever unless otherwise noted:
  - **Asthma.** 2 diagnoses (POV) of ICD-9: 493*; ICD-10: J45.* [BGP ASTHMA DXS] on different visit dates
  - **Hypotension.** 1 diagnosis (POV or Problem List entry where the status is not Deleted):
    ICD-9: 458*; ICD-10: I95.* [BGP HYPOTENSION DXS]
    SNOMED data set PXRM BGP HYPOTENSION (Problem List only)
  - **Heart block greater than 1 degree.** 1 diagnosis (POV or Problem List entry where the status is not Deleted):
    ICD-9: 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, 426.7; ICD-10: I44.1, I44.2, I45.2, I45.3, I45.6 [BGP CMS 2/3 HEART BLOCK DXS]
    SNOMED data set PXRM BGP OVER 1 DEG HEART BLK (Problem List only)
– **Sinus bradycardia.** 1 diagnosis (POV or Problem List entry where the status is not Deleted):
  ICD-9: 427.81; ICD-10: I49.5, R00.1 [BGP SINUS BRADYCARDIA DXS]
  SNOMED data set PXRM BGP SINUS BRADYCARDIA (Problem List only)

– **COPD.** 2 diagnoses on different visit dates of ICD-9: 491.0, 491.1, 491.2*, 491.8, 491.9, 493.2*, 496, 506.4; ICD-10: J41.*, J42, J44.*, J68.4, J68.8 [BGP COPD DXS], or a combination of any of these codes, such as one visit with 491.20 and one with 496

– NMI refusal for any beta-blocker at least once during hospital stay through 7 days after discharge date

– CPT G8011 (Clinician documented that AMI patient was not an eligible candidate for beta-blocker at arrival) (old code), G9190 (Documentation of medical reason(s) for not prescribing beta-blocker therapy [e.g., allergy, intolerance, other medical reasons]) at least once during hospital stay through 7 days after discharge date

**Adverse drug reaction or documented beta blocker allergy**

Defined as any of the following occurring ever:

– POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.0 [BGP ADV EFF CARD RHYTH]
– Beta block* entry in ART (Patient Allergies File)
– Beta block*, bblock* or b block* contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
– Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR BETA BLOCKER

**ASA (aspirin) or Other Anti-Platelet Numerator Logic**

– **ASA medication codes**
  – Defined with medication taxonomy DM AUDIT ASPIRIN DRUGS

– **Other antiplatelet medication codes**
  – Defined with medication taxonomy site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.
• **Contraindications to ASA or other anti-platelet**

Defined as any of the following occurring ever unless otherwise noted:

- Patients with active prescription for Warfarin (Coumadin) at time of arrival or prescribed at discharge, using site-populated BGP CMS WARFARIN MEDS taxonomy
- Hemorrhage diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 459.0; ICD-10: R58 [BGP HEMORRHAGE DXS]
  - SNOMED data set PXRM BGP HEMORRHAGE (Problem List only)
- NMI refusal for any aspirin at least once during hospital stay through 7 days after discharge date
- CPT G8008 (Clinician documented that AMI patient was not an eligible candidate to receive aspirin at arrival) (old code) at least once during hospital stay through 7 days after discharge date

• **Adverse drug reaction, documented ASA, or other anti-platelet allergy**

Defined as any of the following occurring ever:

- POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E935.3 [BGP ADV EFF SALICYLATES]; ICD-10: T39.015* or T39.095* [BGP ADV EFF SALICYLATES 10]
- Aspirin entry in ART (Patient Allergies File)
- ASA or aspirin contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]

- Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ASA

**ACEI/ARB Numerator Logic**

• **Ace Inhibitor (ACEI) medication codes**

Defined with medication taxonomy BGP HEDIS ACEI MEDS:

- **ACEI medications**: Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril).
• **Contraindications to ACEI** defined as any of the following:
  
  – **Pregnancy**: See the definition that follows
  
  
  – **Diagnosis ever for moderate or severe aortic stenosis**
    
    POV or Problem List entry where the status is not Deleted:
    
      [BGP CMS AORTIC STENOSIS DXS]
    
    – SNOMED data set PXRM BGP MOD SEV AORTIC STEN
      (Problem List only)
    
    – **NMI refusal** for any ACEI at least once during hospital stay through 7 days after discharge date.

• **Adverse drug reaction or documented ACEI allergy**

  Defined as any of the following occurring ever:
  
  – POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.6 [BGP ADV EFF ANTIHYPERTEN AGT]; ICD-10: T46.4X5* [BGP ADV EFF ANTIHYPER 10]
  
  – Ace inhibitor or ACEI entry in ART (Patient Allergies File)
  
  – Ace i* or ACEI contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
  
  – Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ACEI

• **ARB medication codes**

  Defined with medication taxonomy BGP HEDIS ARB MEDS:
  
  – **ARB medications**: Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan.)

- **Contraindications to ARB** defined as any of the following:
  - **Pregnancy:** See the definition that follows
  - **Diagnosis ever for moderate or severe aortic stenosis**
    POV or Problem List entry where the status is not Deleted:
    - ICD-9: 395.0, 395.2, 396.0, 396.2, 396.8, 424.1, 425.1, 747.22 [BGP CMS AORTIC STENOSIS DXS]
    - SNOMED data set PXRM BGP MOD SEV AORTIC STEN (Problem List only)
  - **NMI refusal** for any ARB at least once during hospital stay through 7 days after discharge date.

- **Adverse drug reaction or documented ARB allergy**
  Defined as any of the following occurring ever:
  - POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.6 [BGP ADV EFF ANTIHYPERTEN AGT]
  - Angiotensin Receptor Blocker or ARB entry in ART (Patient Allergies File)
  - Angiotensin Receptor Blocker or ARB contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]
  - Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR ARB

**Statins Numerator Logic:**
- **Statin medication codes**
Defined with medication taxonomy BGP PQA STATIN MEDS:

- **Statin medications**: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altocor, Altoprev, Mevacor), Pravastatin (Pravachol), Pitavastatin (Livalo), Simvastatin (Zocor), Rosuvastatin (Crestor).

- **Statin Combination Products**: Niacin-lovastatin, Niacin-simvastatin, Ezetimibe-simvastatin, Amlodipine-Atorvastatin, Sitagliptin-simvastatin, Ezetimibe-atorvastatin.

- **Contraindications to Statins**: defined as any of the following:
  - **Pregnancy**: See the definition that follows
  - **Acute Alcoholic Hepatitis**: defined as POV or Problem List entry where the status is not Deleted during the Report Period:
    - ICD-9: 571.1; ICD-10: K70.10, K70.11 [BGP ALCOHOL HEPATITIS DXS]
    - SNOMED data set PXRM BGP ACUTE ETOH HEPATITIS (Problem List only)
  - **NMI refusal** for any statin at least once during hospital stay through 7 days after discharge date.

- **Adverse drug reaction or documented statin allergy**
  Defined as any of the following:
  - ALT or AST greater than three times the Upper Limit of Normal (ULN) (i.e., Reference High) on two or more consecutive visits during the Report Period
  - Creatine Kinase (CK) levels greater than 10 times ULN or CK greater than (> 10,000 IU/L during the Report Period
  - Myopathy or Myalgia, defined as any of the following during the Report Period:
    - POV or Problem List entry where the status is not Deleted:
      - ICD-9: 359.0 through 359.9, 729.1, 710.5, 074.1; ICD-10: G71.14, G71.19, G72.0, G72.2, G72.89, G72.9, M35.8, M60.80 through M60.9, M79.1 [BGP MYOPATHY/MYALGIA]
      - SNOMED data set PXRM BGP MYOPATHY MYALGIA (Problem List only)
    - Any of the following occurring ever:
POV ICD-9: 995.0 through 995.3 [BGP ASA ALLERGY 995.0-995.3] and E942.9 [BGP ADV EFF CARDIOVASC NEC]

“Statin” or “Statins” entry (except "Nystatin") in ART (Patient Allergies File)

“Statin” or “Statins” (except "Nystatin") contained within Problem List (where status is not Deleted) or in Provider Narrative field for any POV ICD-9: 995.0 through 995.3, V14.8; ICD-10: Z88.8 [BGP ASA ALLERGY 995.0-995.3 and BGP HX DRUG ALLERGY NEC]

Problem List entry where the status is not Deleted of SNOMED data set PXRM BGP ADR STATIN

**Pregnancy Definition**

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.

- At least one visit during the Report Period where the primary provider is not a CHR (Provider code 53) with any of the following:

- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

- CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

- Miscarriage or abortion (see definitions below)

Pharmacy-only visits (clinic code 39) will not count toward this visit. If the patient has more than one pregnancy-related visit during the Report Period, CRS will use the first visit in the Report Period.

**Miscarriage definition:**

...
- **POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: 003.9 [BGP MISCARRIAGE/ABORTION DXS]
- **CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]

- **Abortion definition:
  - **POV ICD-9: 635*, 636*, 637*; ICD-10: O00.*, through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - **CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - **Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**All Medications Numerator Logic**

To be included in this numerator, a patient must have a prescription or a contraindication for *all* of the four medication classes (i.e., beta-blocker, ASA or other anti-platelet, ACEI/ARB, AND statin).

**Test Definitions**

- **ALT**
  - Site-populated taxonomy DM AUDIT ALT TAX
  - LOINC taxonomy

- **AST**
  - Site-populated taxonomy DM AUDIT AST TAX
  - LOINC taxonomy

- **Creatine Kinase**
  - Site-populated taxonomy BGP CREATINE KINASE TAX
  - LOINC taxonomy

**2.7.9.6 Patient List**

List of patients with AMI, with appropriate medication therapy, if any.

**2.7.10 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation**

**2.7.10.1 Owner and Contact**

Dr. Dena Wilson and Mark Veazie
2.7.10.2 Denominators

1. User Population patients ages 18 and older who have a documented diagnosis of ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation any time prior to the end of the Report Period.

2.7.10.3 Numerators

1. Patients who received a prescription for anticoagulant during the Report Period.

2.7.10.4 Definitions

Ischemic Stroke or TIA with Atrial Fibrillation:
POV of any of the following: (ICD-9: 433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, 435.9, 436, 437.1, 438.*, V12.54; ICD-10: G45.0 through G45.2, G45.8, G45.9, G46.0 through G46.8, I63.*, I69.*, Z86.73 [BGP TIA DXS]) and POV ICD-9: 427.31; ICD-10: I48.0 through I48.2, I48.91 (atrial fibrillation) [BGP ATRIAL FIBRILLATION DXS].

Anticoagulant Therapy
Patient must receive a prescription for Warfarin, aspirin, or other anti-platelet during the Report Period to be counted as receiving anticoagulant therapy.

For all prescriptions, medications must not have a comment of RETURNED TO STOCK.

Warfarin Medication
Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.

Aspirin Medication
Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy.

Other Anti-Platelet or Anticoagulant Medication
Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700.

2.7.10.5 Patient List

List of patients with stroke or TIA and atrial fibrillation with anticoagulant therapy, if any.
2.7.11 Heart Failure and Evaluation of LVS Function

2.7.11.1 Owner and Contact
Dr. Dena Wilson, Chris Lamer, PharmD, and Mark Veazie

2.7.11.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.7.11.3 Denominators
1. Active Clinical ages 18 and older discharged with heart failure during the Report Period.

2.7.11.4 Numerators
1. Patients whose left ventricular systolic (LVS) function was evaluated before arrival, during hospitalization, or is planned for after discharge.

2.7.11.5 Definitions

Age
Age of the patient is calculated as of the hospital admission date

Heart Failure
- POV primary diagnosis code of ICD-9: 398.91, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 428.0, 428.1, 428.20, 428.21, 428.22, 428.23, 428.30, 428.31, 428.32, 428.33, 428.40, 428.41, 428.42, 428.43, 428.9, 429.1, 997.1; ICD-10: I11.0, I13.0, I13.2, I50.* and with Service Category H (hospitalization) [BGP HEART FAILURE DXS].

Note: If a patient has multiple admissions matching these criteria during the Report Period, the earliest admission will be used.

Denominator Exclusions
Defined as any of the following:
- Patients receiving comfort measures only (i.e., patients who received palliative care and usual interventions were not received because a medical decision was made to limit care).
- Patients with a Discharge Type of Transferred or Irregular or containing “Death.”
- Patients who had a left ventricular assistive device (LVAD) or heart transplant procedure during hospitalization.

**Comfort Measures**
- POV ICD-9: V66.7 (Encounter for palliative care); ICD-10: Z51.5 documented during hospital stay [BGP PALLIATIVE CARE DXS]

**LVAD or Heart Transplant**
- Any of the following during hospital stay:
  - Procedure ICD-9: 33.6, 37.41, 37.51 through 37.54, 37.61 through 37.66, 37.68; ICD-10: 02HA**,Z, 02PA*RZ, 02RK0JZ, 02RL0JZ, 02UA4JZ, 02WA0JZ, 02WA0QZ, 02WA0RZ, 02WA3QZ, 02WA3RZ, 02WA4QZ, 02WA4RZ, 02YA0Z*, 5A02*10, 5A02*16, 5A02*1D [BGP CRS LVAD/HEART TRANS PROC]

**Evaluation of LVS Function**
- Any of the following:
  - An ejection fraction ordered or documented anytime 1 year prior to discharge date, defined as any of the following:
    - Measurement “CEF”
    - Procedure ICD-9: 88.53, 88.54; ICD-10: B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ [BGP CMS EJECTION FRACTION PROC]
    - CPT 78414, 78468, 78472, 78473, 78480, 78481, 78483, 78494, 93303, 93304, 93307, 93308, 93312, 93314 through 93318, 93350, 93543, 93555 [BGP CMS EJECTION FRACTION CPTS]
  - RCIS (Referred Care Information System) order for Cardiovascular Disorders referral that is ordered during the hospital stay but no later than the hospital discharge date. (RCIS referral defined as:
    - ICD Diagnostic Category Cardiovascular Disorders combined with any of the following CPT Categories: Evaluation or Management, Non-surgical Procedures, or Diagnostic Imaging.)
  - Any of the following documented anytime one year prior to discharge date:
    - Echocardiogram: Procedure ICD-9: 88.72, 37.28, 00.24; ICD-10: B245YZZ, B245ZZ4, B245ZZZ, B246YZZ, B246ZZ4, B246ZZZ, B24BYZZ, B24BZZ4, B24BZZZ [BGP CMS ECHOCARDIOGRAM PROCS]
    - Nuclear Medicine Test: Procedure ICD-9: 92.2* [BGP CMS NUCLEAR MEDICINE PROCS]
Cardiac Catheterization with a Left Ventriculogram: Procedure ICD-9: 37.22, 37.23, 88.53, 88.54; ICD-10: 4A02*N7, 4A02*N8, B205*ZZ, B206*ZZ, B215*ZZ, B216*ZZ [BGP CMS CARDIAC CATH/LV PROCS]

2.7.11.6 Patient List
List of Active Clinical heart failure patients 18 and older who received evaluation of LVS function, if any.

2.8 STD-Related Group

2.8.1 HIV Screening

2.8.1.1 Owner and Contact
Richard Haverkate, MPH

2.8.1.2 National Reporting
NATIONAL (included in National GPRA/GPRAMA Report; reported to OMB and Congress)

2.8.1.3 Denominators
1. Pregnant Active Clinical patients with no documented miscarriage or abortion during the past 20 months and no recorded HIV diagnosis ever.
2. GPRA: User Population patients ages 13 through 64 with no recorded HIV diagnosis prior to the Report Period.

2.8.1.4 Numerators
1. Patients who were screened for HIV during the past 20 months. (With Denominator 1)
2. GPRA Developmental: Patients who were screened for HIV during the Report Period (with Denominator 2).

Note: This numerator does not include refusals.
3. GPRA: Patients who were screened for HIV at any time before the end of the Report Period (with Denominator 2).
4. GPRA Developmental: Number of HIV screens provided to User Population patients during the Report Period, where the patient was not diagnosed with HIV any time prior to the screen.

Note: This numerator does not include refusals. No denominator and is a total count only, not a percentage.

2.8.1.5 Definitions

HIV
Any of the following documented any time prior to the end of the Report Period:

- POV or Problem List entry where the status is not Deleted:
  - ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
  - SNOMED data set PXRM HIV (Problem List only)

Pregnancy:
Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period.
- At least two visits during the past 20 months from the end of the Report Period, where the primary provider is not a CHR (Provider code 53) with any of the following:

- Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]

- CPT 59000-59076, 59300, 59320, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Pharmacy-only visits (Clinic code 39) will not count toward these two visits. If the patient has more than two pregnancy-related visits during the past 20 months, CRS will use the first two visits in the 20-month period. In addition, the patient must have at least one pregnancy-related visit occurring during the reporting period.
The patient must not have a documented miscarriage or abortion occurring after the second pregnancy-related visit or the date the Currently Pregnant field was set to "Yes". The time period is extended to include patients who were pregnant during the Report Period but whose initial diagnosis (and HIV test) were documented prior to Report Period.

- **Miscarriage**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]
- **Abortion**: Occurring after the second pregnancy POV and during the past 20 months.
  - POV ICD-9: 635*, 636*, 637*; ICD-10: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
  - CPT 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
  - Procedure ICD-9: 69.01, 69.51, 74.91, 96.49; ICD-10: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

**HIV Screening**
- CPT 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806, 80081 [BGP CPT HIV TESTS]
- LOINC taxonomy
- Site-populated taxonomy BGP HIV TEST TAX

For the number of HIV screens provided to User Population patients numerator (count only), a maximum of one HIV screen per patient per day will be counted.

**Note:** The time frame for screening for the pregnant patient’s denominator is anytime during the past 20 months and for User Population patients 13 through 64 years of age is anytime during the Report Period.

**2.8.1.6 GPRA 2018 Target**

During GPRA Year 2018, achieve the target rate of 17.3% for the proportion of patients who have ever been screened for HIV.
2.8.1.7 **Patient List**
List of pregnant patients or User Population patients with documented HIV test, if any.

2.8.2 **HIV Quality of Care**

2.8.2.1 **Owner and Contact**
Richard Haverkate, MPH

2.8.2.2 **National Reporting**
Not reported nationally

2.8.2.3 **Denominators**
1. User Population patients 13 and older with at least two direct care visits, (i.e., not contract or PRC) during the Report Period with HIV diagnosis and one HIV visit in last 6 months.

2.8.2.4 **Numerators**
1. Patients who received CD4 test only (without HIV viral load) during the Report Period.

2. Patients who received HIV viral load only (without CD4), during the Report Period.

3. Patients who received both CD4 and HIV viral load tests during the Report Period.

4. Total Numerators 1, 2, and 3.

5. Patients who received at least one prescription for an Antiretroviral medication.

2.8.2.5 **Definitions**
**HIV**
POV ICD-9: 042, 042.0 through 044.9 (old codes), 079.53, V08, 795.71; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]

**Lab Test CD4**
- CPT 86359, 86360, 86361, G9214 [BGP CD4 CPTS]
- LOINC taxonomy
Site-populated taxonomy BGP CD4 TAX

**HIV Viral Load**
- CPT 87536, 87539, G9242, G9243 [BGP HIV VIRAL LOAD CPTS]
- LOINC taxonomy
- Site-populated taxonomy BGP HIV VIRAL TAX

**Antiretroviral Medication**
Defined with medication taxonomy BGP PQA ANTIRETROVIRAL MEDS. Medications must not have a comment of RETURNED TO STOCK.

**Antiretroviral medications are:**

**2.8.2.6 Patient List**
List of patients 13 and older diagnosed with HIV, with CD4 test, viral load or antiretroviral Rx, if any.

**2.8.3 Hepatitis C Screening**

**2.8.3.1 Owner and Contact**
Brigg Reilley

**2.8.3.2 Denominators**
1. User Population patients born between 1945 and 1965 with no recorded Hepatitis C diagnosis.
2. User Population with documented positive Ab result or Hep C diagnosis ever. Broken down by age group of patients born between 1945 and 1965.
3. User Population patients with positive Ab result or Hep C diagnosis and with positive Hepatitis C confirmation result ever. Broken down by age group of patients born between 1945 and 1965.

2.8.3.3 Numerators
1. Patients screened for Hepatitis C ever (Ab test) (with Denominator 1).
   A. Patients with a positive result.
   B. Patients with a negative result.
2. Patients with documented positive Ab result ever (with Denominator 2).
3. Patients with documented Hep C diagnosis ever (with Denominator 2).
4. Patients who were given a Hepatitis C confirmation test (with Denominator 2).
   A. Patients with a positive result.
   B. Patients with a negative result.
5. Patients who ever had a negative confirmation test twelve weeks or greater after a positive confirmation test (cured) (with Denominator 3).
6. A. Patients who had a negative confirmation test twelve weeks or greater after their most recent positive confirmation test (currently cured) (with Denominator 3).

2.8.3.4 Definitions
Hepatitis C Diagnosis
Any of the following documented any time prior to the end of the Report Period:
- POV or Problem List entry where the status is not Inactive or Deleted:
  - ICD-9: 070.41, 070.44, 070.51, 070.54, 070.70 through 070.71, V02.62;
  - ICD-10: B17.10, B17.11, B18.2, B19.20, B19.21, Z22.52 [BGP HEPATITIS C DXS]
  - SNOMED data set PXRM HEPATITIS C (Problem List only)

Hepatitis C Screening (Ab Test)
- CPT 86803
- LOINC taxonomy
- Site-populated taxonomy BGP HEP C TEST TAX
Hepatitis C Confirmation Test
Any of the following documented any time prior to the end of the Report Period:

- CPT 86804, 87520, 87521, 87522, G9203, G9207, G9209 [BGP HEP C CONF CPTS]
- LOINC taxonomy
- Site-populated taxonomy BGP HEP C CONF TEST TAX

If patient has more than one confirmatory test, CRS will first look for a test with a positive result, and if none is found, then will look for a test with a negative result. If there is no test with a result, CRS will use the first test documented.

For patients ever cured numerator, there must be twelve or more weeks between a positive and negative confirmation test result.

Positive Ab Test Result
Defined as a result starting with ">" or containing "Pos", "React", or "Detec".

Negative Ab Test Result
Defined as result starting with "<", or containing "Neg", "Non", "Not", or "None".

Positive Confirmation Test Result
Defined as any number greater than zero, a result starting with ">" or "<", or containing "Pos", "React", or "Detec".

Negative Confirmation Test Result
Defined as a result containing "Neg", "Non", "Not", or "None".

2.8.3.5 Patient List
List of patients with documented Hepatitis C screening or confirmatory test ever, if any.

2.8.4 Chlamydia Testing

2.8.4.1 Owner and Contact
Epidemiology Program: Andria Apostolou, PhD, MPH

2.8.4.2 National Reporting
Not reported nationally
2.8.4.3 Denominators

1. Female Active Clinical patients ages 16 through 25 years. Broken down into age groups: 16 through 20, 21 through 25, 21 through 24.

2. Female User Population patients ages 16 through 25 years. Broken down into age groups: 16 through 20, 21 through 25.

3. Female Active Clinical patients ages 16 through 24 who are identified as sexually active with no hospice indicator during the Report Period. Broken down by age groups: 16 through 20, 21 through 24.

4. Female User Population patients ages 16 through 24 who are identified as sexually active with no hospice indicator during the Report Period. Broken down by age groups: 16 through 20, 21 through 24.

2.8.4.4 Numerators

1. Patients tested for Chlamydia trachomatis during the Report Period.

Note: This numerator does not include refusals.

2. Patients with documented refusal during the Report Period.

2.8.4.5 Definitions

Hospice

- CPT 99377, 99378, G9473 through G9479, G9687 [BGP CPT HOSPICE]
- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

Sexually Active

Any of the following during the Report Period:
- POV ICD-9: 042, 054.10 through 054.12, 054.19, 078.11, 078.88, 079.4, 079.51 through 079.53, 079.88, 079.98, 091.* through 097.*, 098.0 through 098.11, 098.15 through 098.31, 098.35 through 098.89, 099.*, 131.*, 302.76, 339.82, 614.*, 615.*, 622.3, 623.4, 625.0, 626.7, 628.*, 795.*, 796.7*, 996.32, V01.6, V02.7, V02.8, V08, V15.7, V24.*, V25.*, V26.0 through V26.51, V26.81 through V26.9, V27.*, V45.5*, V61.5 through V61.7, V69.2, V72.31 through V72.42, V73.8*, V74.5, V76.2; ICD-10: A34, A51.* through A53.*, A54.00 through A54.1, A54.21, A54.24 through A54.9, A55 through A58, A59.00 through A59.01, A59.03 through A59.9, A60.00, A60.03 through A60.9, A63.*, A64, B20, B97.33 through B97.35, B97.7, F52.6, F53, G44.82, N70.*, N71.*, N93.0, N94.1, N96, N97.*, O94, T38.4*, T83.3*, Z20.2, Z21, Z22.4, Z30.* through Z34.*, Z36, Z37.*, Z39.*, Z3A.*, Z64.0 through Z64.1, Z72.51 through Z72.53, Z79.3, Z92.0, Z97.5, Z98.51 [BGP SEXUAL ACTIVITY DXS]
- Procedure codes ICD-9: 69.01, 69.02, 69.51, 69.52, 69.7, 72.*, 73.*, 74.*, 75.*, 88.78, 97.24, 97.71, 97.73 [BGP SEXUAL ACTIVITY PROCEDURES]
- CPT 11975 through 11977, 57022, 57170, 58300, 58301, 58600, 58605, 58611, 58615, 58970 through 58976, 59000 through 59899, 7601, 7605, 76811, 76813, 76815 through 76828, 76941, 76945, 76946, 80055, 80081, 82105, 82106, 82143, 82731, 83632, 83661 through 83664, 84163, 84704, 86592, 86593, 86631, 86632, 87110, 87164, 87166, 87270, 87320, 87490 through 87492, 87590 through 87592, 87620 through 87622, 87624, 87625, 87660, 87661, 87800, 87801, 87808, 87810, 87850, 88141 through 88155, 88164 through 88175, 88235, 88267, 88269, G0101, G0123, G0141 through G0148, G0475, G0476, H1000, H1001, H1003 through H1005, P3000, P3001, Q0091, S0199, S4981, S8055
- Dispensed prescription contraceptives
- Pregnancy, miscarriage or abortion
- Pregnancy test with no prescription for isotretinoin or x-ray on the date of the pregnancy test or the 6 days after the pregnancy test.

**Pregnancy Definition**

Any of the following:

- The Currently Pregnant field in Reproductive Factors file set to "Yes" during the Report Period
- At least one visit during the Report Period, where the primary provider is not a Community Health Representative (CHR) (Provider code 53) with any of the following:
- **Procedure ICD-9: 72.*, 73.*, 74.* [BGP PREGNANCY ICD PROCEDURES]
- **CPT 59000-59076, 59300, 59400-59426, 59510, 59514, 59610, 59612, 59618, 59620, 76801-76828 [BGP PREGNANCY CPT CODES]

Pharmacy-only visits (clinic code 39) will not count toward the visit.

**Miscarriage definition:**

Any of the following:

- **POV ICD-9: 630, 631, 632, 633*, 634*; ICD-10: O03.9 [BGP MISCARRIAGE/ABORTION DXS]
- **CPT 59812, 59820, 59821, 59830 [BGP CPT MISCARRIAGE]**
Abortion definition:
- **POV ICD-9**: 635*, 636* 637*; **ICD-10**: O00.* through O03.89, O04.*, Z33.2 [BGP MISCARRIAGE/ABORTION DXS]
- **CPT**: 59100, 59120, 59130, 59136, 59150, 59151, 59840, 59841, 59850, 59851, 59852, 59855, 59856, 59857, S2260 through S2267 [BGP CPT ABORTION]
- **Procedure ICD-9**: 69.01, 69.51, 74.91, 96.49; **ICD-10**: 0WHR73Z, 0WHR7YZ, 10A0***, 3E1K78Z, 3E1K88Z [BGP ABORTION PROCEDURES]

Pregnancy Test
- **CPT**: 81025, 84702, 84703

Prescription contraceptives
Medication taxonomy BGP HEDIS CONTRACEPTION MEDS.

Isotretinoin medications
Medication taxonomy BGP HEDIS ISOTRETINOIN MEDS.
- Medications are: Isotretinoin

X-Ray
- **Radiology or CPT**: 70010-76499

Chlamydia Test
- **POV ICD-9**: V73.88, V73.98 [BGP CHLAMYDIA SCREEN DXS]
- **CPT**: 86631, 86632, 87110, 87270, 87320, 87490 through 87492, 87810, 3511F, G9228 [BGP CHLAMYDIA CPTS]
- Site-populated taxonomy BGP CHLAMYDIA TESTS
- LOINC taxonomy

Refusal
- Refusal of Lab or CPT code 86631, 86632, 87110, 87270, 87320, 87490-92, 87810, 3511F, G9228 [BGP CHLAMYDIA CPTS] during the Report Period.
2.8.4.6 Patient List
List of patients with documented Chlamydia screening or refusal, if any.

2.8.5 Sexually Transmitted Infection (STI) Screening

2.8.5.1 Owner and Contact
Andria Apostolou, PhD, MPH

2.8.5.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.8.5.3 Denominators
1. HIV/AIDS screenings needed for key STI incidents for Active Clinical patients that occurred during the defined period. Broken down by gender.

2.8.5.4 Numerators
1. Count only (no percentage comparison to denominator). The total count of Active Clinical patients who were diagnosed with one or more key STIs during the period 60 days prior to the Report Period through the first 300 days of the Report Period. Broken down by gender.

2. Count only (no percentage comparison to denominator). The total count of separate key STI incidents for Active Clinical patients during the defined period.

3. For use with denominator #1: GPRA Developmental: Number of needed HIV/AIDS screenings performed from 1 month prior to the date of first STI diagnosis of each incident through 2 months after.

   Note: This numerator does not include refusals.

4. For use with denominator #1: Patients with documented HIV screening refusal during the Report Period.
2.8.5.5 Definitions

Key STIs

Chlamydia, gonorrhea, HIV/AIDS, and syphilis. Key STIs defined with the following POVs:

- Chlamydia: ICD-9: 079.88, 079.98, 099.41, 099.50 through 099.59; ICD-10: A56.*, A74.81 through A74.9
- Gonorrhea: ICD-9: 098.0 through 098.89; ICD-10: A54.*, O98.2*
- HIV/AIDS: ICD-9: 042, 042.0 through 044.9, 079.53, 795.71, V08; ICD-10: B20, B97.35, R75, Z21, O98.711 through O98.73 [BGP HIV/AIDS DXS]
- Syphilis: ICD-9: 090.0 through 093.9, 094.1 through 097.9; ICD-10: A51.* through A53.*

Logic for Identifying Patients Diagnosed with Key STI (Numerator #1)

Any patient with one or more diagnoses of any of the key STIs defined previously during the period 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period.

Logic for Identifying Separate Incidents of Key STIs (Numerator #2)

One patient may have one or multiple occurrences of one or multiple STIs during the year, except for HIV. An occurrence of HIV is only counted if it is the initial HIV diagnosis for the patient ever. Incidents of an STI are identified beginning with the date of the first key STI diagnosis (see the previous definition) occurring between 60 days prior to the beginning of the Report Period through the first 300 days of the Report Period. A second incident of the same STI (other than HIV) is counted if another diagnosis with the same STI occurs 2 months or more after the initial diagnosis. A different STI diagnosis that occurs during the same 60-day time period as the first STI counts as a separate incident.

Table 2-2: Logic for identifying separate incidents of key STIs

<table>
<thead>
<tr>
<th>Date</th>
<th>Visit</th>
<th>Total Incidents</th>
</tr>
</thead>
<tbody>
<tr>
<td>August 1, 2017</td>
<td>Patient screened for Chlamydia</td>
<td>0</td>
</tr>
<tr>
<td>August 8, 2017</td>
<td>Patient diagnosed with Chlamydia</td>
<td>1</td>
</tr>
<tr>
<td>October 15, 2017</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>October 25, 2017</td>
<td>Follow-up for Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>November 15, 2017</td>
<td>Patient diagnosed with Chlamydia</td>
<td>2</td>
</tr>
<tr>
<td>March 1, 2018</td>
<td>Patient diagnosed with Chlamydia</td>
<td>3</td>
</tr>
</tbody>
</table>
**Denominator Logic for Needed Screenings (Denominator #1)**

One patient may need multiple screening tests based on one or more STI incidents occurring during the time period.

To be included in the needed HIV screening tests denominator, the count will be derived from the number of separate non-HIV STI incidents. HIV screening tests are recommended for the following key STIs: Chlamydia, Gonorrhea, Syphilis.

“Needed” screenings are recommended screenings that are further evaluated for contraindications. The following are reasons that a recommended screening is identified as not needed (i.e., contraindicated).

- Only one screening for HIV is needed during the relevant time period, regardless of the number of different STI incidents identified. For example, if a patient is diagnosed with Chlamydia and Gonorrhea on the same visit, only one screening is needed for HIV/AIDS.
- A patient with HIV/AIDS diagnosis prior to any STI diagnosis that triggers a recommended HIV/AIDS screening does not need the screening ever.

**Numerator Logic**

To be counted in the numerator, each needed screening in the denominator must have a corresponding lab test or test refusal documented in the period from 1 month prior to the relevant STI diagnosis date through 2 months after the STI incident.

- **HIV/AIDS Screening**
  - Any of the following during the specified time period:
    - CPT 86689, 86701 through 86703, 87389 through 87391, 87534 through 87539, 87806, 80081 [BGP CPT HIV TESTS]
    - Site-populated taxonomy BGP HIV TEST TAX
    - LOINC taxonomy
- **HIV Screening Refusal**
  - Refusal of Lab or CPT code 86689, 86701-86703, 87389 through 87391, 87534 through 87539, 87806, 80081 [BGP CPT HIV TESTS] during the Report Period.

**2.8.5.6 Patient List**

List of patients diagnosed with one or more STIs during the defined time period with related screenings or refusal.
2.9 Other Clinical Measures Group

2.9.1 Asthma

2.9.1.1 Owner and Contact
Chris Lamer, PharmD

2.9.1.2 National Reporting
Not reported nationally

2.9.1.3 Denominators
1. Active Clinical patients. Broken down by age groups: younger than 15 years, 15 through 34 years, 35 through 64 years, 65 years and older.

2. Numerator 1 (Patients who have had two asthma-related visits during the Report Period or with persistent asthma). Broken down by age groups: younger than 15 years, 15 through 34 years, 35 through 64 years, 65 years and older.

2.9.1.4 Numerators
1. Patients who have had two asthma-related visits during the Report Period or with persistent asthma (with Denominator 1).
   A. Patients from Numerator 1 who have been hospitalized at any hospital for asthma during the Report Period (with Denominator 2).
   B. Patients from Numerator 1 who have visited the ER or Urgent Care for asthma during the Report Period (with Denominator 2).
   C. Patients from Numerator 1 who have a Severity of 1 (with Denominator 2).
   D. Patients from Numerator 1 who have a Severity of 2 (with Denominator 2).
   E. Patients from Numerator 1 who have a Severity of 3 (with Denominator 2).
   F. Patients from Numerator 1 who have a Severity of 4 (with Denominator 2).
   G. Patients from Numerator 1 who have no documented Severity (with Denominator 2).

2.9.1.5 Definitions
Asthma Visits
Asthma visits are defined as diagnosis (POV) ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS].
Persistent Asthma

Any of the following:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at any time before the end of the Report Period
- Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Severity

Severity is defined as a Severity of 1, 2, 3 or 4 in an active entry in the PCC Problem List for ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]; SNOMED data set PXRM ASTHMA or in V Asthma.

Hospitalizations

Hospitalizations are defined as service category H with primary POV ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS].

ER and Urgent Care

ER and Urgent Care visits are defined as Clinic codes 30 or 80 with primary POV ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS].

2.9.1.6 Patient List

List of patients diagnosed with asthma and any asthma-related hospitalizations, ER, or Urgent Care visits.

2.9.2 Asthma Assessments

2.9.2.1 Owner and Contact

Chris Lamer, PharmD

2.9.2.2 National Reporting

Not reported nationally
2.9.2.3 Denominators

1. Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD). Broken down by age groups: 5 through 14 years, 15 through 34 years, 35 through 64 years, and 65 years and older.

2.9.2.4 Numerators

1. Patients with asthma management plan during the Report Period.
2. Patients with severity documented at any time before the end of the Report Period.
3. Patients with control documented during the Report Period.
4. Patients who were assessed for number of symptom free days during the Report Period.
5. Patients with number of symptom free days score of 0 through 5.
6. Patients with number of symptom free days score of 6 through 12.
7. Patients with number of symptom free days score of 13 through 14.
8. Patients who were assessed for number of school or work days missed during the Report Period.
9. Patients with number of school or work days missed score of 0 through 2.
10. Patients with number of school or work days missed score of 3 through 7.
11. Patients with number of school or work days missed score of 8 through 14.

2.9.2.5 Definitions

Denominator Exclusions

Patients diagnosed with emphysema or COPD at any time on or before the end of the Report Period are excluded from the denominator.

Emphysema

Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted:

- ICD-9: 492.*, 506.4, 518.1, 518.2; ICD-10: J43.*, J68.4, J68.8, J98.2, J98.3 [BGP EMPHYSEMA DXS]
- SNOMED data set PXRM BGP EMPHYSEMA (Problem List only)

**COPD**

Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted:

- ICD-9: 491.0, 491.1, 491.2*, 491.8, 491.9, 493.2*, 496, 506.4; ICD-10: J41.*, J42, J44.*, J68.4, J68.8 [BGP COPD DXS]

- SNOMED data set PXRM BGP COPD (Problem List only)

**Persistent Asthma**

Meeting any of the following four criteria that follow within the year prior to the beginning of the Report Period and during the Report Period:

- At least one visit to Clinic code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493.*; ICD-10: J45.* (asthma) [BGP ASTHMA DXS]

- At least one acute inpatient discharge with primary diagnosis ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]. Acute inpatient discharge defined as Service Category of H

- At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS] and at least two asthma medication dispensing events (see the definition that follows)

- At least four asthma medication dispensing events (see the definition that follows). If the sole medication was leukotriene modifiers, then must also have at least one visit with POV ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS] in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.), or

Meeting any of the following criteria:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at any time before the end of the Report Period

- Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period or

- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.
Dispensing Event

One prescription of an amount lasting 30 days or less. For prescriptions longer than 30 days, divide the days’ supply by 30 and round down to convert. For example, a 100-day prescription is equal to 3 dispensing events:

\[ 100 \div 30 = 3.33, \text{rounded down to 3} \]

Also, two different prescriptions dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed:
\[ \text{November 19, 2018} - \text{November 15, 2018} = 4 \]

- Asthma medication codes for denominator defined with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Beclolecithasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Dyphylline, Theophylline), Short-Acting, Inhaled Beta2 Agonists (Albuterol, Levalbuterol, Pirbuterol), Anti-interleukin-5 (Mepolizumab, Reslizumab). Medications must not have a comment of RETURNED TO STOCK.

Asthma Management Plan

Defined as Patient Education code ASM-SMP.
Severity
Severity documented defined as meeting any of the following criteria:
- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at any time before the end of the Report Period or
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.

Control
Control documented defined as ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS] with Asthma Control recorded in the V POV file.

Symptom Free Days
Number of symptom free days defined as the most recent V Measurement documented during the Report Period.

School or Work Days Missed
Number of school or work days missed defined as the most recent V Measurement documented during the Report Period.

2.9.2.6 Patient List
List of asthmatic patients with assessments, if any.

2.9.3 Medication Therapy for Persons with Asthma

2.9.3.1 Owner and Contact
Chris Lamer, PharmD

2.9.3.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.3.3 Denominators
1. Active Clinical patients ages 5 through 50 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or COPD.
2. Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or COPD. Broken down into age groups: 5 through 14 years, 15 through 34 years, 35 through 64 years, and 65 years and older.

3. Active Clinical patients ages 5 and older with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or COPD who had two or more prescriptions for a Long-Acting Beta2 Agonist (LABA) medication during the Report Period. Broken down into age groups: 5 through 14 years, 15 through 34 years, 35 through 64 years, and 65 years and older.

2.9.3.4 Numerators

1. Suboptimal Control: Patients who were dispensed more than three canisters of a short-acting Beta2 Agonist inhaler during the same 90-day period during the Report Period (with Denominator 1).

2. Absence of Controller Therapy: Patients who were dispensed more than three canisters of short acting Beta2 Agonist inhalers over a 90-day period and who did not receive controller therapy during the same 90-day period (with Denominator 1).

3. Patients who were prescribed two or more controller therapy medications during the Report Period (with Denominator 2).

4. Patients who were prescribed two or more inhaled corticosteroid medications during the Report Period (with Denominator 2).

5. Patients who were not prescribed two or more inhaled corticosteroid medications during the Report Period (with Denominator 3).

2.9.3.5 Definitions

Denominator Exclusions

Patients diagnosed with emphysema or COPD at any time on or before the end of the Report Period are excluded from the denominator.

Emphysema

Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted:

- ICD-9: 492.*, 506.4, 518.1, 518.2; ICD-10: J43.*, J68.4, J68.8, J98.2, J98.3. [BGP EMPHYSEMA DXS]
• SNOMED data set PXRM BGP EMPHYSEMA (Problem List only)

**COPD**

Any visit at any time on or before the end of the Report Period with POV or Problem List entry where the status is not Deleted:

- ICD-9: 491.0, 491.1, 491.2*, 491.8, 491.9, 493.2*, 496, 506.4; ICD-10: J41.*, J42, J44.*, J68.4, J68.8 [BGP COPD DXS]
- SNOMED data set PXRM BGP COPD (Problem List only)

**Persistent Asthma**

Meeting any of the following four criteria that follow within the year prior to the beginning of the Report Period and during the Report Period:

- At least one visit to Clinic code 30 (Emergency Medicine) with primary diagnosis ICD-9: 493.*; ICD-10: J45.* (asthma) [BGP ASTHMA DXS]
- At least one acute inpatient discharge with primary diagnosis ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]. Acute inpatient discharge defined as Service Category of H
- At least 4 outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS] and at least two asthma medication dispensing events (see the definition that follows)
- At least four asthma medication dispensing events (see the definition that follows). If the sole medication was leukotriene modifiers, then must also have at least one visit with POV ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS] in the same year as the leukotriene modifier (i.e., during the Report Period or within the year prior to the beginning of the Report Period.), or

Meeting any of the following criteria:

- Problem List entry where the status is not Inactive or Deleted for ICD-9: 493.*; ICD-10: J45.* [BGP ASTHMA DXS]; SNOMED data set PXRM ASTHMA with Severity of 2, 3 or 4 at any time before the end of the Report Period
- Problem List entry where the status is not Inactive or Deleted for SNOMED data set PXRM ASTHMA PERSISTENT at ANY time before the end of the Report Period
- Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented any time before the end of the Report Period.
**Dispensing Event**

One prescription of an amount lasting 30 days or less. For prescriptions longer than 30 days, divide the days’ supply by 30 and round down to convert. For example, a 100-day prescription is equal to 3 dispensing events:

\[ 100 \div 30 = 3.33, \text{rounded down to 3} \]

Also, two different prescriptions dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:

- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018

Recalculated number of Days Prescribed:

\[ \text{November 19, 2018} - \text{November 15, 2018} = 4 \]

- Asthma medication codes for denominator defined with medication taxonomies:
  - BGP HEDIS ASTHMA MEDS
  - BGP HEDIS ASTHMA LEUK MEDS
  - BGP HEDIS ASTHMA INHALED MEDS
  - Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline), Antibody Inhibitor (Omalizumab), Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol, Formoterol-Mometasone), Inhaled Corticosteroids (Beclolemethasone, Budesonide, Ciclesonide CFC Free, Flunisolide, Fluticasone CFC Free, Mometasone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn), Methylxanthines (Dyphylline, Theophylline), Short-Acting, Inhaled Beta2 Agonists (Albuterol, Levalbuterol, Pirbuterol), Anti-interleukin-5 (Mepolizumab, Reslizumab). Medications must not have a comment of RETURNED TO STOCK.

**Numerator Inclusion**

To be included in the Suboptimal Control and Absence of Controller Therapy numerators, patient must have one or more non-discontinued prescriptions for short acting Beta2 Agonist inhalers totaling at least four canisters in one 90-day period. Short acting Beta2 Agonist inhaler medications defined with medication taxonomy BGP PQA SABA MEDS. (Medications are: Albuterol, Levalbuterol). Medications must not have a comment of RETURNED TO STOCK.
**Controller Therapy**

At least one non-discontinued prescription of controller therapy medications during the same 90-day period.

**Controller Therapy Medications**

Controller therapy medications defined with medication taxonomy BGP PQA CONTROLLER MEDS. (Medications are: Beclomethasone, Budesonide, Budesonide-Formoterol, Ciclesonide, Flunisolide, Fluticasone, Fluticasone-Salmeterol, Fluticasone-vilanterol, Formoterol, Fluticasone-salmeterol, Mometasone, Mometasone-Formoterol, Montelukast, Salmeterol, Theophylline, Zafirlukast, Zileuton). Medications must not have a comment of RETURNED TO STOCK.

**Inhaled Corticosteroid Medications**

Inhaled corticosteroid medications defined with medication taxonomy BGP PQA ASTHMA INHALED STEROIDS. (Medications are: Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Fluticasone-vilanterol, Mometasone, Budesonide-formoterol, Mometasone-formoterol) Medications must not have a comment of RETURNED TO STOCK.

**LABA Medications**

LABA medications defined with medication taxonomy BGP ASTHMA LABA MEDS. (Medications are: Aformoterol, Formoterol, Salmeterol.) Medications must not have a comment of RETURNED TO STOCK.

2.9.3.6 **Patient List**

List of patients with asthma with asthma medications, if any.

2.9.4 **Proportion of Days Covered by Medication Therapy**

2.9.4.1 **Owner and Contact**

Chris Lamer, PharmD

2.9.4.2 **National Reporting**

OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.4.3 **Denominators**

1. Active Clinical patients ages 18 and older who had two or more prescriptions for beta-blockers during the Report Period.
2. Active Clinical patients ages 18 and older who had two or more prescriptions for RAS Antagonists and no documented history of ESRD or one or more prescriptions for ARB/Neprilysin inhibitor combination medications during the Report Period.

3. Active Clinical patients ages 18 and older who had two or more prescriptions for calcium channel blockers (CCB) during the Report Period.

4. Active Clinical patients ages 18 and older who had two or more prescriptions for biguanides and no documented history of ESRD during the Report Period.

5. Active Clinical patients ages 18 and older who had two or more prescriptions for sulfonylureas and no documented history of ESRD during the Report Period.

6. Active Clinical patients ages 18 and older who had two or more prescriptions for thiazolidinediones and no documented history of ESRD during the Report Period.

7. Active Clinical patients ages 18 and older who had two or more prescriptions for DiPeptidyl Peptidase (DPP)-IV Inhibitors and no documented history of ESRD during the Report Period.

8. Active Clinical patients ages 18 and older who had two or more prescriptions for Diabetes All Class medications and no documented history of ESRD during the Report Period.

9. Active Clinical patients ages 18 and older who had two or more prescriptions for statins during the Report Period.

10. Active Clinical patients ages 18 and older who had two or more prescriptions for non-warfarin oral anticoagulants during the Report Period.

11. Active Clinical patients ages 18 and older who had two or more prescriptions for antiretroviral agents during the Report Period.

12. Active Clinical patients with COPD who had two or more prescriptions for long-acting inhaled bronchodilators and no prescriptions for nebulized bronchodilators during the Report Period.

13. Active Clinical patients ages 18 and older who had two or more prescriptions for non-infused disease modifying agents treating multiple sclerosis (MS) totalling 56 days supply or more and no prescriptions for infused medications treating MS during the Report Period.

2.9.4.4 Numerators

1. Patients with proportion of days covered (PDC) greater than or equal to 80% during the Report Period.
2. Patients with a gap in medication therapy greater than or equal to 30 days.

3. Patients with PDC greater than or equal to 90% during the Report Period. (With Denominator 11)

2.9.4.5 Definitions

Denominator Inclusion

Patients must have at least two prescriptions for that particular type of medication on two unique dates of service at any time during the Report Period. Medications must not have a comment of RETURNED TO STOCK. Note: Outside medications and e-prescribed medications (prescription number begins with "X" or days' supply is zero) will not be included in these measures.

For the Non-warfarin anticoagulants measures, the two unique dates of service must be at least 180 days apart and the patient must have received greater than a 60-day supply of the medication during the Report Period. Patients who received one or more prescriptions for warfarin, low molecular weight heparin (LMWH), heparin or an SC Factor Xa inhibitor (defined by medication taxonomy BGP PQA WARFARIN) will be excluded from the denominator.

Index Prescription Start Date

The date when the medication was first dispensed within the Report Period. For all measures except Non-warfarin anticoagulants, this date must be greater than 90 days from the end of the Report Period to be counted in the denominator.

Medications

Medications are defined with the following taxonomies:

| Note: HCL designation is Hydrogen Chloride. HCZL is Hydrochlorothiazide. |

- **BGP PQA BETA BLOCKER MEDS**
  - Beta-blocker medications (Acebutolol HCL, Atenolol, Betaxolol HCL, Bisoprolol fumarate, Carvedilol, Labetalol HCL, Metoprolol succinate, Metoprolol tartrate, Nadolol, Nebivolol HCL, Penbutolol sulfate, Pindolol, Propranolol HCL, Timolol maleate); Beta-blocker combination products (Atenolol-chlorthalidone, Bisoprolol-HCTZ, Nadolol-bendroflumethiazide, Metoprolol-HCTZ, Propranolol-HCTZ, Nebivolol-valsartan)

- **BGP PQA RASA MEDS**
Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril); Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, Fosinopril-HCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Quinapril-HCTZ, Trandolapril-verapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive Combinations (Aliskiren-valsartan, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ, Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipine-HCTZ, Olmesartan-HCTZ, Telmisartan-amlodipine, Telmisartan-HCTZ, Valsartan-HCTZ, Nebivolol-valsartan); Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Aliskiren-HCTZ, Aliskiren-valsartan).

- **BGP PQA CCB MEDS**
  - Calcium-Channel Blocker medications (Amlodipine besylate, Diltiazem HCL, Felodipine, Isradipine, Nicardipine HCL, Nifedipine (long acting only), Verapamil HCL, Nisoldipine); CCB Combination Products (Amlodipine besylate-benazepril HCL, Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Aliskiren-amlodipine, Aliskiren-amlodipine-HCTZ, Telmisartan-amlodipine, Amlodipine-olmesartan, Perindopril-amlodipine, Trandolapril-verapamil HCL, Amlodipine-atorvastatin, Olmesartan-amlodipine-HCTZ)

- **BGP PQA BIGUANIDE MEDS**
  - Biguanides (Metformin); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-Metformin, Canagliflozin-Metformin)

- **BGP PQA SULFONYLUREA MEDS**
  - Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride)

- **BGP PQA THIAZOLIDINEDIONE MEDS**
  - Thiazolidinediones (Pioglitazone, Rosiglitazone); Combination Products (Rosiglitazone-metformin, Pioglitazone-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride, Alogliptin-pioglitazone)
• **BGP PQA DPP IV MEDS**
  - DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptin-pioglitazone, Linagliptin-empagliflozin)

• **BGP PQA DIABETES ALL CLASS**
  - Biguanide medications (see list above); Sulfonylurea medications (see list above); Thiazolidinedione medications (see list above); DPP-IV Inhibitor medications (see list above); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide, Lixisenatide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-Metformin, Linagliptin-empagliflozin, Canagliflozin-Metformin, Empagliflozin-metformin)

• **BGP PQA STATIN MEDS**
  - Statins (Lovastatin, Rosuvasstatin, Fluvastatin, Atorvastatin, Pravastatin, Pitavastatin, Simvastatin); Combination Products (Niacin-lovastatin, Atorvastatin-amlodipine, Niacin-simvastatin, Sitagliptin-simvastatin, Ezetimibe-simvastatin, Ezetimibe-atorvastatin)

• **BGP PQA NON-WARFARIN ANTICOAG**
  - (Apixaban, Dabigatran, Rivaroxaban, Edoxaban)

• **BGP PQA WARFARIN**
  - (Warfarin, Dalteparin, Fondaparinux, Enoxaparin, Heparin)

• **BGP PQA ANTIRETROVIRAL MEDS**

• **BGP PQA ARB NEPRLYSIN INHIB**
  - ARB/Neprilsin Inhibitor Combinations (Sacubitril/Valsartan)

• **BGP PQA LA INHALED BRONCHO MED**
- Aclidinium bromide powder, Budesonide-formoterol fumarate dihydrate aerosol, Fluticasone propionate-salmeterol xinafoate powder, Fluticasone-vilanterol, Formoterol inhalation capsule, Glycopyrrolate, Glycopyrrolate-formoterol, Indacaterol maleate inhalation powder, Indacaterol-glycopyrrolate, Olodaterol aerosol, Salmeterol xinafoate, Tiotropium bromide powder, Tiotropium bromide-olodaterol, Unmeclidinium, Unmeclidinium-vilanterol

- **BGP PQA NEBULIZED BRONCHO MEDS**
  - Albuterol Sulfate, Arformoterol Tartrate, Formoterol Fumarate, Ipratropium Bromide, Ipratropium-Albuterol, Levalbuterol HCl

- **BGP PQA NON-INFUSED MS MEDS**
  - Beta-Interferons (Interferon beta 1a, Interferon beta 1b, Peginterferon beta-1a); Immunomodulators (Glatiramer, Fingolimid, Daclizumab); Pyrimidine Synthesis Inhibitors (Teriflunomide); Nrf2 Activators (Dimethyl Fumerate)

- **BGP PQA INFUSED MS MEDS**
  - Alemtuzumab, Mitoxantrone, Natalizumab, Ocrelizumab

**ESRD**

Any of the following ever:

- CPT 36145 (old code), 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831 through 36833, 50300, 50340, 50365, 50367, 50380, 90918 through 90925 (old codes), 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90951 through 90970, 90989, 90993, 90997, 90999, 99512, G0257, G0308 through G0327 (old codes), G0392 (old code), G0393 (old code), G9231, S2065, S9339 [BGP ESRD CPTS]

- Diagnosis (POV or Problem List entry where the status is not Deleted):
  - SNOMED data set PXRM END STAGE RENAL DISEASE (Problem List only)

- Procedure ICD-9: 38.95, 39.27, 39.42, 39.43, 39.53, 39.93 through 39.95, 54.98, 55.6* [BGP ESRD PROCS]

**Chronic Obstructive Pulmonary Disease (COPD)**

Any of the following during the Report Period:

- COPD: Diagnosis (POV or Problem List entry where the status is not Deleted):
- ICD-9: 491.20, 491.21, 491.22, 493.2*, 496, 506.4; ICD-10: J44.*, J68.4, J68.8 [BGP COPD DXS]
- SNOMED data set PXRM BGP COPD (Problem List only)
- Emphysema: Diagnosis (POV or Problem List entry where the status is not Deleted):
  - ICD-9: 492.*, 506.4, 518.1, 518.2; ICD-10: J43.*, J68.4, J68.8, J98.2, J98.3 [BGP EMPHYSEMA DXS]
  - SNOMED data set PXRM BGP EMPHYSEMA (Problem List only).

Each PDC Numerator

Proportion of days covered equals the number of days the patient was covered by at least one drug in the class divided by the number of days in the patient's measurement period.

The patient's measurement period is defined as the number of days between the Index Prescription Start Date and the end of the Report Period. When calculating the number of days, the patient was covered by at least one drug in the class, if prescriptions for the same drug overlap, the prescription start date for the second prescription will be adjusted to be the day after the previous fill has ended.

Note: If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed: November 19, 2018 – November 15, 2018 = 4

Example of Proportion of Days Covered

Report Period: January 1 through December 31, 2018

- First prescription:
  - Index Rx Start Date: March 1, 2018
  - Days’ Supply: 90
  - Prescription covers patient through May 29, 2018
- Second prescription:
  - Rx Date: May 26, 2018
  - Days’ Supply: 90
  - Prescription covers patient through August 27, 2018
- Third prescription:
Rx Date: September 11, 2018
Days’ Supply: 180
Gap:

September 11, 2018 – August 27, 2018 = 15 days

Prescription covers patient through March 8, 2019

Patient's measurement period:
March 1, 2018 through December 31, 2018 = 306 days

Days patient was covered:
March 1, 2018 through August 27, 2018 +
September 11, 2018 through December 31, 2018 = 292 days

PDC:

\[ \frac{292}{306} = 95\% \]

**Each Gap Numerator**

CRS will calculate whether a gap in medication therapy of 30 or more days has occurred between each consecutive medication dispensing event during the Report Period. A gap is calculated as the days not covered by the days’ supply between consecutive medication fills.

**Example of Medication Gap Greater Than or Equal to 30 Days:**

Report Period: January 1 through December 31, 2018

- First prescription:
  - Rx Date: April 1, 2018
  - Days’ Supply: 30
  - Prescription covers patient through April 30, 2018

- Second prescription:
  - Rx Date: July 1, 2018
  - Days’ Supply: 90
  - Gap #1:
    July 1, 2018 – April 30, 2018 = 61 days

    Prescription covers patient through September 28, 2018

- Third prescription:
  - Rx Date: October 1, 2018
  - Days’ Supply: 90
Gap #2:

October 1, 2018 – September 28, 2018 = 2 days

Prescription covers patient through December 29, 2018

Gap #1 ≥ 30 days

Patient will be included in the numerator for that medication.

2.9.4.6 **Patient List**

List of patients 18 and older prescribed medication therapy medication with proportion of days covered and gap days.

2.9.5 **Primary Medication Non-adherence**

2.9.5.1 **Owner and Contact**

Chris Lamer, PharmD

2.9.5.2 **National Reporting**

Not reported nationally

2.9.5.3 **Denominators**

1. Number of e-prescriptions for newly initiated drug therapy for chronic medications for Active Clinical patients ages 18 and older.

2.9.5.4 **Numerator**

1. Number of medications returned to stock within 30 days.

2.9.5.5 **Definitions**

**Denominator Inclusion**

To be included in the denominator, the e-prescription must be for a chronic medication during the Report Period.

**Denominator Exclusions**

- Any prescription where there is a prescription dispensing record in the preceding 180 days for the same drug.
- Any duplicate medications, defined as any medication that has been e-prescribed twice in a 30-day period with no prescription fill in between the e-prescriptions.
- Any prescription sent to an outside pharmacy, as it is not possible to know if the medication was returned to stock.

**Chronic Medications**

Defined by the following taxonomies:

- **BGP PQA ASTHMA INHALED STEROIDS**
  - Beclomethasone, Budesonide, Ciclesonide, Fluticasone, Flunisolide, Fluticasone-salmeterol, Fluticasone-vilanterol, Mometasone, Budesonide-formoterol, Mometasone-formoterol

- **BGP PQA COPD**
  - Tiotropium, Indacaterol, Olodaterol, Umeclidinium, Glycopyrrolate, Indacaterol-glycopyrrolate, Ipratropium-albuterol, Roflumilast, Luticasone-vilanterol, Glycopyrrolate-formoterol, Ipratropium, Acldinium, Umeclidinium-vilanterol, Tiotropium-olodaterol

- **BGP PQA DIABETES ALL CLASS**
  - Biguanides (Metformin); Biguanide Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-metformin, Pioglitazone-metformin, Repaglinide-metformin, Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Linagliptin-metformin, Alogliptin-metformin, Dapagliflozin-metformin, Empagliflozin-metformin, Canagliflozin-metformin); Sulfonylureas (Chlorpropamide, Glimepiride, Glipizide, Glyburide, Tolazamide, Tolbutamide); Sulfonylurea Combination Products (Glipizide-metformin, Glyburide-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride); Thiazolidinediones (Pioglitazone, Rosiglitazone); Thiazolidinedione Combination Products (Rosiglitazone-metformin, Pioglitazone-metformin, Rosiglitazone-glimepiride, Pioglitazone-glimepiride, Alogliptin-pioglitazone); DPP-IV Inhibitors (Sitagliptin, Linagliptin, Saxagliptin, Alogliptin); DPP-IV Inhibitor Combination Products (Sitagliptin-metformin IR-SR, Saxagliptin-metformin SR, Sitagliptin-simvastatin, Linagliptin-metformin, Alogliptin-metformin, Alogliptin-pioglitazone, Linagliptin-empagliflozin); Incretin Mimetic Agents (Albiglutide, Exenatide, Liraglutide, Dulaglutide, Lixisenatide); Meglitinides (Nateglinide, Repaglinide, Repaglinide-metformin); Sodium glucose co-transporter2 (SGLT2) inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Dapagliflozin-metformin, Linagliptin-empagliflozin, Canagliflozin-metformin, Empagliflozin-metformin)
• BGP PQA RASA MEDS
  – Angiotensin Converting Enzyme Inhibitors (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolopril); Antihypertensive Combinations (Amlodipine-benazepril, Benazepril-HCTZ, Captopril-HCTZ, Enalapril-HCTZ, Fosinopril-HCTZ, Lisinopril-HCTZ, Moexipril-HCTZ, Perindopril-amlodipine, Quinapril-HCTZ, Trandolapril-verapamil); Angiotensin II Inhibitors (Azilsartan, Candesartan, Eprosartan, Irbesartan, Losartan, Olmesartan, Telmisartan, Valsartan); Antihypertensive Combinations (Amlodipine-valsartan, Amlodipine-valsartan-HCTZ, Amlodipine-olmesartan, Azilsartan-Chlorthalidone, Candesartan-HCTZ, Eprosartan-HCTZ, Irbesartan-HCTZ, Losartan-HCTZ, Olmesartan-amlodipine-HCTZ, Olmesartan-valsartan, Telmisartan-amlodipine, Telmisartan-HCTZ, Valsartan-HCTZ, Nebivolol-valsartan); Direct Renin Inhibitors (Aliskiren); Direct Renin Inhibitor Combination Products (Aliskiren-amlodipine, Aliskiren-olmesartan, Aliskiren-HCTZ)
• BGP PQA STATIN MEDS

Numerator Inclusion
To be included in the numerator, the e-prescription medication must have a comment of RETURNED TO STOCK within 30 days of the prescription date (i.e., visit date).

2.9.5.6 Patient List
List of patients 18 and older with an e-prescription for chronic medications, with returned to stock, if any.

2.9.6 Concurrent Use of Opioids and Benzodiazepines

2.9.6.1 Owner and Contact
Chris Lamer, PharmD

2.9.6.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)
2.9.6.3 **Denominators**

1. Active Clinical patients ages 18 and older who had two or more prescriptions for opioids with total days’ supply of 15 or more and no cancer or hospice indicator during the Report Period.

2.9.6.4 **Numerator**

1. Patients who received two or more prescriptions for benzodiazepines with concurrent use of opioids and benzodiazepines for 30 or more cumulative days.

2.9.6.5 **Definitions**

**Denominator**

To be included in the denominator, patients must have at least two prescriptions for opioids on two unique dates of service at any time during the Report Period. The sum of the days’ supply must be 15 or more days during the Report Period.

**Opioid medications**

Medication taxonomy BGP PQA OPIOID MEDS.

- Medications are (excludes injectable formulations): buprenorphine (excludes single-agent and combination buprenorphine products used to treat opioid use disorder), butorphanol, codeine, dihydrocodeine, fentanyl (excludes Ionsys (fentanyl transdermal patch), hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, pentazocine, tapentadol, tramadol). Medications must not have a comment of RETURNED TO STOCK. Note: Outside medications and e-prescribed medications (prescription number begins with "X" or days' supply is zero) will not be included in these measures.

**Hospice**

- CPT 99377, 99378, G9473 through G9479, G9687 [BGP CPT HOSPICE]
- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

**Cancer**

- POV ICD-9: 140.* through 172.*, 174.* through 209.3*, 209.7*, 235.* through 239.*; ICD-10: C00.* through C43.*, C4A.*, C45.0 through C96.*, D37.* through D49.*, Q85.0* [BGP PQA CANCER DXS]
**Numerator**

To be included in the numerator, patients must have at least two prescriptions for benzodiazepines on two unique dates of service at any time during the Report Period, with concurrent use of opioids and benzodiazepines for 30 or more cumulative days.

Concurrent use is identified using the dates of service and days’ supply of a patient's opioid and benzodiazepine prescriptions. The days of concurrent use is the sum of the number of days during the treatment period with overlapping days’ supply for an opioid and a benzodiazepine.

**Benzodiazepine medications**

Medication taxonomy BGP PQA BENZODIAZ OP MEDS.

- Medications are (excludes injectable formulations): alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, midazolam, oxazepam, quazepam, temazepam, triazolam. Medications must not have a comment of RETURNED TO STOCK. Note: Outside medications and e-prescribed medications (prescription number begins with "X" or days' supply is zero) will not be included in these measures.

2.9.6.6 Patient List

List of patients 18 and older with concurrent use of opioids and benzodiazepines, if any.

2.9.7 Medications Education

2.9.7.1 Owner and Contact

Patient Education Program: Chris Lamer, PharmD

2.9.7.2 National Reporting

Not reported nationally

2.9.7.3 Denominators

1. Active Clinical patients with medications dispensed at their facility during the Report Period.

2. User Population patients with medications dispensed at their facility during the Report Period.
2.9.7.4 Numerators

1. Patients who were provided patient education about their medications in any location.

2.9.7.5 Definitions

Patients receiving medications
Are identified any entry in the VMed file for your facility.

Medication Education
Any Patient Education code containing “M-” or “-M” or Patient Education codes DMC-IN, FP-DPO, FP-OC, *-NEB, *-MDI, or FP-TD.

2.9.7.6 Patient List
List of patients receiving medications with med education, if any.

2.9.8 Medication Therapy Management Services

2.9.8.1 Owner and Contact
Chris Lamer, PharmD

2.9.8.2 National Reporting
Not reported nationally

2.9.8.3 Denominators

1. Active Clinical patients 18 and older with medications dispensed at their facility during the Report Period.

2.9.8.4 Numerators

1. Patients who received medication therapy management (MTM) during the Report Period.

2.9.8.5 Definitions

Patients Receiving Medications
Are identified any entry in the VMed file for your facility.
Medication Therapy Management
MTM defined as:
- CPT 99605 through 99607 [BGP CPT MTM]
- Clinic codes: D1, D2, D5

2.9.8.6 Patient List
List of patients 18 and older receiving medications with medication therapy management, if any.

2.9.9 Public Health Nursing

2.9.9.1 Owner and Contact
Tina Tah, RN, BSN, MBA

2.9.9.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.9.3 Denominators
1. User Population patients.

2.9.9.4 Numerators
1. For User Population only, the number of patients in the denominator served by Public Health Nurses (PHNs) in any setting, including Home.

2. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in any setting

3. For User Population only, the number of patients in the denominator served by PHNs in a HOME setting.

4. For User Population only, the number of patients in the denominator served by a PHN driver/interpreter in a HOME setting.

5. Count only (no percentage comparison to denominator). Number of visits to User Population patients by PHNs in any setting, including Home
   A. Number of visits to patients age 0 through 28 days (Neonate)
   B. Number of visits to patients age 29 days to 12 months (Infants)
C. Number of visits to patients ages 1 through 64 years
D. Number of visits to patients ages 65 and older (Elders)
E. Number of PHN driver/interpreter (Provider code 91) visits.

6. Count only (no percentage comparison to denominator). Number of visits to User Population patients by PHNs in Home setting. Broken down into age groups: 0 through 28 days (neonate), 29 days through 12 months (infants), 1 through 64 years, 65 and older (elders).

A. Number of Home visits to patients age 0 through 28 days (Neonate)
B. Number of Home visits to patients age 29 days to 12 months (Infants)
C. Number of Home visits to patients ages 1 through 64 years
D. Number of Home visits to patients ages 65 and older (Elders)
E. Number of PHN driver/interpreter (Provider code 91) visits

2.9.9.5 Definitions

**PHN Visit-Any Setting**
Any visit with Primary or Secondary Provider codes 13 or 91.

**PHN Visit-Home**
Any visit with one of the following:
- Clinic code 11 and a primary or secondary provider code of 13 or 91
- Location Home (as defined in Site Parameters) and a Primary or Secondary Provider code 13 or 91

2.9.9.6 Patient List
List of patients with PHN visits documented.

Numerator codes in patient list:
- All PHN equals Number of PHN visits in any setting
- Home equals Number of PHN visits in home setting
- Driver All equals Number of PHN driver/interpreter visits in any setting
- Driver Home equals Number of PHN driver/interpreter visits in home setting
2.9.10 Breastfeeding Rates

Note: This measure is used to support the reduction of the incidence of childhood obesity.

2.9.10.1 Owner and Contact
Tina Tah, RN, BSN, MBA

2.9.10.2 National Reporting
OTHER NATIONAL (included in new Other National Measures Report; not reported to OMB and Congress)

2.9.10.3 Denominators
1. Active Clinical patients who are 30 through 394 days old.
2. Active Clinical patients who are 30 through 394 days old who were screened for infant feeding choice at the age of 2 months (38 through 89 days).
3. Active Clinical patients who are 30 through 394 days old who were screened for infant feeding choice at the age of 6 months (165 through 209 days).
4. Active Clinical patients who are 30 through 394 days old who were screened for infant feeding choice at the age of 9 months (255 through 299 days).
5. Active Clinical patients who are 30 through 394 days old who were screened for infant feeding choice at the age of 1 year (350 through 394 days).
6. User Population patients ages 30 through 394 days old.
7. GPRA: User Population patients who are 30 through 394 days old who were screened for infant feeding choice at the age of 2 months (38 through 89 days).
8. User Population patients ages 30 through 394 days old who were screened for infant feeding choice at the age of six months (165 through 209 days).
9. User Population patients ages 30 through 394 days old who were screened for infant feeding choice at the age of nine months (255 through 299 days).
10. User Population patients ages 30 through 394 days old who were screened for infant feeding choice at the age of 1 year (350 through 394 days).
2.9.10.4 Numerators

1. Patients who were screened for infant feeding choice at least once (with Denominator 1).

2. Patients who were screened for infant feeding choice at the age of 2 months (38 through 89 days) (with Denominator 1).

3. Patients were screened for infant feeding choice at the age of 6 months (165 through 209 days) (with Denominator 1).

4. Patients who were screened for infant feeding choice at the age of 9 months (255 through 299 days) (with Denominator 1).

5. Patients who were screened for infant feeding choice at the age of 1 year (350 through 394 days) (with Denominator 1).

6. GPRA: Patients who, at the age of 2 months (38 through 89 days), were either exclusively or mostly breastfed (with Denominators 2 and 6).

7. Patients who, at the age of 6 months (165 through 209 days), were either exclusively or mostly breastfed (with Denominator 3).

8. Patients who, at the age of 9 months (255 through 299 days), were either exclusively or mostly breastfed (with Denominator 4).

9. Patients who, at the age of 1 year (350 through 394 days), were either exclusively or mostly breastfed (with Denominator 5).

2.9.10.5 Definitions

Patient Age

Since the age of the patient is calculated at the beginning of the Report Period, this measure may include patients up to 25 months old if they were within the eligible age range on the first day of the Report Period and will not include any patients that were born after the first day of the Report Period. Patients born after the first day of the Report Period will be included in the following Report Period.
Infant Feeding Choice

The documented feeding choice from the file V Infant Feeding Choice that is closest to the exact age that is being assessed will be used. For example, if a patient was assessed at 45 days old as half breastfed and half formula fed and assessed again at 65 days old as mostly breastfed, the mostly breastfed value will be used since it is closer to the exact age of 2 months (i.e., 60 days). Another example is a patient who was assessed at 67 days as mostly breastfed and again at 80 days as mostly formula. In this case, the 67 days’ value of mostly breastfed will be used. The other exact ages are 180 days for 6 months, 270 days for 9 months, and 365 days for 1 year.

In order to be included in the age-specific screening numerators, the patient must have been screened at the specific age range. For example, if a patient was screened at 6 months and was exclusively breastfeeding but was not screened at 2 months, then the patient will only be counted in the 6 months’ numerator.

2.9.10.6 GPRA 2018 Target

During GPRA Year 2018, achieve the target rate of 39.0% for the proportion of 2-month olds who are mostly or exclusively breastfeeding.

2.9.10.7 Patient List

List of patients 30 through 394 days old, with infant feeding choice value, if any.

2.9.11 Use of High Risk Medications in the Elderly

2.9.11.1 Owner and Contact

Dr. Bruce Finke

2.9.11.2 National Reporting

Not reported nationally

2.9.11.3 Denominators

1. Active Clinical patients ages 65 and older with no hospice indicator during the Report Period. Broken down by gender and age groups: 65 through 74 years, 75 through 84 years, and 85 years and older.
2.9.11.4 Numerators

1. Patients who received at least one high risk medication for the elderly during the Report Period.

2. Patients who received at least two high risk medications of the same high-risk medication class for the elderly during the Report Period.

2.9.11.5 Definitions

**Note:** The logic below is a deviation from the logic written by PQA, and more closely matches the HEDIS logic.

- For nitrofurantoin, a patient must have received a single dispensing event with a days’ supply greater than 90 days for any nitrofurantoin product during the Report Period.

- For nonbenzodiazepine hypnotics (BGP HEDIS NONBENZODIAZ MEDS), a patient must have received a single dispensing event with a days’ supply greater than 90 days for any nonbenzodiazepine hypnotic products during the Report Period.

- For medications dispensed during the report period, include any days supply that extends beyond the end of the report period. For example, a prescription of a 90-day supply dispensed on the last day of the report period counts as a 90-day supply.

**Hospice**

- CPT 99377, 99378, G9473 through G9479, G9687 [BGP CPT HOSPICE]

- SNOMED codes 170935008, 183919006, 183920000, 183921001, 284546000, 305336008, 305911006, 385763009, 385765002, 444933003, 445449000, 444933003, 428361000124107, 428371000124100

**High Risk Medications for the Elderly**

Defined with medication taxonomies:

- **BGP HEDIS ANTICHOLINERGIC MEDS**
  - First-generation antihistamines (Includes combination drugs)
    - (Brompheniramine, Carbinoxamine, Chlorpheniramine, Clemastine, Cyproheptadine, Dexamphetamine, Dextromethorphan, Dextropropoxyphene, Dimenhydrinate, Diphenhydramine (oral), Doxylamine, Hydroxyzine, Meclizine, Promethazine, Triprolidine); Antiparkinson agents
    - (Benztropine (oral), Trihexyphenidyl); Antispasmodics (Atropine (excludes ophthalmic), Belladonna alkaloids, Clidinium-Chlordiazepoxide, Dicyclomine, Hyoscyamine, Propantheline, Scopolamine)
• **BGP HEDIS ANTITHROMBOTIC MEDS**
  
  (Ticlopidine, Dipyridamole, oral short-acting)

• **BGP HEDIS ANTI-INFECTIVE MEDS**
  
  (Nitrofurantoin)

• **BGP HEDIS CARDIOVASCULAR MEDS**
  
  - Alpha blockers, central (Guanfacine, Guanabenz, Metyldopa, Reserpine);
  - Cardiovascular, other (Disopyramide, Digoxin, Nifedipine, immediate release)

• **BGP HEDIS CENTRAL NERVOUS MEDS**
  
  - Antidepressants (Includes combination drugs) (Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Paroxetine, Protriptyline, Trimipramine); Barbiturates (Amobarbital, Butabarbital, Butalbital, Mepobarbital, Pentobarbital, Phenobarbital, Secobarbital); Central Nervous System, other (Meprobamate); Nonbenzodiazepine hypnotics (Eszopiclone, Zolpidem, Zaleplon); Vasodilators (Ergoloid mesylates, Isoxsuprine)

• **BGP HEDIS ENDOCRINE MEDS**
  
  - Endocrine (Desiccated thyroid, Estrogens with or without progesterone (oral and topical patch products only), Megestrol); Sulfonylureas, long-duration (Chlorpropamide, Glyburide)

• **BGP HEDIS PAIN MEDS**
  
  - Pain medications (Meperidine, Pentazocine); Non-COX-selective NSAIDs (Indomethacin, Ketorolac [includes parenteral])

• **BGP HEDIS SKL MUSCLE RELAX MED**
  
  - (Includes combination drugs) (Carisoprodol, Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol, Orphenadrine)

**Note:** For each medication, the days’ supply must be > 0. If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:

- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018

Recalculated number of Days Prescribed: November 19, 2018 – November 15, 2018 = 4

Medications must not have a comment of RETURNED TO STOCK.
2.9.11.6 **Patient List**

List of patients 65 and older with at least one prescription for a potentially harmful drug.

2.9.12 **Use of Benzodiazepine Sedative Hypnotic Medications in the Elderly**

2.9.12.1 **Owner and Contact**

Chris Lamer, PharmD

2.9.12.2 **National Reporting**

Not reported nationally

2.9.12.3 **Denominators**

1. Active Clinical patients ages 65 and older.
2. User Population patients ages 65 and older.

2.9.12.4 **Numerators**

1. Patients who received at least two prescription fills for any benzodiazepine sedative hypnotic medications for more than 90 days.

2.9.12.5 **Definitions**

- The patient must have received a cumulative day’s supply for any benzodiazepine sedative hypnotic products greater than 90 days during the Report Period.
- Benzodiazepine sedative hypnotic medications defined with medication taxonomy BGP PQA BENZODIAZ MEDS. (Medications are: Estazolam, Flurazepam, Quazepam, Temazepam, Triazolam)
Note: For each medication, the days’ supply must be > 0. If a medication was started and then discontinued, CRS will recalculate the number of Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date. For example:
- Rx Date: November 15, 2018
- Discontinued Date: November 19, 2018
Recalculated number of Days Prescribed: November 19, 2018 − November 15, 2018 = 4

Medications must not have a comment of RETURNED TO STOCK.

2.9.12.6 Patient List
List of patients 65 and older with two or more prescriptions for benzodiazepine sedative hypnotic medications.

2.9.13 Functional Status in Elders

2.9.13.1 Owner and Contact
Dr. Bruce Finke

2.9.13.2 National Reporting
Not reported nationally

2.9.13.3 Denominators
1. Active Clinical patients ages 55 and older. Broken down by gender.

2.9.13.4 Numerators
1. Patients screened for functional status at any time during the Report Period.

2.9.13.5 Definitions

Functional Status
Any non-null values in V Elder Care for the following:
- At least one of the following ADL fields: toileting, bathing, dressing, transfers, feeding, or continence
• At least one of the following IADL fields: finances, cooking, shopping, housework/chores, medications or transportation during the Report Period.

2.9.13.6 Patient List
List of patients 55 and older with functional status codes, if any.

The following abbreviations are used in the Numerator column:
• TLT. Toileting
• BATH. Bathing
• DRES. Dressing
• XFER. Transfers
• FEED. Feeding
• CONT. Continence
• FIN. Finances
• COOK. Cooking
• SHOP. Shopping
• HSWK. Housework/Chores
• MEDS. Medications
• TRNS. Transportation

2.9.14 Fall Risk Assessment in Elders

2.9.14.1 Owner and Contact
Dr. Bruce Finke

2.9.14.2 National Reporting
Not reported nationally

2.9.14.3 Denominators
1. Active Clinical patients ages 65 and older. Broken down by gender.
2.9.14.4 Numerators

1. Patients who have been screened for fall risk or with a fall-related diagnosis in the past year.

Note: This numerator does not include refusals.

   A. Patients who have been screened for fall risk in the past year.
   B. Patients with a documented history of falling in the past year.
   C. Patients with a fall-related injury diagnosis in the past year.
   D. Patients with abnormality of gait/balance or mobility diagnosis in the past year.

2. Patients with a documented refusal of fall risk screening exam in the past year.

2.9.14.5 Definitions

Fall Risk Screen
Any of the following:

- Fall Risk Exam defined as: Exam code 37
- CPT 1100F, 1101F, 3288F [BGP FALL RISK EXAM CPTS]
- History of Falling defined as: POV ICD-9: V15.88 (Personal History of Fall); ICD-10: Z91.81 [BGP HISTORY OF FALL DXS]
- Fall-related Injury Diagnosis defined as: POV ICD-9: (Cause codes #1 through 3) E880.*, E881.*, E883.*, E884.*, E885.*, E886.*, E888.*; ICD-10: (All codes ending in A or D only) W01.*, W06.* through W08.*, W10.*, W18.*, W19.* [BGP FALL RELATED E-CODES]
- Abnormality of Gait/Balance or Mobility defined as: POV ICD-9: 781.2, 781.3, 719.7, 719.70 (old code), 719.75 through 719.77 (old codes), 438.84, 333.99, 443.9; ICD-10: G25.7*, G25.89, G25.9, G26, I69.*93, I73.9, R26.*, R27.* [BGP ABNORMAL GAIT OR MOBILITY]

Refusal
Refusal of Exam 37

2.9.14.6 Patient List
List of patients 65 years and older with fall risk assessment, if any.
2.9.15  Palliative Care

2.9.15.1  Owner and Contact
Dr. Bruce Finke

2.9.15.2  National Reporting
Not reported nationally

2.9.15.3  Denominators
1. No denominator, count only.

2.9.15.4  Numerators
1. Count only (no percentage comparison to denominator). For patients meeting the Active Clinical definition, the total number of patients with at least one palliative care visit during the Report Period; broken down by age groups: younger than 18 years, 18 through 54 years, 55 years and older.

2. Count only (no percentage comparison to denominator). For patients meeting the Active Clinical definition, the total number of palliative care visits during the Report Period; broken down by age groups: younger than 18 years, 18 through 54 years, 55 years and older.

2.9.15.5  Definitions
Palliative Care Visit
POV ICD-9: V66.7; ICD-10: Z51.5 [BGP PALLIATIVE CARE DXS]

2.9.15.6  Patient List
List of patients with a palliative care visit, if any.

2.9.16  Annual Wellness Visit

2.9.16.1  Owner and Contact
Dr. Bruce Finke

2.9.16.2  National Reporting
Not reported nationally
2.9.16.3 Denominators
1. Active Clinical patients ages 65 and older. Broken down by gender.

2.9.16.4 Numerators
1. Patients with at least one Annual Wellness Exam in the past 15 months.

2.9.16.5 Definitions
Annual Wellness Exam
CPT G0438, G0439, G0402 [BGP ANNUAL WELLNESS CPTS]

2.9.16.6 Patient List
List of patients with an annual wellness visit in the past 15 months.

2.9.17 Optometry

2.9.17.1 Owner: Contact
Dr. Dawn Clary

2.9.17.2 National Reporting
NATIONAL (included in IHS Performance Report; not reported to OMB and Congress)

2.9.17.3 Denominators
1. GPRA Developmental (NQF 0086): Active Clinical patients ages 18 and older with a diagnosis of primary open-angle glaucoma during the Report Period.

2.9.17.4 Numerators
1. GPRA Developmental (NQF 0086): Patients with an optic nerve head evaluation during the Report Period.

2.9.17.5 Definitions
Primary open-angle glaucoma
- Diagnosis (POV or Problem List entry where the status is not Inactive or Deleted):
– SNOMED data set PXRM OPEN ANGLE GLAUCOMA (Problem List only)

**Optic nerve head evaluation**
- CPT: 2027F [BGP OPTIC NERVE HEAD EVAL CPT]

2.9.17.6 **Patient List**
List of patients 18 and older with primary open-angle glaucoma and optic nerve head evaluation, if any.

2.9.18 **Goal Setting**

2.9.18.1 **Owner and Contact**
Patient Education: Chris Lamer, PharmD

2.9.18.2 **National Reporting**
Not reported nationally

2.9.18.3 **Denominators**
1. User Population patients.
2. Number of goal topics set during the Report Period.
3. Number of goal topics met during the Report Period.

2.9.18.4 **Numerator**
1. Number of patients who set at least one goal during the Report Period (with Denominator 1).
2. Number of goals set for ALCOHOL OR OTHER DRUGS (with Denominator 2).
3. Number of goals set for DIABETES CURRICULUM (with Denominator 2).
4. Number of goals set for MEDICATIONS (with Denominator 2).
5. Number of goals set for MONITORING (with Denominator 2).
6. Number of goals set for NUTRITION (with Denominator 2).
7. Number of goals set for OTHER (with Denominator 2).
8. Number of goals set for PHYSICAL ACTIVITY (with Denominator 2)
9. Number of goals set for STRESS AND COPING (with Denominator 2).
10. Number of goals set for TOBACCO (with Denominator 2).
11. Number of goals set for WELLNESS AND SAFETY (with Denominator 2).
12. Number of patients who met at least one goal during the Report Period (with Denominator 1).
13. Number of goals met for ALCOHOL OR OTHER DRUGS (with Denominator 3).
14. Number of goals met for DIABETES CURRICULUM (with Denominator 3).
15. Number of goals met for MEDICATIONS (with Denominator 3).
16. Number of goals met for MONITORING (with Denominator 3).
17. Number of goals met for NUTRITION (with Denominator 3).
18. Number of goals met for OTHER (with Denominator 3).
19. Number of goals met for PHYSICAL ACTIVITY (with Denominator 3).
20. Number of goals met for STRESS AND COPING (with Denominator 3).
21. Number of goals met for TOBACCO (with Denominator 3).
22. Number of goals met for WELLNESS AND SAFETY (with Denominator 3).

2.9.18.5 Definition

Patient Goal Numerator Logic

Goal Set
The Goal Setting value must be "Goal Set" and the Goal Start Date must be during the Report Period.

Goal Met
The Goal Status value must be "Goal Met" and the Date/Time Last Modified must be during the Report Period. The patient is not required to have set a goal during the Report Period.

2.9.18.6 Patient List
List of User Population patients with goal setting information during the Report Period
List of Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Term Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEI</td>
<td>Angiotensin Converting Enzyme Inhibitors</td>
</tr>
<tr>
<td>ADA</td>
<td>American Dental Association</td>
</tr>
<tr>
<td>ADR</td>
<td>Adverse Drug Reactions</td>
</tr>
<tr>
<td>AI/AN</td>
<td>American Indian/Alaska Native</td>
</tr>
<tr>
<td>AMA</td>
<td>Against Medical Advice</td>
</tr>
<tr>
<td>AMI</td>
<td>Acute Myocardial Infarction</td>
</tr>
<tr>
<td>APT</td>
<td>Acute Phase Treatment</td>
</tr>
<tr>
<td>ARB</td>
<td>Angiotensin Receptor Blocker</td>
</tr>
<tr>
<td>ART</td>
<td>Patient Allergies File</td>
</tr>
<tr>
<td>ASA</td>
<td>Aspirin (acetylsalicylic acid)</td>
</tr>
<tr>
<td>ASM</td>
<td>Asthma Management Plan</td>
</tr>
<tr>
<td>BH</td>
<td>Behavioral Health</td>
</tr>
<tr>
<td>BHS</td>
<td>Behavioral Health System</td>
</tr>
<tr>
<td>BI</td>
<td>Brief Intervention</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>BNI</td>
<td>Brief Negotiated Interview</td>
</tr>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary Artery Bypass Graft</td>
</tr>
<tr>
<td>CAGE</td>
<td>Cut Down, Annoyed, Guilty and Eye Opener</td>
</tr>
<tr>
<td>CCB</td>
<td>Calcium Channel Blocker</td>
</tr>
<tr>
<td>CHD</td>
<td>Coronary Heart Disease</td>
</tr>
<tr>
<td>CHR</td>
<td>Community Health Representative</td>
</tr>
<tr>
<td>CK</td>
<td>Creatine Kinase</td>
</tr>
<tr>
<td>CONPT</td>
<td>Continuation Phase Treatment</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>CPT</td>
<td>Current Procedural Terminology</td>
</tr>
<tr>
<td>CRC</td>
<td>Colorectal Cancer</td>
</tr>
<tr>
<td>CRS</td>
<td>Clinical Reporting System</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular Disease</td>
</tr>
<tr>
<td>CVX</td>
<td>Vaccine Code</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>DMD</td>
<td>Doctor of Medical Dentistry</td>
</tr>
<tr>
<td>DNKA</td>
<td>Did Not Keep Appointment</td>
</tr>
<tr>
<td>DPP</td>
<td>DiPeptidyl Peptidase</td>
</tr>
<tr>
<td>Acronym</td>
<td>Term Meaning</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>DPST</td>
<td>Demo/Test Patient Search Template</td>
</tr>
<tr>
<td>DTaP</td>
<td>Diphtheria Tetanus Acellular Pertussis</td>
</tr>
<tr>
<td>DTP</td>
<td>Diphtheria Tetanus and Pertussis</td>
</tr>
<tr>
<td>ER</td>
<td>Emergency Room</td>
</tr>
<tr>
<td>ESRD</td>
<td>End Stage Renal Disease</td>
</tr>
<tr>
<td>ETDRS</td>
<td>Early Treatment Diabetic Retinopathy Study</td>
</tr>
<tr>
<td>ETS</td>
<td>Environmental Tobacco Smoke</td>
</tr>
<tr>
<td>FIT</td>
<td>Fecal Immunochemical Test</td>
</tr>
<tr>
<td>FOBT</td>
<td>Fecal Occult Blood Test</td>
</tr>
<tr>
<td>FY</td>
<td>Fiscal Year</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>GPRA</td>
<td>Government Performance and Results Act of 1993</td>
</tr>
<tr>
<td>GPRAMA</td>
<td>GPRA Modernization Act</td>
</tr>
<tr>
<td>HCL</td>
<td>Hydrochloric Acid</td>
</tr>
<tr>
<td>HCTZ</td>
<td>Hydrochlorothiazide</td>
</tr>
<tr>
<td>HEDIS</td>
<td>Healthcare Effectiveness Data and Information Set</td>
</tr>
<tr>
<td>HHS</td>
<td>Health and Human Services</td>
</tr>
<tr>
<td>HiB</td>
<td>Hemophilic Influenza Type B</td>
</tr>
<tr>
<td>HIV</td>
<td>Human Immunodeficiency Virus</td>
</tr>
<tr>
<td>HPV</td>
<td>Human Papillomavirus</td>
</tr>
<tr>
<td>ICD</td>
<td>International Classification of Diseases</td>
</tr>
<tr>
<td>IFC</td>
<td>Infant Feeding Choice</td>
</tr>
<tr>
<td>IHS</td>
<td>Indian Health Service</td>
</tr>
<tr>
<td>IMM</td>
<td>Immunization</td>
</tr>
<tr>
<td>IPSD</td>
<td>Index Prescription (Rx) Start Date</td>
</tr>
<tr>
<td>IPV</td>
<td>Inactivated Polio Vaccine</td>
</tr>
<tr>
<td>IPV/DV</td>
<td>Intimate Partner Violence/Domestic Violence</td>
</tr>
<tr>
<td>IVD</td>
<td>Ischemic Vascular Disease</td>
</tr>
<tr>
<td>LABA</td>
<td>Long-Acting Beta2 Agonist</td>
</tr>
<tr>
<td>LCSW</td>
<td>Licensed Clinical Social Worker</td>
</tr>
<tr>
<td>LDL</td>
<td>Low-density Lipoprotein</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low Molecular Weight Heparin</td>
</tr>
<tr>
<td>LOINC</td>
<td>Logical Observations Identifiers, Names, Codes</td>
</tr>
<tr>
<td>LVAD</td>
<td>Left Ventricular Assistive Device</td>
</tr>
<tr>
<td>LVS</td>
<td>Left Ventricular Systolic</td>
</tr>
<tr>
<td>M/R</td>
<td>Measles and Rubella</td>
</tr>
<tr>
<td>MAOI</td>
<td>Monoamine Oxidase Inhibitors</td>
</tr>
<tr>
<td>Acronym</td>
<td>Term Meaning</td>
</tr>
<tr>
<td>---------</td>
<td>--------------</td>
</tr>
<tr>
<td>MMR</td>
<td>Measles, Mumps and Rubella (vaccine)</td>
</tr>
<tr>
<td>MPH</td>
<td>Master’s in Public Health</td>
</tr>
<tr>
<td>MTM</td>
<td>Medication Therapy Management</td>
</tr>
<tr>
<td>NHANES</td>
<td>National Health and Nutrition Examination Survey</td>
</tr>
<tr>
<td>NMI</td>
<td>Not Medically Indicated</td>
</tr>
<tr>
<td>NOS</td>
<td>Not Otherwise Specified</td>
</tr>
<tr>
<td>NQF</td>
<td>National Quality Forum</td>
</tr>
<tr>
<td>OMB</td>
<td>Office of Management and Budget</td>
</tr>
<tr>
<td>PCC</td>
<td>Patient Care Component</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous Coronary Interventions</td>
</tr>
<tr>
<td>PDC</td>
<td>Proportion of Days Covered</td>
</tr>
<tr>
<td>PHN</td>
<td>Public Health Nurse</td>
</tr>
<tr>
<td>POV</td>
<td>Purpose of Visit</td>
</tr>
<tr>
<td>PRC</td>
<td>Purchased and Referred Care</td>
</tr>
<tr>
<td>R/M</td>
<td>Rubella/Mumps</td>
</tr>
<tr>
<td>RAS</td>
<td>Renin Angiotensin System</td>
</tr>
<tr>
<td>RCIS</td>
<td>Referred Care Information System</td>
</tr>
<tr>
<td>RN</td>
<td>Registered Nurse</td>
</tr>
<tr>
<td>RPMS</td>
<td>Resource and Patient Management System</td>
</tr>
<tr>
<td>SBIRT</td>
<td>Screening, Brief Intervention, and Referral to Treatment</td>
</tr>
<tr>
<td>SNOMED</td>
<td>Systematized Nomenclature of Medicine</td>
</tr>
<tr>
<td>SNRI</td>
<td>Serotonin-Norepinephrine Reuptake Inhibitors</td>
</tr>
<tr>
<td>SSRI</td>
<td>Selective Serotonin Reuptake Inhibitors</td>
</tr>
<tr>
<td>STD</td>
<td>Sexually Transmitted Disease</td>
</tr>
<tr>
<td>STI</td>
<td>Sexually Transmitted Infection</td>
</tr>
<tr>
<td>TCA</td>
<td>Tricyclic Antidepressants</td>
</tr>
<tr>
<td>TD</td>
<td>Tetanus, Diptheria</td>
</tr>
<tr>
<td>TDaP</td>
<td>Tetanus, Diptheria and Acellular Pertussis</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient Ischemic Attack</td>
</tr>
<tr>
<td>TUHF</td>
<td>Tobacco User Health Factors</td>
</tr>
<tr>
<td>UACR</td>
<td>Urine Albumin-to-Creatinine Ratio</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper Limit of Normal</td>
</tr>
<tr>
<td>URI</td>
<td>Upper Respiratory Infection</td>
</tr>
</tbody>
</table>
Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

**Phone:** (888) 830-7280 (toll free)

**Web:** [http://www.ihs.gov/helpdesk/](http://www.ihs.gov/helpdesk/)

**E-mail:** support@ihs.gov